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ABSTRACT
The work presented in this thesis has focussed on the potential for site 
specific drug delivery to the MSH receptors located on the surface of 
melanoma cells. Methotrexate (MTX) was the drug chosen for this model due 
to its relatively small size (FW:454.5), the wealth of information already 
available on MTX and the facility with which it could be chemically 
manipulated for our purposes.
The potent analogue of the naturally occurring alpha-melanocyte stimulating 
hormone (a-MSH) i.e. [Nle4,D-Phe7]a-M SH was chemically conjugated to 
MTX forming NaMTX-[Nle4,D-Phe7]a-M SH, the study of which comprises 
the bulk of this work.
Although the majority of experiments were performed on the B16 murine 
melanoma cell line, additional cell lines used included: the MeWo human 
melanoma cell line, SVK14 keratinocytes and a transformed 293 human 
embryonic kidney (HEK) cell line, expressing the melanocortin MC3 
receptor.
With reference to drug delivery to melanoma, the binding and internalisation 
following interaction with the MCI receptor was examined. The results of the 
continual and Pulse-Chase labelling suggested that receptor mediated 
endocytosis of 125I-NaMTX- [Nle4,D-Phe7]a-M SH did occur. Acid washing 
steps were taken to determine what proportion of radioactivity associated 
with the cell was intracellular and hence receptor-specific. Continuous 
accumulation of ligand by B16 cells in the presence of NH4C1 led to the 
conclusion that under normal conditions, degradation of 125I-NaMTX- 
[Nle4,D-Phe7] a-M SH occurred in the lysosomes.
The interaction of NaMTX-[Nle4,D-Phe7]a-M SH with the MC3 receptor was 
assessed by competition assays in the presence of 125I- [Nle4,D-Phe7]a-M SH. 
It was established that binding to the MC3 receptor does occur but with 
lower affinity as compared to the affinity for the MCI receptor.
Growth inhibition was studied using the MTT tetrazolium dye cytotoxicity 
assay in the presence of MTX and NaMTX-[Nle4,D-Phe7] a-M SH for all of 
the cell lines described above, so that comparisons of the E.C .50 values 
generated could give valid conclusions as to the efficacy of the latter over the 
former.
Finally the intracellular mass of MTX required to effect growth inhibition of 
B16 cells was determined. This was achieved by the combination of the 
trypan blue assay with the MTT assay and the 3H-MTX uptake assay which 
led to the conclusion that 5.44 x 105 molecules of MTX are necessary to 
produce 50% growth inhibition.
Due to the fact that NaMTX-[Nle4,D-Phe7]a-M SH did not bind selectively to 
MCI receptors and that NaMTX-[Nle4,D-Phe7]a-M SH required a much 
higher (greater than 3 orders of magnitude) extracellular concentration than 
MTX before it exerted the same effects on the cells it has been concluded that 
this conjugate was not as successful as a site specific agent against melanoma 
as was hoped. The low toxicity of the conjugate was assumed to be explained 
by the low capacity of the receptor-mediated internalisation pathway. It was 
not feasible to deliver sufficient MTX by this mechanism, though in the 
future it may be possible to achieve melanoma-specific cytotoxicity if a more 
toxic agent is used.
Acknowledgements
I would like to thank all my supervisors for their support and encouragement, 
Dr. Stephen Moss, Professor D. J. G. Davies and especially Dr. Colin Pouton 
for his constructive criticism and constant optimism in the face of my eternal 
pessimism. I would also like to thank Dr. George Olivier for synthesising the 
peptide and the peptide conjugate employed in this study. Special thanks to 
Ulrike without whose friendship, advice and tolerance this thesis would have 
been infinitely more difficult to write. My thanks also extend to my father and 
my sister, Jill for financial and emotional support and many friends including: 
Emma Cane, Daniel Carey, Dethard Lampe, Neil Merrett, Mairead O' Donnell, 
Andy Richards, Dunevia Thomas, Anne Walsh and Toby Young who all 
played vital roles in maintaining my sanity!
Finally I would like to thank the Royal Pharmaceutical Society of Great 
Britain for their financial support and the collaboration of members of the 
SERC/ DTI funded LINK programme in "Selective Drug Delivery and 
Targeting" and the University of Bath for providing research facilities.
This thesis is dedicated to Eithne Marie-Celine Whelan.
iv
Abbreviations
AML Acute Myeloid Leukaemia
a-M SH alpha - Melanocyte Stimulating Hormone







E.C .50 Effective Concentration of inhibitor at which 50% of





FAB-MS Fast Atom Bombardment-Mass Spectrometry
FCS Foetal Calf Serum
3H-MTX Tritiated Methotrexate
HC1 Hydrochloric acid




HPLC High Performance Liquid Chromatography
I.D .50 Inhibition dose at which 50% of cells were inhibited
relative to control cells.
MALDI-TOF-MS Matrix Assisted Laser Desorption Ionisation - Time Of
Flight - Mass Spectroscopy 
MC Receptor Melanocortin Receptor
Acetonitrile
MSH Inhibiting Factors 








MTX-NLDP N“MTX-[Nle4,D-Phe7] a-M SH
NaOH Sodium Hydroxide
NEAA Non-Essential Amino Acids
NH4C1 Ammonium Chloride
NLDP [Nle4,D-Phe7] a-M SH













RPMI Roswell Park Memorial Institute
S.D. Standard Deviation































Table of Contents ix
Chapter 1.
Introduction 1
1.1. Methods of Drug Delivery 2
1.2. Melanocyte Stimulating Hormone (MSH) 3
1.2.1. Biosynthesis of MSH 5
1.2.2. Functions of MSH 6
1.2.3. Melanocortin Receptors 7
1.2.3.1. MCI Receptors 8
1.2.3.2. MC2 Receptors 9
1.2.3.3. MC3 Receptors 9
1.2.3.4. MC4 Receptors 10
1.2.3.5. MC5 Receptors 10
1.2.4. Uptake of MSH 11
1.2.4.1. Endocytosis and Transcytosis 11
1.2.4.2. Receptor Mediated Endocytosis 12
1.2.4.3. Receptor-Ligand Internalisation 13
1.2.5. Clinical significance of MSH 15
1.2.5.1. Treatment of pigment disorders 15
1.2.5.2. a-M SH in the diagnosis and therapy of melanoma 15
ix
1.2.5.3. a-M SH in the treatment of dementia 16
1.2.6. Cytotoxic MSH complexes 16
1.2.6.1. Daunomycin 17
1.2.6.2. N-Nitrosocarbamoyl -a-M SH compounds 17
1.2.6.3.Diphtheria toxin a-M SH fusion protein 17
1.2.6.4. a-M SH / Antibody conjugates directed to cytotoxic T 17 
cells
1.2.6.5. Melphalan 18
1.2.6.6. ‘" in  18
1.2.7. Biotransformation and Inactivation of MSH 19
1.3. Cytotoxic Drug Classification 20
1.3.1. Alkylating agents 20
1.3.2. Nitrosoureas (Choroethylnitrosoureas) 20
1.3.3. Antimetabolites 20
1.3.4. Antibiotics 21
1.3.5. Vinca Alkaloids 22
1.4. Methotrexate 23
1.4.1. Structure 24
1.4.2. Uptake of MTX 24
1.4.3. Mechanism of Action of MTX 25
1.4.4. Metabolism of MTX 26
1.4.5. Elimination of MTX 27
1.4.6. Methotrexate Resistance 28
1.4.6.1. Reduced affinity of DHFR for MTX 28
1.4.6.2. Increased levels of DHFR due to gene amplification 28
1.4.6.3. Decreased membrane transport of MTX 29
1.4.6.4. Decreased formation of MTX polyglutamates 29
X
1.4.6.5. Altered rates of thymidylate synthesis 29
1.4.7. Degradation of MTX 29
1.4.8. “Rescue” of cells after MTX administration 30
1.4.9. Side effects of MTX 31
1.4.10 Augmentation of MTX cytoxicity 33
1.5. Targeting of MTX 33
1.5.1. Antibody linkage to MTX 34
1.5.1.1. Direct linkage of MTX to monoclonal antibodies 34
1.5.1.2. Indirect linkage of MTX to monoclonal antibodies 35
1.5.1.3. Bispecific monoclonal antibody 37
1.5.2. Disadvantages of drug-antibody targeting 38
1.6. Aims and Objectives 39
C hapter 2 .
M aterials and  M ethods 42
2.1. Cell Lines 42
2.2. Solutions 42
2.3. Grow th M edia and Constituents 43
2.4. Equipm ent 45
2.4.1. Preparation of Glassware 45
2.5. Subculture of cell lines 46
2.6. Freezing of cells and cell storage 47
2.7. Recovery of cells from  storage 47
2.8. Counting of cells 48
2.9. Peptide Synthesis 49
2.9.1. Synthesis of [Nle4, DPhe7]a-M SH 49
2.9.2. Synthesis of A^-MTX-tNle4, DPhe7]a-M SH  50
xi
2.10. Radio iodination o f [NIe4, DPhe7]a-MSH 50
2.11. Radio iodination and purification of IV^MTX-fNIe4, 54 
DPhe7]a-MSH
2.12. Degradation of lv“ -MTX-[Nle4, DPhe7]a-M SH 54
2.13. Radioligand Binding and Internalisation 55
2.13.1. Time Course Experiment 56
2.13.2. Binding Isotherm 57
2.13.3. Competitive Binding Assay 58
2.13.3.1. Equation used for Competition Binding Assay 58
2.13.4. Internalisation of A^-MTX-fNle4, D-Phe7]a-M SH by 59 
B16 cells (in the presence of NH4C1)
2.13.5. Pulse Chase Internalisation of A^-MTX-tNle4, D-Phe7]a  60
-MSH
2.13.6. Pulse Chase Internalisation of A^-MTX-fNle4, D-Phe7]a  60 
-MSH (in the presence of NH4C1)
2.14. Growth Inhibitory effects of MTX and A a -MTX-[Nle4, 61 
D-Phe7]a-M SH  as assessed by the M TT assay
2.15. D eterm ination of the in tracellu lar mass of m ethotrexate 64
necessary to effect cell kill using tritia ted  m ethotrexate
2.15.2. Quench Curve of 3H-MTX 6 6
C hapter 3.
The M TT Assay: Development of an optimised assay of cell 70
viability based on the original M osmann method
3.1. In troduction 70
3.2. Short term  assays 70
3.3. Long term  assays 71
3.4. The MTT assay 72
3.5. Rationale for selection of the MTT assay 74
3.6. Disadvantages of the MTT assay 74
3.7. Linearity of the assay 76
3.8. Spectra of MTT and MTT Formazan 78
3.9. Optimal Incubation Time 79
3.10. Solvents for MTT Formazan 79
3.11. Control experiments with 96 microwell plates 80
3.11.1. Optimal Seeding Density and Growth Period 81
Chapter 4.




4.2.1. MTX-MTT assay 91
4.3. Results 91
4.3.1. B 16 murine melanoma cells 92
4.3.2. MeWo human melanoma cell line 93
4.3.3. SVK14 cells 95




W^-MTX-tNle4, D-Phe7]a-M SH : Experimentation on Uptake 108
and Growth Inhibitory Effects
5.1. Introduction 108
5.2. Degradation of Jv“ -MTX-[Nle4, D-Phe7]a-M SH 109
5.3. Binding studies with A,<X-MTX-|N'Ie4, D-Phe7]a-M SH 111
5.3.1. Binding Isotherm 111
5.3.2. Competition Binding Assays 113
5.4. Internalisation Studies with NaMTX-[125I-Tyr2,Nle4,D- 116 
Phe7]a-MSH
5.4.1. Continual exposure to A^-MTX-tNle4, D-Phe7]a-M SH at 117 
37°C: (In the presence of 20mM NH4CI)
5.4.2. Pulse Chase Internalisation of N“MTX-[125I-Tyr2,Nle4,D- 120 
Phe7] a-MSH: (In the absence of NH4CI)
5.4.3. Pulse Chase Internalisation of N“MTX-[125I-Tyr2,Nle4,D- 121 
Phe7]a-MSH: (In the presence of NH4CI)
5.5. Growth Inhibitory Effects of iVa MTX-[NIe4, D-Phe7]a- 124 
MSH as assessed by the MTT assay
5.5.1. B16 murine melanoma cell line 125
5.5.2. MeWo human melanoma cell line 127
5.5.3. SVK14 keratinocytes 128
5.5.4. Transformed 293 cell lines 130
5.6. Control experiments in the presence of [Nle4, D-Phe7]a- 134 
MSH
5.7. Effects of lysomotropic agents on growth inhibitory 135 







Determination of the intracellular mass of methotrexate 168
required to effect growth inhibition in B16 mouse melanoma
6.1. Introduction 168








The ultimate aim of any medicinal product is to eradicate the symptoms of 
illness and hence cure the patient. Although no drug can be said to be 100% 
risk-free, in many instances the side-effects are judged to be negligible in 
comparison to the beneficial effects. In cancer chemotherapy however, many 
of the commonly used agents e.g. vincristine, daunorubicin and methotrexate 
etc., have side-effects of a more serious nature and in these cases it is 
important to assess whether the benefit : risk ratio is high enough to justify 
their use. To combat these side-effects new approaches have been employed 
under the general heading of drug delivery systems. There are many ways in 
which a drug may be delivered to a diseased area, in order to produce 
"selective toxicity" i.e. " the injury of one kind of living matter without 
harming another kind with which the first is in intimate contact " (Albert, 
1973). This is a departure from the older theories founded upon the belief that 
by killing cells all over the body, the diseased or damaged cells would also be 
killed. This approach has lost a lot of support and momentum due to its 
haphazard nature which caused undesirable effects throughout the body.
This project is focused on melanoma cancer and its treatment by use of site 
specific methotrexate (MTX). Site specific drug delivery has progressed a 
long way from the initial conception of antibodies and "magic bullets" by 
Paul Ehrlich in 1906 (Basu, 1990). The theory of site specific drug delivery 
in this instance relates to the affinity of the melanocortin receptor sites on the 
surface of the cell for the hormone alpha-melanocyte stimulating hormone (a- 
MSH). An analogue of the naturally occurring hormone, [Nle4,D-Phe7]a -
l
MSH, has been used in preference to other analogues due to its stability 
towards oxidation and degradation and its facility of iodination at the tyrosine 
residue (position 2 ) without subsequent loss of biological activity of the 
molecule (Sawyer et al., 1980). [Nle4,D-Phe7]a-M SH is more active than a - 
MSH and showed prolonged effects in some of the assays as well as a higher 
binding affinity, (Tatro et al., 1990).
Once bound to the receptor site, the [Nle4,D-Phe7]a-M SH is internalised and 
then broken down intracellularly in the lysosomes. The aim of attaching MTX 
to the hormone analogue is that this will, in theory, guide MTX to the cell 
surface of cells expressing MSH receptors e.g. melanoma cells, melanocytes 
etc., in preference to the more general pathway followed by the free drug. In 
the normal way MTX uptake is mediated via the folic acid pathway as MTX 
competes for the same receptor site as folate analogues. Due to the uptake of 
MTX by all cell types many unwanted adverse effects are encountered. By 
using the N“MTX-[Nle4,D-Phe7]a-M SH conjugate it is hoped that an 
alternative and more discriminating pathway would be utilised and 
consequently ( 1) fewer drug molecules should be needed for targeting and (2 ) 
fewer side effects should be encountered leading to an overall improvement in 
the chemotherapy of the patient.
1.1. Methods of Drug Delivery.
The mode of transport utilised in order to achieve effective drug concentration 
at the pertinent site of action varies in complexity depending on the ease or 
difficulty with which the target cells are located. Local delivery to the nasal 
mucosa e.g. nose drops, delivery to the rectum e.g. suppositories, delivery to
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the lungs e.g. inhalation treatment for asthma, are all commonly used because 
the sites of action are relatively easy to target and so the agents can be 
delivered directly.
However, site specific drug delivery is the optimum choice for cancer 
chemotherapy. Cytotoxic drugs exert lethal effects not only on the cancerous 
cells but also on healthy tissues and cells especially where the cells have a 
rapid turnover rate e.g. bone marrow. This is achieved by means of attaching 
specific groups e.g. antibodies and hormones, to other non-specific groups 
e.g.: drug moieties, specifically in this case the targeting of methotrexate to 
the melanocortin receptors on the surface of cells by attaching it to the 
hormone analogue [Nle4,D-Phe7] a-MSH.
1.2. M elanocyte Stim ulating Horm one (MSH).
a-M SH is a 13 amino acid posttransational product of the pro­
opiomelanocortin (POMC) gene. The amino acid sequence of a-M SH and 
[Nle4,D-Phe7]a-M SH are given in Figure 1.1. a-M SH, adrenocorticotropic 
hormone (ACTH), P-MSH and 7 -MSH are structurally related pituitary 
peptide hormones and all share a core heptapeptide amino acid sequence: 
M et-Glu/Gly-His-Phe-Arg-Trp-Gly/Asp and are commonly referred to as 
the melanocortins or the melanotropic peptides. Figure 1.2. shows the 
sequence of events in their production (Mains et al., 1977, Mains and Eipper, 
1979, Crine et a l, 1979). The melanotropic peptides and especially a-M SH 
have been the subject of an extensive review by Eberle, (1988). Therefore 
only the information pertinent to this study is mentioned here and no detailed 






Figure 1.1. This figure shows the amino acid sequences of the hormone, a- 
MSH and an analogue of this hormone, [Nle4,D-Phe7]a-MSH.
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(i) p-lipotropin (p-LPH)
POMC matures into: (ii) Adrenocorticotropic hormone (ACTH)
(iii)N-terminal glycopeptide 
(contains 7  - MSH sequence)
further to this ACTH and p-lipotropin are modified:
ACTH: (i) a-MSH
(ii) corticotrophin-Iike intermediate lobe 
peptide (CLIP)
P-lipotropin : (i) 7 -Iipotropin ..........> p-MSH
(ii) P-endorphin > met Enkephalin
Figure 1.2. Sequence of events following excision of POMC gene and 
resulting in the formation of the melanotropins.
1.2.1. Biosynthesis of MSH.
In the mammal, MSH is synthesised mainly in the pars intermedia (P.I.) of 
the pituitary gland also in the brain and the pars distalis (P.D.). However 
there is also some evidence of peripheral tissue synthesis such as in the skin, 
testes and other organs expressing the POMC precursor e.g. placenta and gut. 
In the P.I. the production of MSH occurs in type 1 cells which are rich in 
mitochondria and also contain rough endoplasmic reticulum (RER), Golgi 
apparatus and an abundance of secretory vesicles. The P.I. is poorly 
vascularised and is innervated by three types of nerve fibre in the mammal (i) 
aminergic (mainly dopaminergic) (ii) cholinergic and (iii) peptidergic.
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The biosynthesis and secretion of MSH from the P.I. is under humoral control 
of the hypothalamic factors both excitatory and inhibitory. The inhibitory 
hypothalamic effects are mediated via MSH release inhibiting factors (MIF) 
e.g. dopamine, GABA, serotonin, enkephalin and somatostatin and excitatory 
effects via MSH releasing factors (MRF) e.g. (nor)adrenaline and vasopressin. 
Other regulatory effects on MSH secretion have been suggested to be 
mediated via direct negative or positive feedback loops. Stress provokes a 3- 
10 fold increase in circulating ACTH, a-M SH and other POMC peptides, it is 
thought to act by upsetting the normal balance of stimulatory and inhibitory 
factors. (See Eberle (1988), Chapter 10).
12.1.1. [N W P -P h e7] a-M SH .
This is a structural analogue of the naturally occurring hormone which is 
differentiated by substitution of the Nle4 and DPhe7 in the amino acid 
sequence of a-MSH. It mimics the actions of a-MSH but is 26 times more 
potent than the native hormone (Tatro et al., 1990) and was used extensively 
in this work as part of the drug targeting conjugate to target MTX to 
melanoma cells. Figure 1.1. shows the amino acid sequence of [Nle4,D-Phe7] 
a-MSH.
1.2.2. Functions of MSH.
a-M SH affects pigment cells of amphibians through its effects on 
melanophores. Pigment cells comprise of melanophores, erythrophores, 
xanthophores, leuophores and iridophores, (Fujii and Oshima, 1986). 
Melanophores may be subdivided into dermal and epidermal melanophores 
both of which possess specific organelles, melanosomes in which brown / 
black melanin is synthesised and stored. Melanin formation involves 
production of two types of melanin, eumelanin and phaeomelanin which are
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derived from the same precursor tyrosine. The main functions of a-M SH on 
pigment cells include pigment dispersion, melanogenesis, (Hadley et al., 
1987, Levine et al., 1987) differentiation (dendrite formation), proliferation 
and growth inhibition. Due to this a-M SH is of importance for physiological 
colour change. The alteration of configuration i.e. with the DPhe7 
significantly affects a-M SH by increasing its potency, (Tatro et al., 1990, 
Sahm, 1994).
a-M SH induces a marked increase in tyrosinase activity and tumour 
melanogenesis of B16 melanoma cells whilst retarding the proliferation of 
growth of these murine melanoma cells (Lee et al., 1972); however, Hadley et 
al., (1987) found that proliferation of Cloudman S91 monolayer cultures were 
not inhibited by prolonged exposure to either a-M SH or [Nle4,D-Phe7] a -  
MSH, a finding which was supported by this study.
1.2.3. Melanocortin Receptors.
The existence of multiple melanocortin receptors has been suggested by 
many, (Tatro, 1990, DeWied and Jolles, 1982, Cannon et al., 1986) and five 
have been identified to date, (Mountjoy et al., 1992, Chhajlani and Wikberg, 
1992, Gantz et al., 1993a, Gantz et al., 1993b and Chhajlani et al., 1993). The 
melanocortin receptors are guanine nucleotide-binding protein (G-protein)- 
coupled cell surface receptors through which the POMC-derived peptides e.g.: 
a-M SH, (3-MSH, 7 -MSH and ACTH mediate their actions, (Gantz et al., 
1993(a)). They are the smallest G-protein coupled receptors known, 
containing between 297 and 363 amino acids (Mountjoy et al., 1992). 
Melanocortin receptors are located at many sites throughout the body e.g. 
melanocytes, adrenal cortex, brain, gut and placenta and a number of 
functions are associated with each receptor although the functions of the MC4
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and the MC5 receptors have still to be fully elucidated, (Gantz et al., 1993(b), 
Chhajlani et al., 1993).
I.2.3.I. MCI Receptors:
Mountjoy et al., (1992) identified the murine and human MSH receptor now 
known as the MCI receptor simultaneously to Chhajlani and Wikberg's 
identification of the human MSH receptor (1992).
Mountjoy et al., (1992) stably transfected 293 human embryonic kidney 
(HEK) cells with the gene encoding the melanoma MSH receptor. The cells 
were then incubated with a-M SH, [Nle4,D-Phe7]a-M SH and ACTH which 
resulted in a two to threefold elevation in cAMP relative to the 293 cells 
containing the vector alone. The receptor was specific for peptides with 
melanotropic activity, responding to [Nle4,D-Phe7]a-M SH stimulation more 
than a-M SH and least of all to ACTH.
Chhajlani and Wikberg (1992) described the insertion of the cloned human 
MSH cDNA receptor protein into a vector and transient expression in COS-7 
cells. This cloned receptor specifically bound an 125I- labelled MSH analogue 
namely: 125I- [Nle4,D-Phe7]a-MSH. The bound ligand could be displaced by 
the following melanotropic peptides in decreasing order of potency: [Nle4,D- 
Phe7]a-M SH > a-M SH = (3-MSH > ACTH > 7 -MSH, however it could not be 
displaced by the non-melanotropic peptide : (3-endorphin, findings which all 
agree with Mountjoy et al., (1992).
Functions o f the MCI receptors:
Northern Blot analysis of the murine and human MSH receptors showed the 
specific localisation in melanocytes. Chhajlani et al., (1993) have suggested 
that since the MCI receptors are only expressed in melanocytes this is the 
receptor most likely to mediate melanin synthesis and involvement with the 
growth and pigment production via the melanotropic peptides.
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1.2.3.2. MC2 Receptors.
The human MC2 receptor (ACTH receptor) was cloned by Mountjoy et al. 
(1992) using the same technique as described for the cloning of the MCI 
(MSH) receptor. Northern blot analysis showed that the cloned receptor was 
expressed specifically in the adrenal cortex. It was found primarily across the 
zona fasiculata i.e. the site of glucocorticoid production and also in the 
cortical half of the zona glomerulosa which is the site of aldosterone 
production. The function of the MC2 receptor, due to its localisation and also 
its high binding affinity to ACTH is related to adrenal cortical function, 
(Mountjoy et al., 1992).
1.2.3.3. MC3 Receptors.
The MC3 receptor was characterised by Gantz et al., (1993a). A major 
difference in the pharmacological characteristics between the MCI and the 
MC3 receptor lies in their respective responses to (3-MSH and 7 -MSH. 
Because the MC3 receptor appears to recognise ACTH and a-M SH, p-MSH 
and 7 -MSH equally well, Gantz et al., (1993a) reasoned that the core 
heptapeptide might be the specific site of the melanocortins that is recognised 
by the receptor a theory supported by others, Mountjoy et al., (1992) and 
Chhajlani and Wikberg, (1992). Northern blot analysis performed by Gantz et 
al., (1993a) showed expression of the MC3 receptors in the brain, placenta 
and gut tissue but not in melanoma cells or in the adrenal gland. In situ studies 
showed that they are also expressed in the cortex, thalamus, hippocampus and 
the hypothalamus.
Gantz et al., (1993a) have suggested that the MC3 receptor may partake in 
mediating some of the putative actions of the melanotropins in higher cortical 
functions e.g. behaviour. They have also postulated on the possible roles of
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the MC3 receptor in the switch in sensitivity of the foetal adrenal gland from 
a-M SH to ACTH prior to parturition which was observed by Silman et al., 
(1976) and also the rise in a-M SH levels in maternal circulation in the latter 
stages of pregnancy reported by Clark et al., (1978).
1.2.3.4. MC4 Receptors.
Gantz et al., (1993b) reported the cloning, expression and gene localisation of 
a fourth human melanocortin receptor (MC4). This receptor is expressed 
primarily in the brain and its expression is notably absent from the adrenal 
cortex (MC2), melanocytes (MCI) and placenta (MC3). It is structurally most 
similar to the MC3 receptor with which it shares 58% and 76% overall amino 
acid identity and similarity, respectively (Gantz et al., 1993b).
The functions of this receptor have still to be elucidated although due to its 
expression in the brain, it is thought to be involved in the central nervous 
system (CNS) functions and memory.
1.2.3.5. MC5 Receptors.
MC5 receptors described as MC2 receptors by Chhajlani et al., (1993) who 
first reported their existence, however if the nomenclature of Mountjoy et al., 
(1992) and Gantz et al., (1993a and 1993b) is followed then they are more 
correctly called the MC5 receptors. This receptor is expressed in brain tissue 
but not in melanoma cells. Although the functions of this receptor have not 
been discovered, it is thought that due to their expression in the brain the 
MC5 receptors are more likely to mediate the more diverse actions of MSH 
(Chhajlani et al., 1993). These actions include effects on memory and 
temperature control (Clark et al., 1985) and modulation of immune 
inflammatory responses (Cannon et al., 1986).
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1.2.4. Uptake of MSH.
The uptake of a-M SH into the cells where it exerts its effects is not easy to 
characterise due to the difficulty of radiolabelling the hormone and hence 
tracing the movements of the hormone and its subsequent binding to, and 
internalisation by, the cell. Therefore the analogue [Nle4,D-Phe7] a-M SH is 
used for the internalisation assay techniques and the assumption is that a - 
MSH undergoes the same type of process. The experiments of internalisation 
are described in detail in Chapter 2 and entail the radiolabelling of [Nle4,D- 
Phe7] a-M SH with 125I (Adams, 1993). These studies have led to the 
conclusion that the uptake of [Nle4, D-Phe7] a-M SH in to a cell is brought 
about by receptor-mediated endocytosis (Goldstein et al., 1979).
I.2.4.I. Endocytosis and Transcytosis:
Knowledge of endocytosis and transcytosis is essential for the development of 
drug delivery systems when macromolecules, e.g. dextran, albumin, 
antibodies and hormones, are used as drug or drug carriers. (Poznansky and 
Juliano, 1984).
Endocytosis is a general term that refers to the process by which cells ingest 
extracellular materials by trapping them within inward foldings of the plasma 
membrane that pinch off from the surface to form intracellular vesicles 
(coated vesicles), (Goldstein et al., 1979). Roth and Porter (1964) first 
described coated pits and coated vesicles in the mosquito oocyte. They 
postulated that the uptake of adsorbed proteins from the extracellular fluid 
(ECF) during yolk formation, was mediated via these structures. Subsequent 
investigations found that coated pits and vesicles mediate protein uptake in 
specialised cells of higher animals, (Friend and Farquhar, 1967).
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Macromolecules inside these vesicles can be processed through various 
intracellular organelles and, in some cases, recycled back to the plasma 
membrane. In polarised cells e.g. epithelial cells and hepatocytes, internalised 
macromolecules can be transported to the opposite side of the plasma 
membrane, a process known as transcytosis, (Shen et al., 1992).
Biological pathways have both a passive and active nature and include:
(i) Fluid phase pinocytosis: This is a continuous and non-specific process and 
the means by which extracellular fluid (ECF) is internalised. Shen et al., 
(1992) describe this as a passive and non-saturable process.
(ii) Phagocytosis; which is a process of internalisation of large particles and it 
only occurs in specialised cell types e.g. macrophages and granulocytes, 
(Shen et al., 1992)
(iii) Endocytosis (receptor mediated and non-receptor mediated):
I.2.4.2. Receptor Mediated Endocytosis.
The subject of receptor-mediated endocytosis has been studied extensively, 
(Goldstein et al., 1979, Tomlinson, 1987, Basu, 1990 and Shen et al., 1992). 
10% plasma membrane-associated proteins (receptors) can have special 
affinity for a variety of molecules including peptides and proteins, known as 
ligands, (Shen et al., 1992). It is the means by which the melanotropic 
peptides enter cells, a coupled process by which the peptides are first bound to 
specific receptors (MC1-MC5) and then rapidly internalised by the cell. 
Following binding to the receptor on the cell surface, the ligand-receptor 




Subsequent to the accumulation of ligand-receptor complex in the clathrin- 
coated regions, these coated pits invaginate from the plasma membrane and 
form coated vesicles by pinching inward from the membrane. Once the coated 
vesicles are formed, the clathrin coats are lost resulting in the formation of 
smooth membrane vesicles, known as endosomes, (Shen et al., 1992). 
Examples of ligands entering cells this way include: low-density lipoprotein 
(LDL), transferrin (Tf) and insulin.
Clathrin-independent pathway:
This pathway refers to the formation of vesicles from the invagination of non- 
clathrin-coated plasma membrane. In contrast to the clathrin-dependent 
pathway this process occurs in receptors with a low population and a slow rate 
of internalisation and the exact mechanism of internalisation is still largely 
unknown, (Shen et al., 1992). Ligands such as IgG-ferritin, cholera toxins and 
ricin enter cells in this way.
I.2.4.3. Receptor-Ligand Internalisation.
In some cases internalisation may not be required for the physiological 
function of the ligands because the binding alone may be sufficient to initiate 
the actions associated with the ligand e.g. binding of a-M SH to MSH 
receptors results in increased levels of cAMP, prior to internalisation, 
(Mountjoy et al., 1992, Chhajlani and Wikberg, 1992). The intracellular 
sorting and processing of ligands is controlled by compartments which occur 
in the following sequence: early endosomes, late endosomes, prelysosomes 
and lysosomes.
Endosomes and lysosomes are known to be the major acidic compartments of 
the cell ranging from pH 6.0-4.5, respectively. If ligands are dissociated from
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their receptors in these acidic compartments, they are further transported and 
degraded in lysosomes and their receptors can be recycled e.g. LDL (Basu,
1990).
Ligands that remain associated with the receptor will either (i) recycle with 
their receptor e.g. transferrin or (ii) the ligand-receptor complex will go to the 
lysosome where both will be degraded e.g. epidermal growth factor. The final 
option is for the receptor to be degraded in the lysosome while the ligand is 
transported across the cell e.g. immunoglobulin A, (Shen and Ryser, 1979, 
Basu, 1990).
Figure 1.3. shows the different processes of endocytosis.
A M M A M A /V A /
Figure 13 . A simplified scheme of endocytosis and transcytosis in epithelial cells. Ligands can bind to cither 
the apical (A) or the basolateral (B) membrane. These two membranes arc separated by the tight junction 
(C). After internalization, mem brane-bound ligands will be located in the apical (D) or the basolateral (F.) 
endosome. Endosom e-entrapped ligands can be further processed via the following pathways: (1) apical- 
to-basal (a) or basal-to-apical (b) transcytotic pathway which in%'olves still unknown com partm ents (?). 
(2) endosome-to-lysosome pathways (c and d), followed by the degradation in lysosomes (F) and releasing 
of degraded products via exocytotic pathways (e): and (3) recycling pathways (f) which may or may not
involve the Golgi apparatus (Adapted from Shen el al~, 1992)
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1.2.5. Clinical significance of a-MSH.
a-M SH is produced by and is active in the CNS of animals where it has 
effects on memory, adaptation, nerve generation, fever control and also 
during the foetal development. It has been postulated (Eberle, 1988) that there 
are five areas where a-MSH-related compounds could ultimately be used as 
pharmaceuticals with clinical relevance namely; treatment of pigment 
disorders, diagnosis and therapy of melanoma, treatment of certain types of 
dementia. It is also associated with the enhancement of nerve-regeneration 
and protection from nerve-damage and in the control of fever and 
inflammation.
12.5.1. Treatment o f pigment disorders:
Hadley and co-workers (1987) and Levine et al., (1987) have proposed the 
use of [Nle4,D-Phe7] a-M SH in the correction of acquired integumental 
hypopigmentary disorders and also as an artificial suntan agent. However the 
results of in vitro work are not necessarily representative of the in vivo 
situation and a major drawback of this therapy is the possibility of inducing 
melanoma in the patient.
12.5.2. a-M SH in the diagnosis and therapy o f melanoma:
It has been suggested (MacKie, 1983) that as melanoma tumours are 
dependent upon the endocrine system, a-M SH and other POMC-related 
peptides may be involved in the aetiology of the disease. a-M SH may be 
exploited by determination of its plasma levels, as increased plasma levels 
would indicate a more progressed disease state, and also the detection of a- 
MSH receptors on the biopsies of tumours.
The first line of treatment for melanoma is surgical, however where this is not 
possible either due to the advanced state of the disease or inaccessibility of the 
site, radiotherapy is a possibility. It is known (Cobb, 1956, Seiji and Itakura,
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1966) that melanotic melanoma is more radiation-resistant than any other 
tumour, probably due to the protective effect of melanin brought about by the 
stable free radical nature of melanin. Pretreatment with chlorpromazine (CPZ) 
increases the sensitivity of melanoma by binding and thus inactivating, 
melanin. Mishima (1973) proposed the combination of CPZ and boron 
neutron capture therapy.
1.2.5.3. a-MSH in the treatment o f dementia:
Due to the actions of a-M SH peptides as potent neuropeptides they have been 
investigated with regard to their ability to improve memory of the elderly as 
they were previously successful in stimulating both behaviour and memory of 
experimental animals. One of the a-MSH/ACTH analogues: M et(02)-Glu- 
His-Phe-D-Lys-Phe-NH-(CH2)g-NH2 has been shown to be very active at 
stimulating the cholinergic system (Geiger et al., 1986) and therefore may be 
useful as a potential anti-dementia drug.
1.2.6. Cytotoxic MSH complexes.
The subject of hormone-drug conjugates has been the subject of an extensive 
review by Varga, (1985).
The direction of a toxin specifically into tumour tissues would have obvious 
advantages in terms of selectivity of drug action.
Previously there have been six types of conjugations in combination with 
MSH derivatives (i) daunomycin, (ii) N-nitrosocarbamates, (iii) diphtheria 
toxin, (iv) cytotoxic T cells and (v) melphalan, and (vi) m ln. In this project a 
seventh combination has been synthesised and tested, namely the use of 




The conjugate of (3-MSH with daunomycin exhibits a threefold increase in 
potency towards Cloudman S91 cells relative to free daunomycin, (Varga et 
al., 1977). The specificity of its action is demonstrated by the lack of toxicity 
towards 3T3 fibroblast cells. The data are based solely on in vitro studies and 
in vivo data may or may not support these findings.
1.2.6.2. N-Nitrosocarbamoyl-a-MSH compounds:
By coupling the C-terminal fragments of a-M SH to 2-chloroethylnitroso- 
carbamoyl, products with distinct in vivo inhibitory action on melanoma 
xenografts are yielded, (Jeney et al., 1986). Concentrations of 5()-100mg/kg 
are necessary for significant growth inhibition in mice.
1.2.6.3. Diphtheria toxin-a-MSH fusion protein:
Murphy et al., (1986) constructed a chimeric diphtheria toxin a-M SH gene in 
which the toxin receptor binding domain is replaced by the a-M SH gene 
sequence thus guiding the toxin specifically to melanoma cells. In vitro 
cytotoxicity experiments on human NEL-M1 cells proved the conjugate was 
selectively toxic to these cells whereas control cells were unaffected. In vivo 
studies have yet to confirm the usefulness of this conjugate however a 
possible mode of resistance in humans may be due to the immunisation 
programme of humans in some countries, e.g. United Kingdom, which in turn 
may make it intolerable. Other toxins that have been suggested instead include 
ricin and abrin.
1.2.6.4. a-MSH/ Antibody conjugates directed to cytotoxic T cells:
This method was first introduced by Liu et al., (1988) and is based on the 
findings that MAbs to the invariant component of the T cell receptor (TCR) 
induce cytolytic activity of these cells. The conjugation of [Nle4,D-Phe7] a -
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MSH to these antibodies seems to promote lysis of melanoma cells, B16 and 
6B7 and human M1313 melanoma cells (Liu et al., 1988)
1 2 .6 5 . Melphalan:
Morandini et al., (1994) proposed the introduction of melphalan into a-M SH 
fragments, two C-terminal fragments (Pep3 and Pep4) and two central 
fragments (Pepl and Pep2). This led to an examination of their selectivity as 
well as cytotoxicity against melanoma, carcinoma and fibroblast cells. The 
final analysis was that a clear, selective cytotoxic effect on melanoma cells 
could be observed with Pepl and Pep 2. The cytotoxic effect on melanoma 
cells is likely to be mediated via a-M SH receptors, since there was an 
inhibition of cytotoxic effects in melanoma cells in the presence of an a-M SH 
agonist.
1.2.6.6. in In:
Apart from the obvious advantages of selectively targeting therapeutic agents 
to melanoma, a significant improvement in patient mortality rates could be 
effected by tackling the imaging of metastases. Once localised, these could 
then be surgically removed rather than waiting for symptoms to arise at a 
point where surgery is no longer an option. Bard et al., (1986) have 
successfully managed to target in In to Cloudman S91 melanoma cells both in 
vitro and in vivo by use of a-melanocyte-stimulating hormone (a-MSH). The 
coupling of a-M SH diethylenetriaminepenta-acetic acid (DTPA) followed by 
labelling with 1HIn gave rise to MSH-DTPA-n iIn. This was then incubated 
for 3 hours with Cloudman S91 cells where the presence of 60nM a-M SH 
inhibited the binding of MSH-DTPA-ln In and hence showed the latter's 
specific affinity for MSH receptors. DBA/2 mice were used for in vivo work, 
intraperitoneal injection of MSH-DTPA-H1In and a control polyalanine 
derivative PA-DTPA-n , In were both tested. Tissue distribution showed that
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radioactivity delivered as MSH-DTPA-U1ln was selectively retained by 
tumour tissue.
Further studies by Bard et al., (1990), employed two molecules of MSH with 
DTPA forming: My-MSH-DTPA which was then radiolabelled with in In. 
Although this was equally effective in vitro to their previous conjugate, there 
were enhanced tissue specificity effects in DBA/2 mice bearing the same 
tumour.
1.2.7. Biotransformation and Inactivation of MSH.
Once the melanotropins are released from their cells of origin they may 
undergo biotransformations which modify their innate biological properties. 
This process may occur via the cleavage of single amino acid residues, a - 
MSH breakdown in vitro is approximately exponential with a mean half life 
of 39 minutes for a sample at 37°C and 54 minutes at 4°C in RPMI-FCS 
media and in human plasma the half life is 25 minutes at 37°C and 125 
minutes at 0°C, (Eberle, 1988). Blood clearance of a-M SH is more important 
in skeletal muscle and skin than in the liver and kidneys as shown by 
occlusion experiments.
The advantages of [Nle4,D-Phe7]a-M SH over the native hormone lie in its 
resistance to inactivation by frog and rat serum enzymes, (Castrucci et al., 
1984). The D-Phe7 portion of the [Nle4,D-Phe7]a-M SH adds stability against 
biotransformation and degradation where the a-M SH is susceptible at the 
Phe7-Arg8 bond as a primary source of cleavage. Once cleavage has occurred 
the fragments are attacked by exopeptidases and degraded to free amino acids, 
(Tatro et al., 1990).
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1.3. Cytotoxic Drug Classification.
In general the groups of cytotoxic drugs are characterised by their mechanism 
of action on the target cells and fall into the following five groups:
1.3.1. Alkylating agents:
The alkylating agents act by arresting cell division by alkylating and cross- 
linking guanine bases in DNA e.g. nitrogen mustards., cyclophosphamide and 
chlorambucil. Cyclophosphamide is a biologically inactive nitrogen mustard 
analogue which requires oxidation to express its alkylating activity. It is used 
over a wide range of clinical activities e.g. lymphomas, sarcomas of soft 
tissue and bone and carcinomas of the breast, lung, ovary, cervix and colon, 
(Carter, 1975).
1.3.2. Nitrosoureas: (Chloroethylnitrosoureas)
These agents act principally through alkylation of DNA although 
carbamoylation of proteins by isocyanates generated from the decomposition 
of nitrosoureas, may also contribute to their antitumour activity or toxicity, 
(Schein et al., 1978, Gallant et al., 1993).
Clinical activity has been demonstrated in brain tumours, lymphomas, 
melanoma and gastrointestinal cancers, (Schein et al., 1978).
1.3.3. Antimetabolites:
The antimetabolites impair the synthesis of purine and pyrimidine bases by 
preventing the incorporation of the bases into nucleic acids e.g. methotrexate, 
mercaptopurine and azathioprine. Generally the pharmacokinetics of these 
agents resemble the natural substances with which they compete or replace 
and hence inhibit cell metabolism and growth, (Balis et al., 1983).
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Methotrexate (MTX) is a folate analogue which binds more tightly to 
dihydrofolate reductase (DHFR) than does folate. The conversion of 
dihydrofolate to tetrahydrofolate is thereby inhibited and the pool of reduced 
folates required for the synthesis of thymidylate and purines is depleted, 
(Shen and Azarnoff, 1978).
Therapeutic indications for MTX include, choriocarcinoma, non-Hodgkin's 
lymphomas, osteosarcoma, metastatic meningeal neoplasms, some brain 
tumours, the histiocytoses and carcinomas of the breast, head and neck, lung, 
ovary, cervix and bladder, (Bertino, 1975).
Cytarabine (Cytosine Arabinoside) is another antimetabolite which, after 
intracellular conversion, functions as an antagonist of the physiological 
substrate deoxycytidine triphosphate and also competitively inhibits DNA 
polymerase. Cytarabine triphosphate is also incorporated to a limited extent 
into both RNA and DNA, (Chu, 1971).
It is used primarily for the treatment of leukaemia and lymphoma and is one 
of the most active agents against acute non-lymphocytic leukaemia, (Gale, 
1979).
5-Fluorouracil (5-FU) kills cells by inhibition of thymidylate synthetase thus 
depleting the cell of thymidine nucleotides and thereby inhibiting DNA 
synthesis and impairing RNA metabolism and function, (Balis et al., 1983). 
5-Fluorouracil is active against gastrointestinal, breast, pancreatic, ovarian 
and head and neck carcinomas, (Myers et al., 1976).
1.3.4. Antibiotics:
Antibiotics bind to DNA and prevent replication e.g. daunorubicin and 
actinomycin D. Doxorubicin (adriamycin) and daunorubicin (daunomycin) 
are glycosidic antibiotics found in different species of the fungus
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Streptomyces. Structurally they consist of a planar tetracycle ring linked by a 
glycosidic bond to the amino sugar, daunosamine, (Young et al., 1981). Both 
drugs act primarily by intercalation with DNA, although other binding or free 
radical reactions may explain some of the toxicity and antitumour effects. 
Doxorubicin is clinically active against a wide range of malignancies e.g. 
acute leukaemias, non-Hodgkin's lymphomas, Hodgkin's disease and many 
carcinomas. Daunorubicin is mainly used for acute leukaemias, (Young et al., 
1981).
1.2.5. Vinca Alkaloids:
Alkaloids arrest metaphase of the cell cycle and hence prevent cell 
proliferation e.g. vinblastine and vincristine. The vinca alkaloids are naturally 
occurring, dimeric indole derivatives initially isolated from the periwinkle 
plant, (Balis et al., 1983). Although the antitumour effect of the vinca 
alkaloids has been largely attributed to their ability to arrest mitosis by 
dissolution of microtubular mitotic spindles, they also inhibit a variety of 
biosynthetic pathways which possibly contributes to their cytotoxicity, 
(Creasey, 1978).
Vinblastine is used mainly in the treatment of Hodgkin's disease and testicular 
cancer. Vincristine has a much broader spectrum of action against acute 
lymphocytic leukaemia, the lymphomas, breast cancer and a number of 
paediatric solid tumours. Vindesine has shown activity against solid tumours 
e.g. colorectal cancer, lung cancer and breast cancer, (Balis et al., 1983).
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1.4. Methotrexate.
Methotrexate is an antimetabolite which exerts cytotoxic actions in the S 
phase of the cell cycle, maximal effects are exhibited in the logarithmic 
growth phase when the cells are rapidly proliferating. The effect of MTX on 
the cloning efficiency of cells was clearly related to the growth rate of the 
culture from which the cells were taken for testing. MTX kills cells at 6.7 
times the rate and produced a 20 fold greater inhibition of deoxyuridine 
incorporation into DNA from logarithmic as opposed to plateau phase cells, 
(Hryniuk et al., 1969).
MTX was first synthesised in 1949 by Seeger et al., and first clinically used in 
1953 in the treatment of childhood acute lymphoblastic leukaemia (ALL). It 
has a number of unique features which are responsible for its popularity in 
research and treatment. MTX is active in a wide scale of different malignant 
diseases for example: childhood acute lymphoblastic leukaemia (ALL), (van 
der Kleijn, 1984), osteogenic sarcoma (Embleton et al., 1981), non-Hodgkin's 
lymphomas, osteosarcoma (Balis et al., 1983), human small cell lung cancer 
(Curt et al., 1985), treatment of psioriasis (Chabner, 1982) an effect which is 
synergistically enhanced by oral psoralen photochemotherapy (PUVA) 
(Morison et al., 1982) and rheumatoid arthritis (Furst and Kremer., 1988).
It has the largest dose range of application (3-33,600 mg/m2) (Borsi and Moe, 
1987) and many different routes of administration (i.v., i.m., p.o., i.thecal. 
and i. ventricular).
It is the only antineoplastic agent which has an antidote (folinic acid) in 
clinical use, (Bernard et al., 1991).
The determination of MTX concentration in serum is a clinical routine and its 
level in other biological fluids (CSF, urine) is easily measured.
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1.4.1. Structure.
Methotrexate (MTX) is classified as an antimetabolite and is the 4-NH2 N-10 
methyl analogue of folic acid. MTX consists of three major parts similar to 
the physiological folate co-factors, (Seeger et al., 1949):
(i) a multi-ring pteridine group, (ii) para-aminobenzoic acid and (iii) terminal 
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1.4.2. Uptake of MTX.
MTX is a relatively large (FW:454.5), polar, lipid-insoluble molecule and 
transport into the cells occurs via one of two mechanisms, (Warren et 
a l,  1978).
The first and most common pathway of entry is an active process i.e. it 
requires energy and it is carrier mediated and is saturable, (Goldman et al.,
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1968, Huennekens and Henderson, 1975). MTX in addition to leucovorin, 
competes for uptake into the cell. In vitro evidence (Kamen et al., 1988) 
suggests that the internalisation could be mediated via a surface membrane 
receptor (folate binding protein which has the properties of a membrane 
receptor) that recycles.
The internalisation process involves several steps, folate binding to the 
membrane receptor, the ligand-receptor complex then moves into the cell and 
once inside the cell the ligand is released from the receptor in an acidic 
intracellular compartment and moves into the cytoplasm after which the 
unoccupied receptor returns to the cell surface. This membrane folate binder 
has a high affinity for 5-methyltetrahydrofolic acid (utilised by cells for the 
biosynthesis of methionine, serine, deoxythymidylic acid and purines) but at 
least a 10 fold higher affinity for folic acid and a 5-10 fold lower affinity for 
MTX (Kamen and Capdevila, 1986).
The second process is not as well documented and is thought to involve a 
diffusion of molecules of MTX (Warren et al., 1978, Hill et al., 1979). This 
process occurs in the presence of very high concentrations of MTX (> 
20mM). Although it is less efficient due to its passive nature, the advantage of 
this route of entry is that it enables the uptake of MTX into cells where this 
would otherwise be impossible due to the saturation of uptake pathway caused 
by the high extracellular concentrations of MTX.
1.4.3. Mechanism of Action of MTX.
Once inside the cell, MTX binds to DHFR and thus inactivates this enzyme. 
This is significant because DHFR is a vital enzyme in the reduction of 
dihydrofolic acid (FH2) to tetrahydrofolate (FH4) and thus maintains the 
intracellular levels of the latter. The result of inhibition of DHFR is a
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diminished level of FH4 which in turn causes depletion of thymidylate and 
purine synthesis which require N5-10 methylene FH4 and N10 formyl FH4 
respectively, (Chabner and Young, 1973). Concentrations of 107M MTX or 
greater will be sufficient to block both of these reactions and the consequence 
of inhibition of either reaction results in cessation of DNA synthesis. In order 
to ensure that MTX works most effectively to halt the reduction of FH2, it is 
imperative that an excess of MTX is present to combat the competition for 
substrate that will inevitably ensue as the intracellular level of FH2 rises. 
Levels of MTX in excess of DHFR must also be present to ensure inhibition 
of enzyme activity (Bertino, 1975, Jolivet et al., 1983).
1.4.4. Metabolism of MTX.
Methotrexate is metabolised to (i) polyglutamates, (ii) 7-hydroxy- 
methotrexate (7-OH-MTX) and (iii) 4-amino-4-deoxy-N10-methylpteroic acid 
(DAMPA).
Intracellularly MTX is comprehensively catabolised to polyglutamate 
derivatives (Jolivet et al., 1983) and the consequences of this are as follows:
1. MTX polyglutamates accumulate to a higher equilibrium state with 
extracellular drug than does the parent compound.
2. MTX polyglutamates have either an equal if not higher affinity for DFLFR 
than free MTX and they appear to dissociate less readily which implies a 
lower threshold of inhibition.
3. The intracellular retention time of polyglutamates increases with chain 
length, however, it is independent of the extracellular concentration of MTX.
4. The cytotoxicity of MTX can be augmented by the chemical addition of 
glutamyl residues which in turn extend the inhibitory enzymatic effects to 
include not only DHFR but also thymidylate synthetase (Szeto et al., 1979)
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and aminoimidazolecarboxamide ribonucleotide transformylase (Baggott, 
1983).
The biotransformation from MTX to 7-OH-MTX may be mediated via 
hepatic parenchymal cells. 7-OH-MTX effects MTX by competing with MTX 
for uptake however it has one hundred fold less activity than MTX to inhibit 
DHFR. Due to its high level of insolubility in aqueous solution it has been 
implicated as a possible mediator of potentially fatal renal failure in high dose 
MTX (HD-MTX) therapy. The advantage of 7-OH-MTX is that the 
polyglutamyl derivatives formed are retained longer intracellularly than 7- 
OH-MTX and bind tightly to DHFR (Lankelma et al., 1978, Bremnes et al., 
1989, Fahrig et al., 1989).
DAMPA exhibits two hundred fold less activity than MTX in inhibiting 
DHFR and its biological importance is thought to be minimal (Jolivet et al., 
1983).
1.4.5. Elimination of MTX.
The elimination of MTX is biphasic, bile is the major excretory route for 
MTX (50%) and 7-OH-MTX (3.6%) (Bremnes et al., 1989).
Plasma disappearance of MTX occurs in 3 phases:
1. Initial elimination due to distribution of MTX into tissues and also into bile 
and urine.
2. Drug elimination via biliary and renal excretion (postulated enterohepatic 
cycling of the drug).
3. Intracellular confinement of MTX as polyglutamates and strong binding to 
target enzymes.
Elimination of 7-OH-MTX favours elimination in the bile due to the fact that 
it is less water soluble and more lipophilic than MTX (Fahrig et al., 1989).
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1.4.6. Methotrexate Resistance.
MTX resistance can occur in many ways including a reduction in affinity of 
DHFR for MTX, increased levels of DHFR due to gene amplification of 
DHFR synthesis, decreased membrane transport of MTX, decreased 
formation of MTX polyglutamates and varying rates of thymidylate synthesis.
1.4.6.1. Reduced affinity o f DHFR fo r  MTX:
This mechanism of resistance may occur naturally or may be brought about 
by the chemical modification of DHFR by mutation of eight amino acids at 
positions pertinent to the hydrogen bonding or hydrophobic interactions with 
MTX (Thillet et al., 1988).
1.4.6.2. Increased levels o f DHFR due to gene amplification:
Gene amplification may occur in situ (Juraskova, 1988) and this mechanism 
of resistance is investigated by Assaraf and Schimke, (1987) using 
fluoresceinated MTX and flow cytometry to identify MTX transport 
deficiency. In terms of its toxicity towards oxygenated or hypoxic tumour 
cells, MTX shows no preferential toxicity (Teicher et al., 1981). However 
rodent cell lines can develop resistance to MTX during hypoxic stress i.e. 0 2 
concentration <10 ppm for 24 hours prior to reoxygenation, (Sanna and 
Rofstad, 1994) and the mechanism of drug resistance is thought to be 
mediated via the amplification of the DHFR gene (Rice et al., 1987) although 
this was not confirmed by other studies (Wilson et al., 1989, Sakata et al., 
1991, Kalra et al., 1993).
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1.4.6.3. Decreased membrane transport o f  M TX:
This may occur in cases where the active uptake system has been affected and 
there is a reduction in the affinity of the carrier for MTX, (Zager et al., 1973, 
Hill et al., 1979, Underhill and Flintoff, 1989). The transport kinetics of MTX 
satisfy the criteria of the carrier model and maintains, at least in part, the same 
transport mechanism as folic and folinic acid. The elucidation of these 
transport characteristics may help to clarify the nature of transport defects 
which have been noted in several lines of malignant cells, (Goldman et al., 
1968)
1.4.6.4. Decreased formation o f M TX polyglutamates:
Although it is clear that polyglutamation allows enhanced accumulation of 
free MTX and extends drug action in addition to promoting inhibition of more 
enzymes, the evidence that decreased polyglutamation accounts for resistance 
is still preliminary (Jolivet et al., 1983). This mechanism of resistance is not 
well characterised biochemically but was reported for a human breast cancer 
cell line (Cowan and Jolivet, 1983).
1.4.6.5. Altered rates o f  thymidylate synthesis:
The lower the rate of thymidylate synthesis the less susceptible a cell line will 
be to MTX because the rate of synthesis is an important determining factor of 
MTX cytotoxicity, (Moran et al., 1979, Haber et al., 1993).
1.4.7. Degradation of MTX.
In the pH region of 7 there seems to be a first order rate constant and the 
minimum degradation rate was observed at pH 6.6-8.2 . Hansen et al., (1983) 
obtained a pH rate profile from first order kinetic plots and demonstrated a
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maximum stability of MTX in aqueous solution at pH 7. In the pH range of 7- 
7.5 the rate of degradation was 0.04 d ay s1 but at pH >6.5, N 10-methyl-folic 
acid was the only degradation product formed (Hansen et a l ,  1983).
1.4.8. "Rescue” of cells after MTX administration:
There are many ways in which cells may be "rescued" after administration of 
MTX:
(i) Delivery of the drug to the cell may be decreased by hydrolysis of the 
extracellular drug (carboxypeptidase G l) or by physical means (charcoal 
absorption), (ii) increase in cellular dihydrofolate concentration (sufficient to 
displace MTX), (iii) administration of hypoxanthine and thymidine, (Moran et 
al., 1979), (iv) indirect rescue could be mediated via the use of protein 
synthesis inhibitors e.g. asparaginase. Normal cells can increase their 
production of protein but tumour cells cannot, and therefore experience the 
synergistic effects of the sequential combination. The most well known 
method of rescue however is, (v) folinic acid (citrovorum factor). Schoenback 
et al., (1950) first reported on the reversal of MTX and aminopterin toxicity 
by folinic acid. The exact mechanism of action is unclear although it may be 
mediated by one of the following mechanisms (a) competitive inhibition of 
entry of MTX in to the cell (b) decreased polyglutamation of MTX arising 
from competition at the level of folylpolyglutamate synthase and /  or (c) 
provision of reduced folate cofactors thereby preventing the blockage of 
tetrahydrofolate synthesis within the cells. The administration of folinic acid 
has also been studied to gain the most effective regimen for patients on high 
dose MTX therapy or with compromised renal function. Although many 
differences have been observed between the in vitro and in vivo treatment
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regimens, these were minimised as much as possible by Bernard et al., (1991) 
who examined the effects of folinic acid (FA) on MTX.
An inverse relationship was noted between the degree of MTX cytotoxicity 
reversal and duration of time interval between MTX and FA administration. 
Between 18 and 24 hours after MTX administration, FA could still effectively 
act to decrease the cytotoxic effects however at time intervals greater than 
this, FA was not able to do so. By decreasing the time interval, MTX 
cytotoxicity was partially or even totally reversed by FA. This was however 
dependent on the cell line tested and the ratio of FA:MTX, (Bernard et al.,
1991).
1.4.9. Side effects of MTX.
The side effects of MTX relate to the fact that MTX inhibits the growth of all 
rapidly dividing tissue. The side effects most notably associated with MTX 
therapy include: leukopenia, thrombocytopenia and reticulocytopenia,
(Condit, 1971). All replicating forms in the bone marrow are affected and 
although recovery follows in the next few days, this may adversely affect 
patients who have a folate deficiency or impaired marrow function.
The toxicity of MTX may also be enhanced by impaired renal function and 
the presence of compromised kidney function is a major indication for the use 
of citrovorum factor rescue (Bleyer, 1981, Bertino, 1975), although fever has 
also been reported with high dose MTX therapy even in the presence of 
citrovorum factor (Gottlieb et al., 1970).
Moderate doses of MTX may result in mucositis but the degree of this is due 
to both the dose and duration of drug administration (Jolivet et al., 1983).
High dose (HD) MTX therapy has definite antitumour activity in various 
types of leukaemia e.g. osteosarcoma, non-Hodgkin's lymphoma, in
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adenocarcinoma of the head and neck and in small cell lung cancer, (Frei et 
al., 1980). HD MTX therapy i.e. 1-30 g/m2, duration of infusion (range 6-42 
hours), and frequency of administration (range weekly to every 3 to 4 weeks) 
in the presence of leucovorin rescue, is usually well tolerated although 
toxicity varies with the pretreatment characteristics of the patient and dosage 
regimen used (Hryniuk and Bertino, 1969).
For each target tissue there is a critical minimum extracellular level 
(concentration threshold) and a critical minimum duration of exposure (time 
threshold), both of which must be exceeded for toxicity to occur. The severity 
of toxicity is directly proportional to the duration of MTX exposure beyond 
the time threshold and relatively less dependent on the magnitude of MTX 
elevation above the extracellular concentration threshold, (Balis et al., 1983). 
Nausea, anorexia, vomiting and occasionally diarrhoea may also follow MTX 
administration especially if high doses are given (1-5 mg/kg), (Bertino, 1975). 
Toxic doses may lead to gastrointestinal ulceration and bleeding. The 
occurrence of skin rashes is common in 10-20% of patients and varies in 
severity from a pruritic type rash to vasculitis and widespread herpetiform 
skin eruption, (Bertino, 1975). Hair loss may occur in 5-10% of patients 
especially older patients. The two types of liver damage associated with the 
administration of large doses and long duration of MTX are: (i) a reversible 
transient toxicity and (ii) hepatic fibrosis, respectively, (Bertino, 1975, Jolivet 
et al., 1983). Left upper quadrant pain, postulated by Hryniuk and Bertino 
(1969) to be due to splenic capsule inflammation has been reported in 
leukaemic patients treated with large doses of MTX. Unexpected side effects 
may be due to the binding of MTX to melanosomes (Wilczok et al., 1990). 
Finally MTX is known to be a potent abortifacient especially in the first 
trimester. It has also been reported to impair spermatogenesis, although this
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returned to normal after therapy, (Jolivet et al., 1983) and may be mutagenic 
(Bertino, 1975).
1.4.10. Augmentation of MTX cytotoxicity:
Goldman et a l ,  (1968) discovered that sodium azide and iodoacetate 
prevented efflux of MTX from cells and therefore enhanced its toxicity. 
Vincristine increases the intracellular levels of MTX (Zager et al., 1973) and 
is used in combination therapy. While depletion of thymidine and 
hypoxanthine, in tissue culture, from the medium prevents tumour cells from 
salvaging them and hence contributes to toxicity (Haber et al., 1993).
1.5. Targeting of MTX:
Methotrexate exhibits many limitations in terms of (i) toxicity, (ii) resistance,
(iii) metabolism, (iv) limited access to sites in the body, (v) short half life and 
(vi) large volume of distribution.
To overcome these problems a structural analogue of MTX e.g. trimetrexate, 
has been used either to overcome MTX resistance (Romanini et al., 1989) 
and also in combination with 5,10-dideazatetrahydrofolate (DDATHF) and 
10-propargyl-5,8-dideazafolate (PDDF) to exert synergistic effects (Gaumont 
et al., 1992). The other solution to circumvent some of the intrinsic problems 
associated with the use of MTX involves structural variations on the basically 
efficacious molecule for example the chemical conjugation to: antibodies, 
high molecular weight dextrans, bovine serum albumin and hormones which 
has formed the basis for reviews by Sezaki and Hashida (1984) and Sinko et 
al., (1987).
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1.5.1. Antibody linkage to MTX:
Many different studies have been performed on the effects of conjugating, 
directly or indirectly, MTX to antibodies raised against a particular target 
antigen expressed by the cells in question, (Ghose and Blair, 1978, Garnett et 
al., 1983, Kawashima et al., 1994, Endo et al., 1987, Endo et al., 1988, 
Hudecz et al., 1993).
MTX has been seen as a suitable candidate for conjugation with antitumour 
antibodies because the time dependent nature of its cytotoxic activity may be 
compatible with the slow kinetics at the tumour site of the i.v. administered 
antibodies (Halpem et al., 1983).
1.5.1.1. Direct linkage o f MTX to monoclonal antibodies:
In the direct conjugation of MTX to monoclonal antibodies of a mouse 
mammary tumour (MM46), Endo et al., (1988) found that the active ester 
reacts not only with the amino groups but also with carboxyl groups to give 
conjugates with varying bond stability. These differences in bond stability 
have lead to subsequent differences in the uptake systems for the conjugates. 
The amide bond-linked MTX is taken up by the cells via endocytic 
internalisation whereas the more unstable bond (ester-linked) tends to release 
the MTX extracellularly and hence this MTX enters via the active uptake 
pathway. The latter mechanism contributes to the non-specific cytotoxicity of 
the IgG-MTX conjugates. Treatment with hydroxylamine decreases the 
cytotoxicity of aMM46-MTX conjugate by one sixth of the untreated 
conjugate, due to its effect of the extracellularly released MTX. It would be 
expected that free MTX reaches the cytosol more efficiently than conjugated 
MTX whose entry depends on many factors including: (i) efficiency of 
antigen-mediated endocytosis, (ii) lysosomal digestion of IgG-MTX and (iii)
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the permeability of the lysosomal membrane to digested IgG-MTX molecules. 
Those results suggest that an oligopeptide spacer between the antibody and 
MTX would enhance the activity of the conjugates.
1.5.1.2. Indirect linkage o f MTX to monoclonal antibodies:
Due to the fact that there are only a small number of functional groups 
available per antibody molecule which may be successfully used for chemical 
coupling, without significant loss of antibody-binding activity, carrier 
molecules have become very popular, (Garnett et al., 1983). Indirect 
conjugation of drug to antibody i.e. by use of a carrier may help to overcome 
the limitations in number of drug molecules capable of direct attachment to 
the antibody. Human serum albumin (HSA), is commonly used as a carrier as 
it is relatively stable in aqueous media and has a large number of amino 
groups in addition to a single thiol group which makes it a good choice (the 
latter characteristic is important as it allows only single antibody binding), 
(Sezaki and Hashida, 1984).
Work has been done by Garnett et al., (1983) using the carrier-linked MTX 
(MTX-HSA) chemically coupled to a monoclonal antibody raised against 
human osteogenic sarcoma cell line, 79IT. Although this drug-carrier- 
antibody conjugate resulted in some specificity against antibody reactive cell 
lines and also toxicity which was equipotent to free MTX, it was still 
necessary to investigate whether: (i) the in vitro results were representative of 
an in vivo situation and (ii) the uptake and subsequent mechanism of action of 
the conjugate was similar or dissimilar to that of the free MTX.
To mimic the in vivo situation, both (MTX32-HSA)1.3-791T/36 and MTX 
were incubated with 79 IT cells for 15 minutes before removal of unbound 
material and subsequent assessment of cytotoxicity. This brief exposure was
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devised to represent the action in the vascular system, and the results showed 
a higher degree of cytotoxicity of the (MTX32-HSA)1.3-791T/36 over the free 
MTX. By competition binding of the (MTX32-HSA)1.3-791T/36, in the 
presence of free antibody, with antibody sensitive and antibody-insensitive 
cells, it was shown that the cytotoxic actions of the conjugate were reduced in 
the former but not in the latter. This demonstrated that antibody binding was 
crucial for selective cytotoxicity.
Further studies on (MTX32-HSA)1.3-791T/36, (Garnett et al., 1985) were 
performed to examine the mechanism of action of (MTX32-HSA)j.3-791T/36 
in comparison to that of free MTX. Results showed that folinic acid exerted 
inhibitory effects on the cytotoxic actions of the (MTX32-HSA)1.3-791T/36 
which was greater than the inhibitory effects on MTX but nonetheless may 
imply a similar route of entry to MTX. The assumption is that this occurs by 
the cleavage of MTX from HSA in the lysosomes which, once released 
extracellularly may enter the cell via the folic acid pathway followed by 
MTX. Another hypothesis based on the effects of the lysomotropic agents, 
NH4G , in inhibiting the (MTX32-HSA)j.3-791T/36 proposes that the 
conjugate may be endocytosed and further to this, found in an acidic 
intracellular compartment.
The degradation products of tritosomal digestion of this (MTX32-HSA)j_3- 
791T/36 have also been the source of extensive studies by Fitzpatrick, 
(1994). Four derivatives were found by HPLC analysis and were identified as 
tritosomes, MTX-Lys (a-e), MTX-Lys(e-a) and free MTX. The total release 
of MTX in any form corresponded to 5.6% of the input conjugated MTX and 
only 9.9% of this released material was underivatised MTX. This result was 
surprising in that such a low level of drug release could be associated with a 
conjugate that is more cytotoxic than MTX alone, against the target cell line.
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The conclusion of this study was that in addition to a carrier molecule, it 
would be advantageous to also include a spacer, so the final conjugate is: 
drug-spacer-carrier-antibody. This spacer would ensure that upon digestion by 
lysosomal enzymes, free MTX is efficiently released.
Results of Whiteley et al., (1981) suggest that carrier bound drugs do have 
altered properties from those exhibited by the free entity, however they do not 
necessarily lead to enhanced drug action in a particular host. MTX-BSA is 
retained for longer period in vivo but in vitro results suggest lower uptake of 
the carrier bound drug. Covalent binding and subsequent injection of MTX to 
BSA, MSA, bovine IgG, chymotrypsinogen and various molecular weight 
dextrans result in higher and more prolonged serum concentrations in addition 
to decreased rate of excretion of MTX compared to free drug. It is thought 
that the response to carrier bound MTX may be caused by altered 
pharmacokinetics but also indicates that carriers play more than a passive role. 
MTX and MTX-BSA are taken up via different transmembrane transport 
mechanisms (Chu et aL, 1981) in vitro the entry of carrier-bound entities is 
thought to be via pinocytosis (DeDuve et al., 1974) and this may be one way 
to overcome resistance in affected cell lines. This is also true of poly-L-lysine 
conjugated to MTX which was taken up into Chinese Hamster cells resistant 
to free MTX, due to transport deficiency, (Shen and Ryser, 1979).
I.5.I.3. Bispecific monoclonal antibody:
A more advanced conjugation involves a bispecific monoclonal antibody 
against both MTX and a human tumour associated antigen (Pimm et al., 
1990). This double pronged attack on the tumour specifically enhanced the in 
vitro cytotoxicity of MTX-HSA for gp72 positive tumour cells. The ratio of
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MTXiHSA was also of the order 40:1 which was an improvement on the 
direct linkage to the antibody.
1,5.2. Disadvantages of drug-antibody targeting.
Monoclonal antibody-mediated targeting is the most versatile and general 
modality of drug delivery at present according to Basu (1990). However 
cytotoxic moieties conjugated to such antibodies should be delivered 
specifically to the selected cell type. Although MAb can direct 
immunoconjugates with a high degree of selectivity to target cells there are 
still limitations due to:
(i) the number of cell surface antigens
(ii) the number of drug molecules attachable to the antibody
(iii) poor efficiency of internalisation of conjugates, leading to:
(iv) reduced accumulation of pharmacologically effective intracellular 
concentrations of the drug
(v) cross reactivity with non-target cells.
(vi) potential immunogenicity in vivo
Differences which exist between the in vitro and in vivo results of monoclonal 
antibody (MAb) data may be due to the fact that tissue culture cells are in 
exponential growth and any cell line that differentially expresses a measured 
antigen during this growth phase would demonstrate altered Mab binding. 
Another possible source of discrepancy between the in vitro and in vivo data 
may arise as a result of the altered stability of radiolabels in vivo,n iIn versus 
125I, (Halpern et al., 1983). Hudecz et al., (1993) concluded that MTX 
immunoconjugates produced less impressive responses in vitro and in vivo 
than similar conjugates of doxorubicin, daunomycin or mitomycin C, due to 
influences of the carrier on the biodistribution of MTX-branched polypeptide
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conjugates (Hudecz et al., 1992). The covalent attachment of MTX to 
branched polypeptides results in reduction of in vitro cytotoxicity and this is 
attributed not to the relative size of the carrier nor the amino acid sequence 
but to the identity of the terminal amino acid. However the incorporation of 
glutamic acid in to the side chain did significantly prolong the blood clearance 
of MTX-branched polypeptides, (Hudecz et al., 1993).
1.6. Aims and Objectives.
The main obstacle to be overcome in the treatment of cancer is the fact that 
cancerous cells exhibit few or no differences from normal tissues to provide a 
basis for selective toxicity and as a result side effects frustrate effective 
therapy. The aim of this study is to minimise the arbitrary side effects 
associated with the drug of choice i.e. methotrexate (MTX) by conjugating it 
to an analogue of the naturally occurring hormone a-M SH, namely, [Nle4,D- 
Phe7]a-MSH. Therefore the disadvantages associated with the folic acid 
uptake pathway of MTX leading to a general distribution of MTX throughout 
the body, may be surmounted by use of receptor-mediated drug delivery i.e. 
using the natural uptake pathway of the hormone. In theory the [Nle4,D-Phe7] 
a-M SH will localise the MTX to a melanoma cell specific receptor, and once 
bound, the receptor-ligand complex will be internalised. Although MTX is not 
usually associated with the treatment of melanoma cancer, it is the model drug 
used in this study due to its small size, (FW: 454), relative to [Nle4,D-Phe7]a- 
MSH (FW:1648) which minimises any size /  conformational difficulties at the 
receptor site, and ease of chemical attachment of the analogue [Nle4,D-Phe7]a  
-MSH, forming N“MTX-[Nle4,D-Phe7]a-MSH.
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To effectively employ this method of drug delivery a detailed knowledge of
(i) the nature of the ligand, (ii) relative distribution of the receptor on various 
cell types and (iii) the intracellular pathway followed by the receptor-ligand 
complexes is necessary. To this end, many binding and internalisation studies 
were undertaken to elucidate the pathways taken by [Nle4,D-Phe7]a-M SH and 
N“MTX-[Nle4,D-Phe7]a-MSH.
Most importantly the growth inhibitory effects of MTX and NaMTX-[Nle4,D- 
Phe7]a-M SH in a variety of cells lines were examined to see whether the 
N“MTX-[Nle4,D-Phe7]a-M SH had an improved level of efficiency. The 
effects of [Nle4,D-Phe7]a-MSH, and lysosomal degrading agents; (monensin 
and chloroquine) were also examined.
A number of cell lines were employed; B16 murine melanoma cells gave rise 
to much of the experimental work and results. It is a cell line that has been 
used extensively in our laboratories and hence many of its characteristics have 
already been the subject of other studies, (Richards, 1992, Erskine-Grout, 
1993, Adams, 1993, Sahm, 1994). MeWo human melanoma cells were also 
used as a comparative melanoma cell line although it was known that human 
melanoma cells do not possess nearly as many MSH receptors on their cell 
surface. SVK14 keratinocytes were employed specifically because they 
possess few, if any, MSH receptors on their surface and hence would be a 
valid control in the study of any site specific actions attributed to N“MTX- 
[Nle4,D-Phe7]a-M SH. 293 cells transformed with the gene encoding the MC3 
receptor were used to test if the actions of NaMTX-[Nle4,D-Phe7]a-M SH 
were associated specifically with the MCI receptor i.e. B16 and MeWo cells 
or if the effects were also equally prominent in cells expressing the MC3 
receptors. This would have serious repercussions on the usefulness of 
NaMTX-[Nle4,D-Phe7]a-MSH since MC3 receptors are located in the gut,
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placenta but also in the brain and CNS side-effects would be 
counterproductive to the aim of this study. 293 cells transformed with the 
pcDNA neo vector alone, were used to elucidate whether the process of 
transfection in any way enhanced the cells susceptibility to N“MTX-[Nle4,D- 





Although the majority of the work presented utilises the B16 murine 
melanoma cell line, other work was performed on human-derived cell lines 
listed below.
All cells were propagated in RPMI-1640 medium with the exception of the 
293 cell lines which had a 1ml supplement of fungizone (250p.g/ml) to the 
medium.
CELL LINE OBTAINED FROM: GROW N IN:
B16 L.Kelland. I.C.R. Sutton RPMI-FCS
293 (vector only) R.Cone.Vollum Inst. Oregon. RPMI-FCS
293(vector with encoded 
gene for MC3 receptor)
R.Cone. Vollum Inst. Oregon. RPMI-FCS
(fungizone)
MeWo L.Seymour. University of Keele. RPMI-FCS
SVK14 J.Taylor. I.C.R.F. RPMI-FCS
2.2. Solutions:
Water:
The water employed in the preparation of media and solutions was freshly 
double glass distilled by a bi-distillation Fistreem Still (Fisons Ltd.) fitted with 
a Fistreem predioniser (Fisons Ltd.).
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Balanced Salt Solution:
Phosphate buffered saline (PBS) (without calcium and magnesium) was 
obtained from Oxoid Ltd. in tablet form. Ten tablets were dissolved in 1L of 
freshly double distilled water and then distributed in to 100ml bottles which 
were then sterilised and stored at 4°C.
Ethvlenediaminetetraacetic Acid (EDTAk
A 0.02% w/v EDTA solution was prepared by dissolution in sterile PBS. Once 
dissolved the solution was passed through a 0.2|im diameter filter (Sartorius 
Ltd.) and 20ml aliquots were pipetted into sterile universals (Sterilin Ltd.). 
These were then kept frozen at -20°C until required.
Base Solutions:
Sodium bicarbonate (7.5% w/v) and sodium hydroxide (2M), both from BDH 
Chemicals were prepared with double distilled water, sterilised and stored at 
room temperature.
Trvpan Blue:
Trypan blue stain was obtained from Sigma Ltd. and was stored as a 0.1% 
solution (in PBS) at room temperature.
2.3. Growth Media and Constituents:
RPMI 1640 (Flow Laboratories) was obtained as lOx liquid concentrate 
containing phenol red indicator but deficient in L-glutamine and sodium 
bicarbonate.
Supplements to the medium included L-glutamine (200mM), an antibiotic 
solution (pen/strep) of penicillin (5000IU/ml) and streptomycin (5000jig/ml), 
fungizone, (amphotericin B 250qg/ml) and non-essential amino acids (NEAA) 
which were all obtained from Gibco Laboratories.
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Storage:
Growth medium and NEAA were refrigerated at 4°C, while L-glutamine and 
pen/strep were frozen at -20°C.
Foetal Calf Serum (FCS):
FCS from Flow Laboratories was batch-tested for the support of cell growth 
and was supplemented at 10%v/v to normal growth medium. Batch No: 10835 
was used for all experiments. Serum arrived in 500ml glass bottles and was 
stored at -20°C prior to usage.
All cell growth media were aseptically prepared from sterile components 
according to the following formulae. Media were then stored at 4°C and what 
remained unused after two weeks was discarded.
RPMI-FCS





N aH C 03 (7.5% w/v) 13.5ml
FCS 55.6ml
All media required the addition of a small volume (approx. 1ml) of sterile 1M 
NaOH (BDH Chemicals) in order to achieve a final pH of 7.2-7.4. 
Autoclave-labile solutions were sterilised in small volumes by membrane 
filtration using sterile 0.2pm filters from Sartorius Filters. All other solutions 
were sterilised in an autoclave (British Sterilizer Co. Ltd., Swingclave Type 
SFT-LAB) at 121°C for 15 minutes.
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2.4. EQUIPMENT:
All cells were stored in 2ml ampoules and shelved in the vapour phase of a 
Union Carbide LR-40 liquid nitrogen store at approximately -148°C.
Sterile tissue culture flasks (25, 75, 175cm2) were purchased from Falcon 
Laboratories. Tissue culture tubes (100 x 16mm) were obtained from Sterilin 
Ltd. Polypropylene 2ml ampoules with screw caps, used for the storage of cells 
at -148°C were obtained from Corning Laboratories.
All sterile operations involving the cells were performed in a vertical 
recirculating laminar flow cabinet (MDH Ltd.). Protocols which did not 
require sterility were performed at the laboratory bench.
An inverted biological microscope WILD M40 (Wild Heerbrugg Ltd.) was 
used for the observation of growing cell cultures and the haemocytometer 
counting of cells.
The cultures were incubated in a LEEC PF2 anhydric incubator (Laboratory 
and Engineering Company) with forced air circulation and adjusted 
thermostatic controls which gave a constant temperature of 37°C. The 
consistency of temperature was checked regularly with a digital thermometer 
which had a thermocouple probe (Jenway Ltd.).
2.4.1. Preparation of Glassware:
Glassware was soaked in a 2% solution of RBS25 (Fisons Ltd.) at 
approximately 40°C for 30 minutes. After three rinsings in single distilled 
water it was left to stand in double distilled water for no longer than one hour. 
The glassware was then air-dried and sterilised by dry heat at 160°C 
(Gallenkamp Sterilising Oven) for a minimum of one hour.
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Non-glass items; e.g. pipette tips, were treated in a similar manner but after 
drying they were autoclave sterilised (Drayton Castle Laboratory Steriliser) at 
121°C for 15 minutes.
2.5. Subculture of cell lines:
Although the time taken for different cell lines to reach confluency varied, the 
cells were all subcultured once this confluent state was deemed to have been 
attained. This was defined as when the entire lower surface of the culture flask 
was covered by cells and also further growth was restricted by contact 
inhibition and the depletion of available nutrients in the media (this was 
optically observed by the colour change of media to yellow).
Initially the culture was examined visually in order to confirm the healthy 
appearance of the cells and the absence of any free-floating cellular debris or 
other signs of contamination.
At the laminar flow cabinet, the old medium was decanted off and the cells 
were washed twice with 5ml aliquots of PBS. The flask was gently agitated in 
order to ensure the cell monolayer was completely rinsed during each wash. 
2ml of 0.025% EDTA was then introduced to the flask and it was placed in the 
incubator for 10 minutes.
Upon removal the flask was shaken to encourage dislodgement of the cells 
before the addition of 5ml of fresh media.
Using a sterile, plugged Pasteur pipette, the cell suspension was aspirated and 
transferred to a sterile test tube so that cell density could be determined prior to 
the inoculation of a new passage of cells. A constant seeding density of 1 x 106 
cells per 175cm2 flask was used in the presence of 45ml of fresh media. The 
cells were gassed for 25 seconds with a mixture of 5% C 0 2 / 95% air and 
incubated at 37°C.
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2.6. Freezing of cells and cell storage:
In order to ensure adequate stocks of cells, cells were routinely frozen. Once 
they had reached confluence, the cells were detached (as previously described) 
and the suspension placed in a centrifuge (Jouan B3-11 Bench centrifuge) at 
1000 x g for 10 minutes.
The supernatant was then decanted leaving the cell pellet, which was then 
resuspended in filter sterilised RPMI-FCS which contained 10% DMSO 
(cryoprotectant). Replicate volumes of 1.5ml were pipetted in to polypropylene 
ampoules (J.Bibby Sciences) and then placed in to a liquid nitrogen store. Here 
the cells cooled to below -70°C in the vapour of the liquid nitrogen at a rate of 
1°C per minute. Once the cells were uniformly frozen, they were transferred to 
a liquid nitrogen freezer (Union Carbide LR-40) for long term storage.
2.7. Recovery of cells from storage:
Once removed from the nitrogen store, an ampoule was placed in pre-warmed 
(37°C) water in an incubator and allowed to thaw rapidly for 2-3 minutes. The 
contents of the ampoule were then aseptically transferred to a sterile tube 
containing 9ml of fresh medium. This was then centrifuged at 1000 x g for 10 
minutes, after which the supernatant was removed and the cells resuspended in 
3ml of growth medium. Finally the contents were poured into a new 175cm2 
flask containing 45ml of growth medium and gassed and incubated in the 
normal manner.
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2.8. Counting of Cells:
1. Cells were detached and 0.4ml of the cell suspension was transferred 
to a sterile test tube.
2. 0.1ml of 0.1% Trypan blue dye solution was added and mixed 
thoroughly.
3. Using a Pasteur pipette, a small amount of the mixture was loaded
onto a grid haemocytometer and the number of viable cells in the four
corners and the central square were counted.
Trypan blue dye is excluded from cells which have an intact cell 
membrane i.e. are viable.
4. The number of cells per ml was calculated using the following 
equation:
viable cells per ml= (total cells in all 5 chambers! x 104
4
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2.9. PEPTIDE SYNTHESIS :
2.9.1. Synthesis of [Nle4, DPhe7]a-M SH :
The synthesis of this peptide and the peptide derivative of methotrexate (MTX) 
was carried out by Dr. G.W.J. Olivier, however the main points of the methods 
used will be described.
Peptides were prepared by solid-phase using Fmoc strategy (Atherton and 
Sheppard, 1989). The carboxamide forms of the peptides were prepared using 
the AM-linker on Pepsin K resin. All the amino acid reagents were employed 
as their pentafluorophenyl esters with the exceptions of serine, where the 3,4- 
dihydro-4-oxobenzotriazin-3-yl ester was used, and Fmoc-D-Phe-OH, which 
was treated with DIC and HOBT to form its HOBT ester in situ.
Side chain protecting groups were as follows: Arginine;
methoxytrimethylbenzenesulphonyl (Mtr), Glutamic Acid; f-butoxy (OBut), 
Histidine; f-butoxycarbonyl (Boc), Lysine; (Boc), Serine; f-butyl (But), 
Tyrosine; (But). In each case a four fold molar excess of reagents was used. 
Deprotection and cleavage was effected by the use of 2% EDT, 2% anisole and 
1% water in TFA for 12 hours, at room temperature.
Peptide purification took place using semi-preparative HPLC with a gradient 
elution of 0.1% TFA in water and 0.1% TFA in acetonitrile water (70:30) at a 
flow rate of 3ml per minute.
The eluent was monitored by UV spectrophotometry at 217nm. Fractions were 
collected at 30 second intervals and checked by analytical scale HPLC. Peptide 
fractions containing the peptide were then pooled and freeze-dried. 
Confirmation of peptide purity was undertaken by co-chromatographic 
techniques with purchased [Nle4,D-Phe7]a-M SH (Sigma Chemical Co.), FAB- 
MS and MALDI-TOF MS: a-M SH M+H calculated; 1664.8, found 1664; 
[Nle4,D-Phe7]a-M SH, M+H calculated 1646.8, found 1647.
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Stock concentration of peptide (1 mg/ml) was made up in sterile 0.1 mM HC1 
and was stored at 4°C prior to usage.
2.9.2. Synthesis of Aa -MTX-[NIe4, DPhe7] a-MSH:
To prepare NaMTX-[Nle4,D-Phe7]a-M SH, F m o c - [ N l e 4, D - P h e 7] - a - M S H  on 
resin was deprotected, at the N terminus, using 20% piperidine in DMF. A 
mixture of MTX and diisopropylcarbodiimide (DIPCDI) in DMF were added 
to form the NaMTX-[Nle4,D-Phe7]a-M SH product. FAB-MS was used for 
confirmation of the identity. It is noteworthy that NaMTX-[Nle4,D-Phe7]a- 
MSH was expected to be a mixture of two products coupled to the a  or y 
carboxyl groups of the glutamate residue of MTX. Also racemisation at this 
glutamate residue occurred making the product a mixture of 4 compounds. 
HPLC suggested similar amounts of the 4 species.
2.10. Radio iodination of [Nle4,D-Phe7]-a-MSH:
[Nle4,D-Phe7]-a-M SH was iodinated at the tyrosine residue (position 2) using 
Chloramine T methods described by Eberle (1988). The preliminary 
purification was performed using a disposable extraction column. This product 
was further purified using reversed phase HPLC to allow separation of the 
monoiodinated and the di-iodinated compounds.
Solutions:
Solutions 1 to 4 were prepared as stock solutions and stored at 4°C, whereas 
solutions 5 to 8 were prepared on the day of the experiment.
1. 0.25M Na2H P04
2. 0.25M NaH2P 0 4
3. 1% TFA (Aldrich)
4. 50, 60, 80% methanol with 1 % TFA.
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5. 0.25M phosphate buffer (pH 7.4) From (1) and (2)
6. 0.25% BSA in 0.05M phosphate buffer (pH 7.4)
7. 1% Polypep (Sigma) in 0.05M phosphate buffer (pH 7.4)
8. 0.1% Chloramine T (BDH Chemicals Ltd.) in H20  (dissolved
immediately prior to use).
Preconditioning of the Column:
A C l8 reverse phase 'Bond Elut' column packed with Spherisorb ODS was 
prepared and conditioned in the following way;
3 x 1ml 1% TFA 
3 x 1ml 80% methanol /  1% TFA
1 x 1ml 1% Polypep (solution 7)
3 x lm l 80% methanol /  1% TFA
3 x lm l 1% TFA
Iodination Procedure:
1.5|il of stock [Nle4,D-Phe7]-a-M SH (1 mg/ml) was placed in an eppendorf to 
which 20jil of phosphate buffer was added. In the fume cupboard, 10|il of 
125INa (equivalent to 1.5mCi) was added to the peptide and finally lOfil of
0.1% Chloramine T initiated the reaction which was allowed to proceed for 30 
seconds, and then halted by the addition of 0.6ml of BSA.
The reaction mixture was then transferred to the column, which was then 
washed in the following way ( in order to remove any free Na125I ):
2 x lm l 0.25M phosphate buffer.
4 x lm l 50% methanol / 1% TFA.
2 x lm l 60% methanol / 1% TFA.




Once the methanolic fractions had been loaded, the chromatography was 
achieved using an exponential gradient as follows; the eluate was monitored at 
217nm.
TIME(mins) SOLVENT A (%) SOLVENT B (%) GRADIENT
0 95 5 Linear
5 95 5 Linear
50 40 60 Exponential
55 40 60 Exponential
60 95 5 Linear
where, A= 0.1 % TFA /  H20
B= 70% Acetonitrile, 0.1% TFA /  H20
lml fractions were collected every minute from 25 to 40 minutes after 
injection. Free [Nle4,D-Phe7] a-M SH was eluted first, followed by 
monoiodinated and finally di-iodinated peptide (see figure 2.1.). The 
radioactivity of the fractions was assessed by reading them on a gammacounter 
(LKB 1277 Gammamaster) and those fractions associated with the peak of the 
monoiodinated peptide were pooled and the activity of the final mixture 
counted.
The radiolabelled peptide was then stored in solution at -20°C for no longer 
than 3 weeks.
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Calculation o f Radiotracer Concentration:
Assumption:
Ratio of 125I : [Nle4,D-Phe7]-a-M SH, 1 : 1 .
1 matom 125I = 1 x 103 moles [125I-Tyr2]-[Nle4,D-Phe7]-a-M SH 
Specific Activity of carrier free Na 125I = 80.5 x 1012 Bq / matom 
1 mole [125I-Tyr2]-[Nle4,D-Phe7]-a-M SH = 80 x 1012 x 103 Bq
Since:
1 Bq = 1 disintegration per second 
1 Bq = 60 disintegrations per minute
the efficiency of the gammacounter was 70%
Therefore:
1 mole[125I-Tyr2]-[Nle4,D-Phe7]-a-M SH = 80.5 x 1012 x 103 x 60 x 70. cpm
100
= 3.38 x 1018 cpm.
No. of cpm equivalent to:
0.5ml of 1M 125I-[Nle4,D-Phe7]-a-MSH = 1.69 x 1015 cpm.
Therefore :
no. of cpm in a given sample = no. of moles of 125I-[Nle4,D-Phe7]a-M SH 
1.69 x 1015cpm
53
2.11.Radioiodination and purification of NaMTX-[Nle4,D-Phe7]a-MSH:
The procedure was performed according to the protocol of Richards (1992) 
and was identical to that previously described for [Nle4,D-Phe7]-a-M SH with 
the following exceptions;
(i) The volume of peptide solution employed was 5|il. (Stock solution 
1 mg/ml).
(ii) Reaction time with Chloramine T was 5 minutes.
(iii) Subsequent to the completion of the reaction the column was washed 
as indicated below;
2 x lm l 0.25M phosphate buffer.
2 x lm l 40% methanol /  1% TFA.
2 x lm l 50% methanol /  1% TFA.
2 x lml 60% methanol / 1% TFA.
Only the residue from the 60% methanolic washes were retained and purified 
(approx. 2ml).
(iv) UV detection of the unconjugated peptide took place at 217nm, 
however this was altered to 310nm for the conjugated peptide due to the 
presence of the MTX chromophore. (See figure 2.2.)
2.12. Degradation of N«MTX-[Nle4,D-Phe7]a-MSH:
3.05 x 105 B16 cells were seeded per 25cm2 tissue culture flasks. 10ml of 
RPMI-FCS containing 5 x 105M NaMTX-[Nle4,D-Phe7]a-M SH was added. 
The cells were gassed and placed in an incubator at 37°C. At various time 
intervals (24, 48 and 72 hours) a flask was removed and the medium decanted. 
The medium was then centrifuged and analysed by HPLC at 217 and 300nm 
using a linear gradient. A control flask which contained no N“MTX-[Nle4,D-
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Phe7]a-M SH was treated in a similar manner. The table below shows the 
gradient of the two solvents A and B used for the HPLC analysis and the time 
intervals.






where: A = 0.1 % TFA /  H20
B = 70% MeCN / 0.1 % TFA /  H2Q
2.13. RADIOLIGAND BINDING AND INTERNALISATION:
Materials:
Serum Free Medium (SFM):
This was prepared by the addition of 50ml RPMI-1640 to 13.5ml of NaHC03 
and purified water to 500ml.
HEPES: (7V-(2-hvdroxyethyD piperazine-N'-2-ethane sulphonic acid)
(lOx concentration):
6g HEPES was added to 100ml SFM and buffered to pH 7.2-7.4 using 1M 
NaOH.
Aliquots of 5ml were stored at -20°C.
Bovine Serum Albumin (BSAKlOx concentration):




This was prepared by the addition of 25mM HEPES and 0.2% BSA to serum 
free medium using the quantities indicated below:
5ml of HEPES, 5ml of BSA and SFM to 50ml.
Citric Acid Buffer:
A 0.1M Citric acid monohydrate buffer was employed consisting of 10.5lg  of 
citric acid, 2.72g of NaCl and 11.72ml of 1M NaOH which was then made up 
to a volume of 500ml with double distilled deionised water. This buffer had a 
pH of 2.5 which was sufficient for the removal of externally bound ligand 
from the surface of the cells (Adams, 1993). It was stored at 4°C and 
prepared monthly.
20mM NH±C\:
0.5345. of NH4C1 was made up to 500ml with SFM. This solution was 
prepared every four weeks and stored at 4°C.
2.13.1. Time Course Experiment:
This experiment was performed to ascertain the time necessary for a particular 
cell line to attain saturation binding with a specific ligand.
Protocol:
1. Cells were seeded at a density of 5 x 105 cells per well in 24 well 
plates, gassed and incubated in the normal way.
2. On removal from the incubator they were washed twice with SFM and 
allowed to cool to 4°C.
3. 0.5ml of binding buffer containing a fixed concentration (0.1 nM) of 
125I-[Nle4,D-Phe7]-a-M SH was added to the cells. Eight of the sixteen 
replicate wells also received an excess quantity (10'6M) of non- 
iodinated ligand in order to assess the non-specific binding.
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4. The cells were then re incubated on ice at 4°C.
5. At various time intervals (30, 60, 120, 240, 480 and 1440 min.) the
cells were removed and the residual peptide was removed by two
rinsings with SFM.
6. The cells were then lysed and removed by the addition of 0.5ml NaOH
(1M) and the radioactivity associated with the cells determined by 
reading on the gammacounter.
2.13.2. Binding Isotherm:
Using a method adapted from Siegrist et al. (1988), the binding assays were
carried out in accordance with those described by Erskine-Grout (1993).
Protocol:
1. Cells were seeded at a density of 5 x 105 cells per well in 24 well 
plates, gassed and incubated overnight in the normal manner.
2. On removal from the incubator they were washed twice with SFM and 
allowed to cool to 4°C.
3. 0.5ml of binding buffer containing varying concentrations of 125I- 
[Nle4,D-Phe7]-aM SH was added to the cells. Eight of the sixteen 
replicate wells also received an excess quantity (1 x 10'7M)of non 
radiolabelled ligand in order to assess the non-specific binding.
5. The cells were then reincubated at 4°C, on ice for 8 hours, after which 
the residual peptide was removed by two washings of ice-cold SFM.
6. After this the cells were lysed and removed by the addition of 0.5ml of 
1M NaOH. The radioactivity was then read on the gammacounter and 
the estimation of receptor number and the association constant was 
calculated using MINSQ non linear least square regression suitable for 
ligand binding analysis.
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2.13.3. Competitive Binding Assay:
Competition binding was observed using the same protocol as described for
the binding isotherms, however the binding buffer contained a fixed amount
of the radiolabelled peptide (usually 1 x 10-10M) and varying concentrations 
of the peptide to be tested in the range of 106 -1 0 12 M.
2.13.3.1. Equation used for Competition Binding Assay:
The equation below was used in order to ascertain the dissociation constants 
for the unlabelled conjugate versus the tracer;
cpm (test conc.) = ( (cpm max. - cpm min.) TAP + cpm min.
[A] + (KdA) ([B] /  KdB)
where:
cpm test = cpm bound at appropriate conc. of inhibitor
cpm max = maximum bound cpm
cpm min = minimum bound cpm (non-specific)
receptor specific cpm = cpm max- cpm min
[A] = concentration of radio tracer
[B] = concentration of unlabelled competitor 
(KdA) = dissociation constant of radio tracer
(KdB) = dissociation constant of radiolabelled competitor
The above equation was derived from the following considerations:
The relative % maximum binding of the tracer [A] is given by:
Fraction of maximum binding = (cpm test - cpm min')
(cpm max - cpm min)
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Non-linear regression analysis was used to estimate parameters from the data
using the equation above.
Fraction of maximum binding =_______fAl
[A] + (KdA )[B ]/K dB
2.13.4. Internalisation of NaMTX-[NIe4,D-Phe7]a-MSH by B16 cells:
(in the presence of20m M  NH4Cl)
1. 5 x 105 cells per well were seeded in 24 well plates, gassed and 
incubated overnight in RPMI-FCS at 37°C.
2. On removal from the incubator the plates were washed twice with 
SFM and then re incubated for 15 minutes at 37°C in SFM containing 
20mM NH4C1.
3. Plates were then inverted to remove the SFM and 1 x 10_10M 125I- 
N“MTX-[Nle4,D-Phe7]a-M SH in 0.5ml binding buffer (with NH4C1) 
was added to the cells. Eight of the sixteen replicate wells also had an 
excess (1 x 10’7M) of non-iodinated material in order to assess the 
non-specific binding.
4. The cells were again incubated at 37°C and removed at the following 
time intervals; 15, 30, 60, 90,120, 180 and 240 minutes.
5. At the end of the required time the binding buffer was discarded and 
half of the wells were subjected to an acid wash at 4°C for 5 minutes, 
after which all the plates were washed twice with ice cold SFM.
6. The cells were then lysed by the addition of 0.5ml 1M NaOH and the 
contents of each well assayed for activity on the gammacounter.
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2.13.5. Pulse Chase Internalisation of N“MTX-[Nle4,D-Phe7]a-M SH  :
1. Cells (5 x 105 per well) were seeded in 24 well plates, gassed and 
incubated overnight at 37°C.
2. The following day the plates were washed twice with SFM, and then
0.5ml binding buffer containing 1 x 10_10M NaMTX-[125I Tyr2,Nle4,D- 
Phe7]a-M SH was placed on the cells which were then incubated at 
4°C for 2 hours.
3. The radioactivity was then washed off with SFM and the plates were 
incubated at 37°C for various time points; 15, 30, 60, 90, 150 and 240 
minutes.
4. After each time period half of the wells were treated with an acid wash 
at 4°C for 5 minutes and then all the cells were washed twice with 
SFM.
5. The cells were then digested with 0.5ml of 1M NaOH and the 
radioactivity present in each well read on the gammacounter.
2.13.6. Pulse Chase Internalisation of NaMTX-[NIe4,D-Phe7]a-M SH  in 
the presence of NH4CI:
The protocol was exactly the same as for the previous internalisation however 
the cells were treated with SFM containing NH4C1 (20mM) for 15 minutes at 
37°C prior to the addition of the radiolabelled peptide. Subsequent washings 
were all done with SFM that contained NH4C1.
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2.14. Growth Inhibitory Effects of MTX and NaMTX-[Nle4,D-Phe7]a- 
MSH as assessed by the MTT Assay:
Methotrexate (MTX'): [(+) Amethopterin] (4-amino-10-methylfolic acid)
FW: 454.4 C20H22N8O5
Initially this was obtained in powder form from Sigma Chemical Co. and 
dissolved in a mixture of PBS: NaOH (0.1M) 90:10 however as the NaOH 
interfered with the cells, for the assays described, the MTX was purchased 
from Lederle Laboratories as a single sterile vial containing 50mg Na2MTX / 
2ml (pH 8.5). Routinely made to 1.1 x 102M with sterile RPMI-FCS (from 






('3-r4.5-dimethvlthiazol-2-vll-2.5 diphenvltetrazolium bromide): Thiazolvl 
Blue (MTT):
FW: 414.3 C18H 16N5SBr
This was obtained as lg  powder (Sigma Chemical Co.) and was dissolved in 
PBS and then sterile filtered to achieve a stock concentration of lOmg/ml.
n-r4.5-dimethvlthiazol-2-vll-3.5-diphenvlformazan (MTT Formazanl:
FW: 335.4 C 18H 17N5S
Obtained lg  powder from Sigma Chemical Co. and made up in 




This was purchased in 1 litre volumes from Aldrich Chemicals.
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After preliminary experiments to ascertain the optimum conditions for the
assay, the following protocol was routinely observed:
Protocol:
1. Serial dilutions of MTX or NaMTX-[Nle4,D-Phe7] were prepared 
using RPMI-FCS as a diluent, from 1.1 x 10'2M down to 1.1 x 1 0 13M.
2. Cells were then seeded in 96 micro well plates at a density of 4 x 103 
cells per well.
3. 200|il of the MTX or NaMTX-[Nle4,D-Phe7] solution was added to 
each well with 8 replicates per concentration gradient.
4. The cells were then gassed and incubated at 37°C for a period of time 
which allowed three doublings of the cells under investigation.
5. Control cells were treated in a similar manner but the growth 
inhibitory agent was omitted.
After 72 hours: (MTT Assay)
6. On removal from the incubator, each plate was inverted in order to 
dispose of the medium. Each well was then washed (carefully to avoid 
detachment) twice with SFM.
7. 20|il of a lOmg/ml solution of MTT was then added to each well and 
supplemented with 180pl of RPMI-FCS, before being incubated at 
37°C for a further 3 hours.
8. After 3 hours, the MTT was removed by inversion of the plate and 
200p.l DMSO was pipetted into each well. The plates were then 
agitated on an orbital mixer (A500 Jencons Scientific Ltd.) for 5 
minutes to ensure complete solubilisation of the Formazan blue 
crystals.
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9. Finally the plate was read on an Titertek plate reader at a test
wavelength of 540nm and a reference wavelength of 690nm.
Results were then analysed using a standard Excel (Microsoft) 
speadsheet.
2.15.1. Determination of the intracellular mass of methotrexate necessary
to effect cell kill using tritiated methotrexate:
[3',5',7-3H] Methotrexate, Sodium salt. 3H-MTX
This was obtained as the freeze-dried solid from Amersham Life Sciences. It
had a specific activity of 470GBq/mmol (12.7 Ci/mmol) and was stored at
-20°C.
1. Once the cells had been seeded at 4 x 103 per well, serial dilutions of 
the 3H-MTX were added to the cells and the plate was then incubated 
for 72 hours.
2. Once removed from the incubator the unbound 3H-MTX was removed
by washing the cells 5 times with SFM. This was done carefully to 
avoid detachment.
3. The cells were then taken up in a 1M solution of NaOH, to which an
equal volume of 1M HC1 was added in the scintillation vial. Finally 
2ml "Optiphase" scintillation fluid was placed into the vial.
4. The individual vials (which each represent one well) were then read
twice on the (3-emitter scintillation counter. The first reading was done 
immediately after detachment and the final reading was performed 72 
hours later. The latter was used for all the subsequent calculations.
5. The "dpm" readings obtained were then related to the specific activity 
of the 3H-MTX in order to assess the number of molecules of MTX 
which were taken up by the cell.
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6. Two more 96 well plates were seeded with B16 cells at 4 x 103cells 
per well. These were incubated at 37°C in the presence of varying 
concentrations of MTX (1.1 x 10*2M down to 1.1 x 10*13M) as per 
protocol 2.14.
After 72 hours:
7. The MTT assay was performed on one of the plates and this gave an 
estimate of the E.C.50 value.
8. The cells in the second plate were counted as per protocol 2.8. and this 
gave another estimate for the E.C.50 value.
9. Therefore, two estimates of the intracellular mass may be determined 
per experiment i.e. from the E.C.5o values generated from the MTT 
and Trypan Blue viability assays.
Sample Calculation:
An E.C.50 value of 5 x 10'8M MTX estimated from the MTT assay, 
which corresponds to a level of: "x" moles 3H-MTX/well
and corresponds to: "y" cells/well
which implies: "x/y" moles /cell
Therefore:
x/y multiplied by Avogadros no.= "z" no. of molecules MTX/ cell 
Conclusion:
The cells require "z" no. of molecules MTX in order to reduce the viability of 
the cells to 50% relative to control cells.
i.e. an extracellular concentration of 5 x 10 8M ensures that "z" no. of 
molecules of MTX reaches the intracellular regions and effects growth 
inhibition.
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2.15.2 Quench Curve of 3H-MTX:
1. Using ten scintillation vials, 10p.l of a known amount of 3H-MTX was 
placed in each along with 2ml of "Optiphase" scintillation fluid.
2. Each vial, with the exception of the first one, was then "quenched" 
with varying amounts of chloroform, 
50,100,200,400,600,800,1000,1500 and finally 2000|il.
3. The vials were then put on the Rackbeta scintillation counter and the 
standard curve was plotted. The points obtained were then 
programmed into the machine for future use. See figure 2.3.
Calculations:
In the tritiated methotrexate obtained there are 9.25 MBq of activity.
500|il o f PBS was added.
Therefore:
9.25 x 106 Bq in 500^1 
lBq = 1 decay per second
9.25 x 106dps in 500fil 
5.55 x 108 dpm in 500)il 
1.11 x 106 dpm per |il
Hence if there is a 1:1000 dilution ,
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Figure 2.1. This figure shows the radioactive counts obtained from the 
reaction products of the iodination of [Nle4,D-Phe7]a-M SH as measured 
by UV adsorption at 217nm. Peaks 1 and 2 are thought to represent the 
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Figure 2 .2 . This figure shows the radioactive counts of products from the 
iodination of N“MTX-[Nle4,D-Phe7]a-M SH. Peak 1 is thought to 
represent the mono-iodinated conjugate and peak 2 the di-iodinated 
conjugate.
68
QUENCH CORRECTION CURVE FOR3H-MTX
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Figure 2.3. This Figure represents the quench correction curve for 3H- 




The MTT Assay: Development of an optimised assay of 
cell viability based on the original Mosmann method.
3.1. INTRODUCTION:
A routine assay of viability or toxicity was required to be established. There are 
several viability or cytotoxicity assays available. For this study the MTT assay 
was chosen as it was judged to be the most useful assay procedure to employ 
for a number of reasons (see Sections 3.4. and 3.5.). The MTT test is a simple 
colorimetric assay based on the ability of living cells to reduce a tetrazolium 
based compound (MTT) to an insoluble blue formazan product, (Mosmann, 
1983, Amould et al., 1990). Listed below are some of the other common assays 
together with their respective advantages and disadvantages:
3.2. Short term assays: Viability
Dye Exclusion:
Viable cells are impermeable to nigrosin, Trypan blue and hence by uptake of 
the dye, the cells are assumed to have a damaged membrane. This allows 
viability to be assessed by microscopy.
However, dye exclusion tends to overestimate viability e.g. 90% of cells thawed 
from liquid nitrogen may exclude Trypan blue but only 60% prove to be capable 
of attachment 24 hours later.
Dye Uptake:
Viable cells take up diacetyl fluorescein and hydrolyse it to fluorescein to which 
the cell membrane of live cells is impermeable. Live cells fluoresce green, dead 
cells do not. Non-viable cells may be stained with ethidium bromide or
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propidium bromide and will fluoresce red. Viability is expressed as the 
percentage of cells fluorescing green. This technique is labour intensive and not 
suitable for routine quantitative screening.
3.3. Long term assays:
Plating Efficiency:
Frequently cells subjected to toxic influences e.g. antineoplastic drugs, will only 
show an effect several hours or days later.
Plating efficiency, as measured by the number of cells proliferating after a 
certain drug stress, is the best measure of survival and proliferative capacity, 
provided that the cells plate with a high enough efficiency so that the colonies 
can be considered representative. Unfortunately many animal cells have poor 
plating efficiencies particularly freshly isolated normal cells. This test is also 
time consuming to set up and analyse, particularly where a large number of 
samples are involved and the duration of each experiment may be anything from 
two to four weeks.
Microtitration Assays:
These are an alternative to the plating efficiencies as they can assay cells at 
higher densities:
(i) Chromium Release: [51Cr]3+
Reduced 51Cr2+ is taken up by the cells and oxidised to 51Cr3+ to which the 
membrane of viable cells is impermeable. Dead cells release the 51Cr3+ into the 
medium. A reduction in viability is detected by gammacounting aliquots of 
media from cultures previously labelled with Na251CrC>4 for released 51Cr.The 
test works well for experiments lasting a few hours but over longer periods, 
spontaneous release of 51Cr may be a problem.
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(ii) Methionine:r35Sl
Active protein synthesis requires uptake of methionine. Thus total 35S uptake 
over a fixed time period is a reflection of the number of viable cells present in a 
culture.
(iii) Thymidine: PHI
Labelling with thymidine 3H examines the rate of DNA synthesis of the cell 
population.
(iv) Uridine: PHI
Labelling with uridine examines the rate of RNA synthesis of the cell 
population.
(v) Semiautomated microculture method:
This was devised by Finlay et al. (1984) using methylene blue stain, the cells are 
grown, treated with the drug under investigation and then stained cells are air- 
dried and solubilised. Absorbance of the stained cells is determined using a 
spectrophotometer and the optical density is directly related to cell viability.
(vi) Tetrazolium dve fM T P metabolic assay:
This method employs the use of MTT: (3-[4,5-Dimethylthiazol-2-yl]-2,5- 
diphenyltetrazolium bromide, Thiazoyl blue), which is a tetrazolium dye. The 
reaction which takes place is the reduction of the tetrazolium salt to a blue 
coloured product (MTT Formazan) by the mitochondrial enzyme succinate 
dehydrogenase. This reaction can only take place in the presence of active 
mitochondria i.e. in the presence of viable cells.
3.4. The M TT Assay:
Even though it was originally developed to measure living cell numbers in 
lymphocytes by Mosmann (1983), the MTT assay has been modified and 
subsequently used in many systems e.g. primary cultured hepatocytes (Oka et
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al., 1992), macrophages, (Jiao et al., 1992) leukaemic cells, from cell lines and 
patients with acute myeloid leukaemia (AML), (van de Loosdrecht et al., 1994) 
and lung cancer cell lines, (Carmichael et al., 1988).
The MTT assay has also been one of the subjects of comparative in vitro 
cytotoxicity tests in conjuction with neutral red (NR) assay, uridine 
incorporation and protein measurements, (Husoy et al., 1993). The areas of 
comparison were performance and sensitivity of these toxicity assays and also 
the intraassay agreement. The MTT assay exhibited no problems with regard to 
reproducibility of results although a general recommendation for more 
comparative studies to be undertaken with this assay was given by the authors. 
The cytotoxicities of drugs such as melphalan and daunorubicin were measured 
in a P388D1 mouse macrophage cell line and B16 mouse melanoma cell line 
using the MTT and tritiated thymidine uptake assays, (Amould et al., 1990). 
The results indicated that while both assays were found to be similar in terms of 
sensitivity and reproducibility, both for adherent and floating cell lines, the MTT 
assay had the advantages of low cost and time saving and also avoided the 
problems related to the manipulation and counting of radioactivity. Carmichael 
et al. (1987a and 1987b) compared the efficacy of the MTT assay with a 
clonogenic assay and a dye exclusion assay in their assessments of 
chemosensitivity and radiosensitivity of certain cell lines. In both cases the MTT 
assay yielded reproducible results and due to its ability to be semiautomated it 
was thought to be of great value in screening large numbers of potential 
chemosensitising and radiosensitising agents. It is also useful in drug screening 
with panels of human tumour cells lines examined by Alley et al. (1988) and 
was found to supersede the prototype tetrazolium salt, triphenyl tetrazolium 
chloride due to the latter's shortcomings vis a vis , slow reaction rate, lack of 
tissue localisation and susceptibility to reoxidation. The MTT assay is used
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today in the United States National Cancer Institute's anticancer drug screening 
program (Alley et al., 1988).
In addition to its use in comparative assays, the MTT assay has been used as an 
adjunct to other assay procedures e.g. digital cell image analysis (Etievant et al., 
1991). In this instance the MTT assay assessed the effects, on cell proliferation, 
of a range of drugs e.g. navelbine and adriamycin whereas the digital cell image 
analysis assessed the effects of the same drugs on cell kinetics. Thus both the 
proliferation and the kinetics of the cell line could be investigated 
simultaneously.
3.5. Rationale for selection of the MTT assay:
The MTT assay was selected for the current project due to the relative ease of 
the protocol which ensured that:
(a) A sufficient number of replicates could be performed.
(b) The time taken for the assay and also to process the results was 
relatively short.
(c) There were no radiolabelled substances involved.
(d) It yielded efficient and accurate results which were easily understood as
they could be directly related to cell viability.
(e) MTT is relatively inexpensive to purchase.
(f) The MTT assay can be used for all cell types.
3.6. Disadvantages of the MTT Assay:
The disadvantages of the MTT assay relate mainly to the fact that the MTT 
formazan product is insoluble and therefore must be solubilised by the addition 
of an organic solvent. In recently described tetrazolium assays e.g. the MTS 
assay, (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulpho-
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phenyl)-2H tetrazolium, inner salt) described by Buttke et al., (1993) and Cory 
et al., (1991) or the XTT assay, (sodium 3'-[l-[(phenylamino)-carbonyl]-3,4- 
tetrazolium]-bis(4-methoxy-6-nitro)benzene-sulphonic acid hydrate, (Scudiero 
et al., 1988, Roehm et al., 1991), the need for a solvent is obviated by the 
production of a water soluble product.
Neither of these assays are without their own complications, however. The 
MTS assay needs the incorporation of an electron-coupling agent such as 
phenazine methosulphate (PMS) as an intermediate electron acceptor in the 
conversion of MTS to its formazan product, (due to the fact that MTS is 
anionic at physiological pH). MTS is suitable if more than one assay is to be 
performed at the same time i.e. it can be used in combination with the 3[H]TdR 
assay.
The main advantage of this assay seems to be that in the presence of PMS the 
absorbance values are higher i.e. it can be used for cells where there is a minimal 
detection range. For work with the melanoma cells this was not a requirement 
as the values obtained were always high enough to be detected and analysed. 
With the XTT assay, many problems arise (Roehm et al., 1991) (i) there is a 
slow rate of colour formation, it takes 4 hours at least and will still be reacting 
after 8 hours, (ii) not all cell lines can be used with XTT, (iii) even those cells 
that can metabolise XTT can only do so in an efficient manner when an electron 
coupling agent e.g. PMS (Scudiero et al., 1988) or menadione, (Gam et al., 
1994) is added, (iv) the product yielded is orange-yellow which absorbs 
maximally at 450nm, this implies that yellow metabolites and reagents can 
potentially interfere with the spectrophotometric assay and (v) the XTT reagent 
must be prepared daily unlike MTT or MTS. For our purposes the MTT assay 
gave results that were reproducibly consistent and even though the 
solubilisation step entailed the use of the potentially hazardous
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dimethylsulphoxide (DMSO), this solvent solubilised the product completely 
with speed and ease. DMSO is not favoured by others (Scudiero et al., 1988) 
due to the safety hazard of personnel exposure to large quantities of the solvent 
and also the deleterious effects of DMSO on laboratory equipment.
The only other disadvantage of the MTT assay and it is one that it shares with 
all other microtitration techniques, is that it is impossible to distinguish between 
differential responses between cells within a population and the degree of 
response in each cell. This implies that a 50% inhibition of cells could mean that 
50% of the cells respond or that each cell is inhibited by 50%. Hence the MTT 
assay is not able to distinguish between the cytostatic or cytocidal effects of the 
agent. This may seem like a big drawback but, in the light of comparative 
studies (Amould et al., 1990; Carmichael et al., 1987a,b) where the MTT assay 
is tested along with more established techniques e.g. clonogenic assays and dye 
uptake, the I.D .50 values derived show a strong correlation between the 
methods, thus confirming the value of this assay for routine in vitro cytotoxicity 
assays.
3.7. Linearity of the assay:
In order to establish the range within which the assay was linear insofar as it 
complied with the Beer-Lambert law, experiments were undertaken, the results 
of which are shown in Figure 3.1. The experiment involved the measurement of 
the absorbance of varying concentrations of MTT formazan (Sigma M2003) in 
DMSO at 540 and 690nm. Figure 3.2. shows the readings obtained for varying 
concentrations of MTT formazan (Sigma M2003) in DMSO using a 
spectrophotometer at 540nm and Figure 3.3. is an expansion of Figure 3.2. in 
which the extent of linearity is shown.
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According to the Beer Lambert law,
logUol = e e l  
( I )
or, e = A
cl
where:
I0 = Intensity of the incident light
(or the light intensity passing through a reference cell)
I = Light transmitted through the sample solution 
A = Absorbance of the solution 
c = Concentration of the solute in mol / dm3 
1 = Path length of the sample in cm 
e = molar absorptivity
(correctly expressed in units of 1 0 2 m2 / mol)
Figure 3.1. shows that the Beer Lambert Law holds up to an absorbance of 1.0 
and is close to linear up to an absorbance of 2.0AU.
Figures 3.2. and its expansion in 3.3, clearly show that above an absorbance of 
2.0AU, the graph reaches a plateau and the Beer-Lambert relationship does not 
hold.
Another test for linearity was carried out using cells (B16 murine melanoma) 
which were seeded at a variety of densities in the microwells. MTT was then 
added and the cells were supplemented with growth medium in the normal way. 
After a 3 hour incubation the assay was conducted in the usual manner to 
produce the results shown in Figure 3.4. Seeding densities within the range 1.8 
x 102 cells per well and 5 x 104 cells per well were used, (eight replicates were 
performed in each case). A significant absorbance was obtained at a level of 1.5 
x 104 cells which persisted up to a value of 0.94AU which corresponded to 5 x 
104 cells per well.
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3.8. Spectra of MTT and MTT Formazan:
In order to demonstrate whether MTT interfered with the assay of MTT 
formazan at the test wavelength, an equimolar (5 x 105M) concentration of 
MTT and MTT formazan were assayed using a spectrophotometer. The results 
are shown in the table below and also in Figure 3.5. At 540nm MTT did not 
interfere with the assay of MTT formazan as MTT does not absorb at that 
wavelength. These data also show that the reference wavelength used (690nm) 
was appropriate as it does not interfere with the test, unlike the reference 
wavelength that was used by Sladowski et al. (1993), 630nm, at which point 
there was still too much absorption due to the formazan product. The reference 
wavelength (690nm) was used to correct for any precipitation of serum protein 
which may have occurred.
Table 3.5. Spectrophotometric absorbance readings obtained at various 











620nm 0 .0 2 0 0.312
630nm 0.017 0 .2 1 1
690nm 0.008 0 .0 2 2
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3.9. Optimal Incubation Time:
Mosmann (1983) found that the optimal incubation time was 4 hours, however 
this was questioned by Denizot and Lang (1986) who found that "in view of the 
relatively small increase in sensitivity obtained between 3 and 4 hours, we chose 
3 hours". Hansen et al., (1989) reduced incubation time again as they noted that 
after 1-2 hours the final optical density had been produced. In this study it was 
found that a 3 hour incubation period was adequate.
3.10. Solvents for MTT formazan:
The Mosmann method used acid-isopropanol (0.4N HC1 in isopropanol) as the 
solvent for MTT Formazan but isopropanol is known to precipitate serum 
proteins (Sandberg, 1977) and this solvent also causes a phenomenon known as 
"colour fading" where the MTT Formazan exhibited a very blunted absorbance 
at 570nm and an increase in absorbance at 300 and 420nm. This colour fading 
was explained by an irreversible shift in absorbance maximum which seemed to 
be a direct result of medium acidification.
Denizot and Lang, (1986) opted for the use of propanol or ethanol as having 
eliminated the serum protein from the assay, the formazan could then be 
dissolved in pure organic solvent. This elimination process involves extra 
washing steps and makes the procedure more time consuming and less accurate 
as there is a risk of losing cells and formazan (Hansen et al., 1989). Twentyman 
and Luscombe (1987) tried a number of solvents and found that mineral oil and 
acid isopropanol were slow to dissolve the formazan crystals and that 
solubilisation was still incomplete after 5 minutes agitation on a plate shaker but 
that DMSO "dissolved the formazan crystals extremely rapidly without 
excessive agitation". DMSO has been used in many assay protocols cf: 
Carmichael et al., (1987a, 1987b), Stratford and Stephens (1989), Jabbar et al.,
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(1989) and Alley et al.t (1988), the latter of whom undertook an assessment of 
other formazan solvent systems including DMF, hexane and propylene glycol, 
but elected to use DMSO on the grounds of the improved chemical stability of 
culture generated MTT formazan in DMSO. The other advantage of DMSO is 
that it rapidly solubilises serum protein and this accounts for the improved 
extraction and detection of MTT formazan generated within cultured cell 
systems. In all the work presented here DMSO was used. Spectrophotometric 
grade was used in order to stabilise absorbance readings and also reduce 
background absorbance.
3.11. Control experiments with 96-microwell plates:
Control experiments were performed to validate the method and are shown in 
Figure 3.6. Wells containing 4 x 104 cells were exposed to MTT and showed 
the characteristic absorption profile of the formazan derivative (Col 1-3, n=24). 
Data points are means and S.D. of absorbance values obtained using a range of 
filters available on the microplate reader. Maximum absorbance occurred at 
530nm. By 690nm the absorbance due to MTT formazan was low and this 
wavelength could be used to subtract the baseline absorbance of approximately 
0.1 from that which was due to the formazan derivative. Other data represented 
on the plot show the absorbance of other control experiments. The plastic plate 
itself had an absorbance in the region of 0.04AU (Col 11-12., n=16). The 
solvent, DMSO, added to the blank absorbance by approximately 0.03. (Col. 10, 
n=8 ). The presence of 4 x 104 cells in the well in the absence of any MTT gave 
the plot shown by the filled circles (Col 4-6., n=24). The presence of medium 
alone in the absence of cells is shown by Col. 7-9 (n=24).
80
3.11.1. Optimal Seeding Density and Growth Period:
The growth of B16 cells was assessed over a 72 hour period. Seeding densities 
of 2.60 x 103, 4.03 x 103, 5.38 x 103, 1.07 x 104 and 2.15 x 104 cells per well 
were used and the cells were then counted with a haemocytometer.
Table 3.8.(a). This table shows B16 cells seeded at given densities (Column 1) 
and allowed to proliferate for 72 hours before being manually counted with a 
haemocytometer. Columns 2 and 3 represent the number of cells per well 








2.69 xlO3 2.19 x 104 3.81 x 104
4.03 x 103 4.31 x 104 2.81 x 104
5.38 x 103 2.83 x 104 4.72 x 104
1.07 x 104 6.94 x 104 9.44 x 104
2.15 x 104 3.5 x 104 1.03 x 105
The optimum seeding density is one which allowed exponential growth over 72 
hours and at the time of the assay, otherwise if the control cells were allowed to 
plateau then no deductions could be made in any subsequent growth inhibitory 
assays, as to whether the rest of the cells were affected by the antineoplastic 
agent or whether this could be attributed to the natural decline of the cell 
population.
Table 3.8 .(a) shows that the first three densities seem to be proliferating well, 
however the last two have reached confluence and have proceeded to decline. 
On visual inspection it was clear that these cells were in decline even though this
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is not reflected in the table above. Thus, the optimal seeding density lies 
between 2.69 x 103 and 1.07 x 104 cells per well. An experiment was then 
undertaken to check whether the final cell counts could be related to the linear 
portion of the MTT formazan graphs (Figures 3.1., 3.2. and 3.3.). 4 x 103, 8 x 
103 and 1.2 x 104 cells per well were seeded for 3, 5 and 7 days and the results 
of this study are shown below:
Table 3.8.(b): This shows the results of a 3, 5 and 7 day incubation period with 
seeding densities of 4 x 103, 8 x 103 and 1.2 x 104 B16 cells per well. The values 
are given as net absorbance (540-690nm). Each value is the mean of 4 wells.
Net Absorbance (54( -690nm)
SeedingDensity 3Day(AU) 5Day(AU) 7Day(AU)
4x 103 cells/well 0 .8 6 8 1.073 0.909
8 X 103 0.755 0.954 0.882
1.2  x 104 0.802 0 .8 6 6 0.922
4 x 103 cells per well was chosen as the lower limit for seeding B16 cells as 
experiments in which 1 x 103 cells per well and 2.5 x 103 cells per well were 
used, failed to proliferate. On the basis of the results above, it was decided that, 
for future work, a seeding density of 4 x 103 cells per well would be used and 
also an incubation time of 72 hours.
72 hours was chosen because B16 cells undergo 3 doublings within this time 
and hence will reach a level of approximately 3.2 x 104 cell/well, which has the 
advantages of (i) being within the limits of the capacity of the well and (ii) 
eliciting absorbance values that are still within the linear range, (iii) enabling 
more rapid results as more experiments may be set up within a given time 
period and (iv) ensuring that the medium has not been depleted of nutrients,
82
(during a 7 day incubation the cells would need refeeding and this would have 
introduced an unnecessary risk of contamination).
Another important point is that as with all cells, B16 cells go through phases in 
their life cycle, from the initial lag phase, where the cells are becoming 
accustomed to the new environment (medium, temperature, atmosphere), 
through the logarithmic or growth phase when the cells multiply up to a level of 
confluence which then plateaus off to signify the commencement of the 
declining phase due to the depletion of nutrients, space etc., when the cells 
begin to die. Ideally the absorbance values should be located in the region of the 
logarithmic phase of growth, (positive slope) i.e. a value of approximately 
1.0AU for the control cells so that (i) it is within the linear range and (ii) the 
E.C.5o can be defined as the concentration of inhibitor corresponding to 0.5AU. 
This will be a real indication of the number of viable cells at the time of assay. In 
contrast if a value of 1.0AU was found for the control cells but it was on the 
negative slope (decline phase) then this could not be associated with a 
respective E.C .50 because the cells at this point would be subject to influences 
other than the cytostatic agent e.g. nutrient depletion, space confinement 
leading to contact inhibition, hence no clear conclusions could be drawn about 
the efficacy of the agent.
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CONCENTRATION OF MTT FORMAZAN (M)
Figure 3.1. Net absorbance readings (540-690nm) obtained for increasing 
concentrations of MTT formazan in DMSO using a Titertek platereader at 
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CONCENTRATION OF MTT FORMAZAN
Figure 3.2. Absorbance readings (540nm) obtained for increasing 
concentrations of MTT forma/an in DMSO as measured by a 
spectrophotometer.
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MTT FORMAZAN CONCENTRATION (M)
Figure 3.3. Absorbance readings (540nm) obtained for increasing 
concentrations of MTT formazan in DMSO as measured by a 
spectrophotometer. Concentrations up to 5 x 10'4M are used in order to 
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Figure 3.4. Net absorbance (540-690nm) due to M TT formazan after 3 
hours at 37°C versus seeding density of B16 cells. A test wavelength of 
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Figure 3.5. Absorbance readings obtained for 5 x 1 0 5M of M TT and MTT 
form azan at various wavelengths from 400nm to 750nm.
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Figure 3.6. This figure shows control experiments which were perform ed to validate 
the M TT assay. A 96 microwell plate was used for the experiment and  the columns 
were used as follows:
4 x 104 cells per well, with medium and MTT, followed after 3 hours by DMSO. 
4 x 104 cells per well with medium without MTT or DMSO.
No cells, but medium and MTT, followed after 3 hours by DMSO.
DMSO alone.
Empty plastic microwell plate.
O Col.1 - 3  
•  Col.4 - 6  
V  Col.7 - 9  
T Col.lU 
□ Col.1 1 - 1 2
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CHAPTER 4. 
Assessment of cytotoxicity of methotrexate (MTX) 
using the MTT assay.
4.1. INTRODUCTION:
The overall aim of this project was to deliver the antineoplastic agent, MTX, to 
a specific receptor on the surface of melanoma cells and to therefore minimise 
non-specific side-effects. It was hoped to achieve this goal by the attachment 
of MTX to the hormone analogue [Nle4,D-Phe7]a-M SH as this would direct 
the MTX to the melanocortin receptors on the cell surface. Before assessing 
the specific improvements, if any, that NaMTX-[Nle4,D-Phe7]a-M SH yielded, 
it was first necessary to elucidate the effects of the free MTX on melanoma 
and non-melanoma cell lines.
Methotrexate is an antimetabolite which acts most effectively during the S- 
phase of the cell cycle and can be potentially cytotoxic when this coincides 
with the logarithmic growth phase. As the concentration of extracellular MTX 
increased in the microwell the viability of the cells decreased. The MTT assay 
exploited the relationship between extracellular concentration of MTX and cell 
viability because only cells with active mitochondria can reduce the MTT 
(yellow) to its MTT Formazan (blue/purple) product. This test yielded results 
which could be (i) observed visually i.e. the depth of the purple colour 
reflected the level of viability of the cells and (ii) quantitatively assessed by the 
Titertek platereader where the net absorbance values could be related to the 




Concentrations of MTX ranging from 102 to 1 0 12M were employed in order 
to find where the E.C .50 value lay. Once this was determined, the range was 
narrowed to get a more accurate estimate.
All the cells were seeded at a density of 4 x 103 cells/well in 96 microwell 
plates. The cells were exposed to MTX in medium, over an incubation period 
equivalent to three doubling times of the cell line under investigation. The 
MTT assay was then performed. Control cells were treated in exactly the same 
way but the MTX was omitted.
4.3. R esults:
The E.C .50 value was defined as the concentration of MTX that reduced the net 
absorbance (540-690nm) of the cells to 50% of that exhibited by the control 
cells.
B16 murine melanoma cells:
As can be seen from the table 4.1 and Figures 4.1. and 4.2., the E.C.50 value 
lay between 2 x 109M and 4 x 10 8M MTX (approx.) which gave an average 
value of 1.67 x 10'8M. Therefore not all of the B16 cells were as susceptible to 
MTX as others even though the protocol observed was identical in all cases. 
This level of variation was common for B16 cells throughout all of the work 
presented. Further experiments (see Chapter 6 ) confirmed this by yielding 
values in the same range.
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4.3.1. B16 murine melanoma cells:
M TX-M TT assay:
Table 4.1. This table represents the mean net absorbance values calculated by 
subtracting the reference aborbance readings at 690nm from the test 
absorbance readings at 540nm. The columns labelled 39, 42, 43, 44, and 47 
represent the results of five separate experiments. Each value is the mean of 8 
replicates with the exception of the control cells which involved 16 replicates. 
Column 1 contains the concentrations of MTX used. The E.C.50 and standard 
deviation values were generated using the MINSQ non-linear regression 
program (weighting =2).
NET MEAN ABSORBANCE (AU)
MTX (M) (39) (42) (43) (44) (47)
C ontrol 1.142 2.240 1.923 1.776 2.108
1.1 x lO 11 2.188 2.103 1.412
1.1 xlO 10 2.433 2.113 1.927
2.2 x lO 10 1.708 1.584 1.985
5.5 xlO-10 2.119 1.800 2.060
1.1 xlO 9 0.653 1.192 2.069 1.505
2.2 x lO 9 1.847 1.610 1.598
5.5x10 9 2.228 2.003 1.940
1.1 x lO 8 0.385 0.433 1.909 1.425
2.2 xlO 8 1.463 1.488 0.870
5.5 xlO 8 0.946 0.839 0.527
1.1 xlO 7 0.240 0.261 0.582 0.423 0.171
2.2 xlO 7 0.336 0.408 0.290
5.5x10 7 0.174 0.273 0.158
1.1 x lO 6 0.175 0.182 0.214 0.152 0.180
1.1 x lO 5 0.120 0.128 0.165 0.117 0.174
1.1 xlO 4 0.139 0.115 0.200 0.120 0.188
1.1 xlO 3 0.171 0.118 0.132
1.1 xlO 2 0.144 0.085 0.105
e .c .50(M) 5.3 xlO 9 2.0 xlO-9 3.0 x lO 8 4.0 1 0 8 6 .3 x l0 9
S.D.(+/-) 3.1 x 109 1.0 x 1 0 9 5.9 x 10 9 7.4 x 10 9 3.1 xlO 9
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4,3.2. MeWo human melanoma cell line;
MTX-MTT Assay:
Growth experiments were undertaken to optimise the conditions of the assay 
and it was found that a 6 day incubation period allowed the cells to double 
three times (doubling time of MeWo = 48 hours (Figure 4.3.(a)). This 
incubation time was also suitable because it avoided the refeeding of the cells. 
The cells were seeded at a density of 4 x 103 cells/well which, as can be seen 
from Figure 4.3.(b), after 3 doubling reaches a level of 3.2 x 104 cells/well 
which yields absorbance readings in the region of 1.0 AU.
Table 4.2 shows the results of three replicate experiments with the MeWo cell 
line and the E.C.50 values obtained. From the results shown in table 4.2 and 
Figures 4.4. and 4.5. it was clear that the MeWo cells were inhibited by MTX. 
As the concentration of MTX increased from 10'13 to 102M so the absorbance 
values and hence viability of the MeWo cells decreased. The E.C.50 values 
ranged from 4 x lO 9 to 9 x 1 0 11 M MTX (approx.) and lead to a mean E.C.50 
value for MeWo cells of 1.31 x 10*9 M MTX. This value was an order of 
magnitude lower than the value for B16 cells and implied that the MeWo cells 
were more sensitive to the effects of the antimetabolite.
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Table 4.2. This shows the results of three replicate experiments (71,73 and 76) 
in which the MeWo cells were incubated for 6 days at 37°C with various 
concentrations of MTX (shown in Column 1). The results are presented as net 
mean absorbance readings (540-690nm). Each point is the mean of eight 
replicates with the exception of control values which are the mean of sixteen 
replicates. The E.C.50 and standard deviation values were generated using the 
MINSQ non-linear regression program (weighting=l).
NET MEAN ABSORBANCE (AU)
MTX (M) 71 73 76
Control 2.141 2.476 1.097
1.1 x 10 13 2.486
1.1 x 1 0 12 1.632 2.014 1.235
1.1 x 1 0 11 1.607 1.916 1.309
1.1 x 10 10 1.384 0.952 0.611
1.1 x 1 0 9 1.167 0.582 0.538
1.1 x 10 8 0.642 0.254 0.349
1.1 x 10 7 0.277 0.104 0.248
1.1 x 10 6 0.350 0.111 0.164
1.1 x 10 5 0.297 0.108 0.149
1.1 x 10 4 0.233 0.119
1.1 x 10 3 0.270 0.104
1.1 x 10 2 0.233 0.058
e .c .50(M) 3.7 x 109 1.0 x 10 10 9.4 x 1 0 11
S.D.(+/-) 1.0 x 1 0 9 4.0 x 1 0 11 7.0 x 1 0 11
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4.3.3.SVK14 cells:
SVK14 cells were keratinocytes and therefore possessed few if any MSH 
receptors. It would be expected that due to this MTX alone would act quite 
efficiently at killing the cells via the folic acid pathway, which was present, 
however the N“MTX-[Nle4,D-Phe7]a-M SH conjugate would not be expected 
to produce such a dramatic effect on the viability of the cells because of the 
restricted entry pathway.(See chapter 5).
The results shown in table 4.3 and Figure 4.6 represented the effects of MTX 
on these keratinocytes. It was quite clear from experiment no. 88, that an 
extracellular concentration of 1.1 x 1 0 UM MTX or greater was effective at 
killing the cells. In experiment no. 94, the concentrations of MTX were more 
dilute i.e., down to l.lxlO*13 M but this was still too concentrated for the cells. 
Hence, it can be deduced that an extracellular concentration of 1 0 13 M or 
greater was effective at inhibiting the growth of SVK14 keratinocytes.
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Table 4.3. This shows the results of two replicate experiments (88,94) 
performed with SVK14 keratinocytes. The net mean absorbance is calculated 
by subtracting the reference readings (690nm) from the test readings(540nm). 
Each point is the mean of eight replicates. Control values are the mean of 
sixteen replicates. Concentrations of MTX(M) are given in column 1. It was 
not possible to estimate accurate values for the E.C.J0 values using the MINSQ 
non-linear regression programme.
NET MEAN ABSC)RBANCE (AU)
MTX (M) 8 8 94
Control 0.960 1 .1 2 1
1.1  x 10  13 0.073
1.1  x 1 0 12 0.030
1.1  x 10  11 0.027 0.037
1.1  x 1 0 10 0.025 0.028
1.1  x 10  9 0.025 0.037
1.1  x 1 0 8 0.027 0.027
1.1  x 1 0 7 0.034 0.032
1.1  x 1 0 6 0.032 0.031
1.1  x 1 0 5 0.033 0.025
1.1  x 10  4 0.031 0.028
1.1  x 10  3 0.037
1.1  x 10  2 0.033
e . c .50 < 10 UM < 10 13M
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4.3.4, Transformed 293 cell lines;
Native 293 cells are derived from human embryonic kidney (HEK) cells and 
do not contain the MC3 receptor. These cells are transfected with a vector 
(pcDNA neo) which contained the gene encoding for the MC3 receptor. 
Subsequently selection was used to obtain a clone with stable expression of the 
MC3 receptor. Control 293 cells were also transduced with pcDNA neo and 
these were used on a comparative basis to see whether the process of 
transfection of the vector altered the cells response to either MTX or N“MTX- 
[Nle4,D-Phe7]a-MSH. In table 4.4. and Figure 4.7 the results of two 
experiments using transformed 293 cells with and without MC3 receptors are 
shown labelled as 146 and 147 respectively.
Table 4.4. This shows the net mean absorbance values (540-690nm) for 293 
cells transfected with the vector holding the encoded gene for MC3 receptors 
(146) and 293 cells which possessed the vector but no encoded gene (147) 
obtained after incubation with a range of concentrations of MTX (column 1). 
Each point is the mean of eight replicates.The e . c .50 and standard deviation 
values were generated using the MINSQ non-linear regression program 
(weighting=l).
NET MEAN AEISORBANCE
MTX (M) 146 147
Control 0.815 0.970
1.1 x 1 0 13 0.696 0.598
1.1 x 1 0 12 0.664 0.253
1.1 x 10 11 0.496 0.291
1.1 x 10  10 0.264 0.204
1.1 x 1 0 9 0.406 0.186
1.1 x 1 0 8 0.152 0.133
1.1 x 1 0 7 0.101 0 .1 2 0
1.1 x 10 6 0.156 0.116
1.1 x 1 0 5 0.093
1.1 x 10  4 0 .112 0.130
E.C.,ft(M) 3.0 x 1 0 11 2.8 x lO 13
S.D.(W-) 2 .8  x 1 0 11 3.0 x 10 13
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The results presented in table 4.4. and Figure 4.7., suggested that the 
transformed 293 cells without the MC3 receptors were more sensitive to the 
effects of MTX than the 293 cells with the MC3 receptors i.e. less MTX was 
necessary in order to effectively inhibit the growth of these cells. This result 
was not established by replication during this study, and though non-linear 
regression appeared to give good estimates of E.C .50 values, visual inspection 
suggests the errors involved were considerable, so that it was not clear how 
significant was the difference between the two experiments.
4.4. Summary.
The cell lines examined exhibited an increasing order of sensitivity to MTX as 
follows:
B16 < MeWo < transformed 293 cell line (with MC3 receptor) < transformed 
293 cell line (without MC3 receptor) < SVK14 keratinocytes.
MTX was assumed to be taken up via the folic acid transport pathway present 
in all cells. The cumulative results of five separate experiments using the B 16 
cell line are shown in Table 4.1. It can be seen from the range over which the 
E.C .50 values lay, that these data were reproducible. The standard deviation 
values also indicated an acceptable level of intraexperimental differences. 
After Experiments "39" and "42" were performed, more concentrations were 
included to give a fuller profile of the inhibitory effects of MTX on these 
murine melanoma cells. MeWo human melanoma cells were more (tenfold) 
sensitive to the effects of MTX as shown by the differences in their respective 
average E.C .50 values. It was also noticed while performing the experiments 
that as the passage of the MeWo cell line increased from "71" (passage I 2l) to 
"76" (passage I 2()  there was an increased sensitivity to the effects of MTX.
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This was the only cell line where such a phenomenon was noticed by the 
operator and whether this sensitivity to MTX would have continued over 
further passages needs to be determined in future work. As with the B16 cells 
the standard deviation showed that intraexperimental differences were not 
high. Some of the control values for the absorbance for both the B16 and the 
MeWo cell lines were greater than 2.0AU and hence outside the limits of 
linearity. The MINSQ non-linear regression programme was used with a 
weighting=l which took account of this potential source of error. SVK14 
keratinocytes displayed the greatest degree of sensitivity. Unfortunately only 
two experiments were performed and an accurate value for the e .c .50 was not 
obtained. It was still clear however that these cells only needed an extracellular 
concentration of 1 0 13M or greater MTX to effect cell death. Preliminary 
experiments were performed using transformed 293 cells with and without 
MC3 receptors. The results of which are shown in Table 4.4., the 293 cells 
with MC3 receptors, although more sensitive to MTX than either B16 or 
MeWo cell lines were more resistant than the 293 cells without MC3 receptors 
or SVK14 keratinocytes. SVK14 keratinocytes and both of the transformed 
293 cell lines are used as control cell lines and their results will gain more 
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Figure 4.1. Net absorbance readings (540-690nm) obtained with B16 cells 
incubated with MTX. Each point is the mean of 8  replicates. Control 
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LOG CONCENTRATION OF MTX
Figure 4.2. Relative values obtained for absorbance of B16 cells exposed 
to MTX. The results of 4 replicate experiments are shown. Each point is 
the mean of 8  wells. Error bars have been omitted for clarity.
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Figure 4.3.(a). Growth curve obtained for MeWo cells seeded at 5 x 
104cells per well in RPMI-FCS. Cells were incubated at 37°C and 
counted using the Trypan Blue dye exclusion assay. Error bars have been 
omitted for clarity.
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Figure 4.3.(b). Net absorbance readings (540-690nm) obtained for MeWo 
cells versus the number of cells seeded per well. Each point is the mean of 
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Figure 4.4. Net absorbance readings (540-690nm) obtained for MeWo 
cells exposed to MTX. Each point is the mean of 8  wells. Control values 
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LOG CONCENTRATION OF MTX
Figure 4.5. Relative values obtained for the absorbance of MeWo cells 
exposed to MTX. Results of 3 replicate experiments are shown. Each 
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LOG CONCENTRATION OF MTX
Figure 4.6. Absorbance readings obtained at test (540nm) , reference 
(690nm) and net absorbance (540-690nm) readings for SVK14 
keratinocytes exposed to MTX.Each point is the mean of 8  wells. 
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Figure 4.7. Net absorbance readings (540-690nm) obtained for 
transformed 293 cells with (146) and without (147) MC3 receptors. Each 




Uptake and Growth Inhibitory Effects.
5.1. Introduction.
Methotrexate was chosen as the model drug in this study of site-specific drug 
delivery to melanoma cells. In order to increase the site specificity with which 
MTX exerted its inhibitory effects on melanoma cells, the molecule was 
chemically coupled to an analogue of the naturally occurring hormone, a -  
MSH namely: [Nle4,D-Phe7]a-M SH on an equimolar basis, forming the 
hormone-drug conjugate, NaMTX-[Nle4,D-Phe7]a-M SH . The hypothesis was 
that if MTX was not taken up by its normal route i.e. the folic acid pathway 
but rather by a cell-specific receptor-mediated process (in this case utilising the 
a-M SH receptor) then the targeting of the drug to melanoma could be 
exploited and the side effects could be markedly reduced.
Binding experiments were performed with the radiolabelled conjugate 
N“MTX-[125I-Tyr2,Nle4,D-Phe7]o-MSH in the presence of both the MCI and 
the MC3 receptors. The results of these experiments allowed the estimate of 
the affinities of the ligand for the different receptors. Competition binding 
assays were done and gave Kd values for the unlabelled conjugate. The 
targeted molecule is the unlabelled rather than the radiolabelled NaMTX-[Nle4- 
,D-Phe7]a-M SH and since radiolabelling affects the affinity of ligands for 
receptors, the affinity of the unlabelled moiety should be known.
Internalisation experiments were also performed with continuous exposure and 
Pulse-Chase labelling protocols in the presence and absence of NH4C1. These 
experiments traced the path of the N“MTX-[125I-Tyr2,Nle4,D-Phe7]a-M SH
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once it had bound to the receptor and helped to elucidate the intracellular fate 
of the ligand.
The inhibition of growth by N“MTX-[Nle4,D-Phe7]a-M S H  on a range of cell 
lines was investigated using the same assay as for MTX alone and hence the 
results of both (see Chapter 4 for MTX results) may be compared.
5.2. D egradation of N“MTX-[Nle4,D-Phe7]a -M S H .
See chapter 2.12. for a detailed protocol.
To assess the degradation of NaMTX-[Nle4,D-Phe7]a-M SH  and hence to 
determine whether or not it is degraded into MTX and / or [Nle4,D-Phe7]oc- 
MSH, 3.05 x 105 B16 cells were seeded per 25cm2 tissue culture flasks. 10ml 
of RPMI-FCS containing 5 x 10*5M NaMTX-[Nle4,D-Phe7]a-M SH  was 
added. It should be noted that this concentration exceeds the E.C .50 . The cells 
were gassed and placed in an incubator at 37°C. At various time intervals (24, 
48 and 72 hours) a flask was removed and the medium decanted. The medium 
was then centrifuged and analysed by HPLC at 217 and 310nm. A control flask 
which contained no NaMTX-[Nle4,D-Phe7]a-M SH  was treated in a similar 
manner.
Figure 5.1 represents the HPLC trace of [Nle4,D-Phe7]a-M SH (labelled 
NLDP) at 217nm and 310nm. [Nle4,D-Phe7]a-M SH is known to be detected at 
217nm (see purification procedure, Chapter 2.10.) and this trace demonstrated 
that the [Nle4,D-Phe7]a-M SH is eluted at 48-52 minutes with detection at this 
wavelength whereas no absorption at 310nm was observed.
The elution profiles of the NaMTX-[Nle4,D-Phe7]cc-MSH (labelled MTX- 
NLDP) at 217nm and 310nm are shown in Figure 5.2.. Detection at 217nm 
shows that elution of the peptide takes place at 48-52 minutes as described
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previously. Detection at 310nm shows the three peaks associated with the 
chromophore of MTX, which occurs at 50-52 minutes.
Figure 5.3. shows the effects of incubating the NaMTX-[Nle4,D-Phe7]a-M SH 
with B16 cells in medium over a 72 hour period. It is clear that although there 
are more peaks associated with the profiles, these are probably due to any 
debris which may have accumulated over this time, but essentially the profile 
o f the conjugate initially and after 72 hours remains similar.
Figure 5.4. gives the HPLC traces at 217nm of (i) the medium alone (RPMI), 
(ii) the [Nle4,D-Phe7]a-M SH alone (NLDP), (iii) the N“MTX-[Nle4,D-Phe7]a- 
MSH (MTX-NLDP) at a concentration of 5 x 105M in medium and also (iv) 
NaMTX-[Nle4,D-Phe7]a-M SH (10 5M) in medium in the presence of B16 cells 
for 48 and (v) 72 hours. It should be noted that although they appear to elute at 
different times, in fact this is not the case, rather the chromatograms are 
automatically displaced by the printer in order to prevent any overlapping 
which subsequently allows a clearer visualisation of each sample individually. 
The RPMI produced no peaks which was to be expected, the [Nle4,D-Phe7]a - 
MSH alone produced a single narrow peak at 48-52 minutes. The elution 
profiles for the sample NaMTX-[Nle4,D-Phe7]a-M SH and those injected on 
days 2 and 3 were very similar and show no major new peaks on day 3 which 
indicates that the majority of the sample has remained intact.
Finally Figure 5.5. shows the HPLC traces at 310nm, where it is expected that 
the chromophore of MTX is eluted. The [Nle4,D-Phe7]a-M SH does not exhibit 
any peaks at this wavelength, whereas the N“MTX-[Nle4,D-Phe7]a-M SH 
shows the expected three peaks which were shown previously in Figure 5.2. 
The profiles of the NaMTX-[Nle4,D-Phe7]a-M SH on days 1, 2, and 3 exhibit 
similar peaks, at elution times of 48-52 minutes. The profile of MTX alone and 
also that exhibited by the samples on days 1, 2 and 3 for elution time 40-42
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exhibit similar peaks which must be due to the MTX. From the results of these 
traces it was clear that the major peaks associated with the individual 
molecules and also the NaMTX-[Nle4,D-Phe7]a-M SH initially, still remain 
virtually the same after 72 hours exposure to B16 cells and hence it may be 
deduced that substantial degradation of N“MTX-[Nle4,D-Phe7]a-M SH had not 
taken place.
5.3. Binding studies with NaMTX-[125I-Tyr2,Nle4,D-Phe7]a-M SH .
5.3.1. Binding Isotherm.
A binding isotherm is a method of determining the affinity of a particular
125ligand for a particular receptor, in this case the ligand was NaMTX-[ I- 
Tyr ,Nle4,D-Phe7]a-M SH and the receptors under investigation were the 
melanocortin 1 (M CI) and the melanocortin 3 (MC3) receptors. The results 
were expressed as the dissociation constant (Kd). The greater the Kd, the lower 
the affinity of the ligand for the receptor i.e. the more likely the ligand and 
receptor will remain dissociated. It can be described by the following equation:
Ka
[L] + [R] < =  > [LR]
Kd
where:
[L] = Concentration of the ligand
[R] = Concentration of receptor
[LR] = Concentration of ligand-receptor complex
Ka = affinity constant for the forward reaction
Kd = dissociation constant for the reverse reaction
note: ( Affinity constant = 1 /  Kd)
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Clearly it is advantageous when targeting a hormone to a receptor that the 
affinity is high as this implies a stronger association between the two which is 
also assumed to lead to increased levels of internalisation of the ligand- 
receptor complex.
Previous work performed with the radiolabelled hormone analogue 125I- 
[Nle4,D-Phe7]a-M SH yielded Kd values in the region of 0.5nM for the MCI 
receptor, (Erskine-Grout, 1993) (see Figure 5.6) and 1.66nM for the MC3 
receptor, (Sahm, 1994). The threefold reduction in the affinity with which the 
125I-[Nle4,D-Phe7]a-M SH bound to the MC3 receptor relative to the MCI 
receptor showed some degree of selectivity of the ligand for the MCI receptor. 
Although most studies of a-M SH receptors on melanoma cells were based on 
model systems such as the B16 mouse melanoma, more recently human 
melanoma cell lines have been investigated. The MeWo human melanoma cell 
line (M CI) was examined in this study to determine the Kd value for 125I- 
[Nle4,D-Phe7]a-M SH. Initial time course experiments showed that no further 
increase in binding was apparent after 8 hours (Figure 5.7.) and hence this was 
the incubation period used. Figure 5.8. shows the results of a typical binding 
isotherm, and a Kd value of 5.82 x 108M was determined, (n=3). Thus the 
MeWo cell line possessed MCI receptors with a tenfold lower affinity for the 
125I-[Nle4,D-Phe7]a-M SH ligand than the corresponding MCI receptors on the 
B16 cell line. From this it can be deduced that although the same receptor was 
expressed in both cell lines, the affinity of both for 125I-[Nle4,D-Phe7]a-M SH 
was quite different. This value was not surprising as it has been established by 
other workers, (Eberle et al., 1993) that human melanoma do not bind with as 
high an affinity as murine cell lines. It is also true that MeWo human 
melanoma cells do not express as many receptors on their cell surface which, 
although having no effect on the binding affinity, still makes the
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reproducibility of the experiments more difficult. The advantage of using 
established cell lines e.g. B16 mouse melanoma, was the ease with which they 
were cultured in large quantities and the reproducibility of their responses. 
Isotherms with N aMTX-[1251-Tyr2,Nle*,D-Phe7] a  -MSH :
The effect of the NaMTX-[125I-Tyr2,Nle4,D-Phe7]a-M SH conjugate on the 
MCI receptor was determined in this study and gave a Kd value of 7.35nM. 
This value was fourteen times lower than the value yielded with the 125I- 
[Nle4,D-Phe7]a-M SH for the same receptor. This showed that the coupling of 
the MTX to the N-terminus of the ligand may have been responsible for 
inducing conformational problems at the receptor site. Steric hindrance which 
may have resulted from the increase in size of the ligand may account for the 
reduction in binding affinity. The binding of N“MTX-[125I-Tyr2,Nle4,D-Phe7]a  
-MSH was assessed in the 293 cell line transfected with the gene encoding the 
MC3 receptor and a Kd of 1.69nM was found. This value is lower than that for 
the MCI receptor and therefore implied a slightly higher binding affinity of 
NaMTX-[125I-Tyr2,Nle4,D-Phe7]a-M SH to the MC3 receptor. Interestingly the 
affinities o f the 125I-[Nle4,D-Phe7]a-M SH and N“MTX-[l25I-Tyr2,Nle4,D- 
Phe7]a-M SH  for the MC3 receptor are almost equal. This would seem to 
indicate that the MC3 receptor is not as sensitive to substitution at the N- 
terminus of the ligand as the MCI receptor. The results of these binding 
isotherms are given in Figures 5.9. and 5.10.
5.3.2. Com petition Binding Assays.
Chapter 2.13.3. contains a detailed account of the methods employed.
The most important value to consider for drug targeting is the Kd value of the 
unlabelled moiety i.e. NaMTX-[Nle4,D-Phe7]a-M SH because this what was 
hoped to be used in the future for the site specific delivery of MTX to
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melanoma. It has been shown with the binding isotherms that the NaMTX- 
[125I-Tyr2,Nle4,D-Phe7]a-M SH did not selectively bind to the MCI receptor 
and further that the MCI receptor was more susceptible to conformational 
changes.
A competitive binding assay assesses the ability of a ligand to displace a 
radioactive ligand from the receptor site. It is necessary that the Kd of the 
radioactive ligand for the receptor is known in order that the affinity of the 
unlabelled ligand may be calculated using the equation given in section
2.13.3.1.
Previous work was done to establish the affinity of the MCI receptor for 
N“MTX-[Nle4,D-Phe7]a-M SH and a Kd value of 1.54nM was found, 
(Erskine-Grout, 1993).
In this study three replicate binding experiments were done on the transformed 
293 cells (with MC3 receptor) which gave an average value for Kd of 1.06 x 
10’7 for NaMTX-[Nle4,D-Phe7]a-M SH . This was over a hundred fold lower 
affinity for the ligand with the MC3 receptor than for the MCI receptor. This 
has clear advantages in drug targeting terms since it implies that the unlabelled 
conjugate i.e. the targeting moiety, will exhibit a hundred fold increase in 
affinity and hence selectivity towards receptors on melanocytes (MCI) in 
preference to receptors located in the brain (MC3) leading to a reduction of 
any CNS side-effects. Figure 5.11. shows the results of a competitive binding 
assay.
In table 5.1 below, a list of the ligands together with their respective affinities 
(expressed as dissociation constant) for either the MCI or the MC3 receptor 
are given.
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Table 5.1. Relative affinities of various ligands for the two melanocortin 
receptors (MCI and MC3) under investigation.
LIGAND MCI receptor MC3 receptor
_____________________________ (B16 cells)______________________
a-M SH K d: 2.06 x 10 8 M 
(+/-) 5.31 x 10*9 
n=3 
(Sahm,1994)
Kd: 2.07 x 10 6M 
(+/-) 1.18 x 10-6 
n=3 
(Sahm, 1994)
[Nle4,D-Phe7]a-MSH Kd: 2.02 x 1 0 9 M 
(+/-) 7.81 x 10 11 
n=3 
(Sahm,1994)
Kd: 2.15 x 1 0 8 M 





Kd: 0.48 x 1 0 9 M 
(+/-) 0.076 x 10-9 
n=5
(Erskine-Grout, 1993)
Kd: 1.66 x 1 0 9 M 





Kd: 1.54 x 10 9M 
(+/-) 2 .01  x 1 0 10 
n=3
(Erskine-Grout,1993)
Kd: 1.06 x 10 7 M 






Kd: 7.35 x 10'9M 
(+/-) 2.48 x 10 9 
n=3
(This study)
Kd: 1.69 x 10 9 M 




5.4. In ternalisation Studies with N“M TX-[125I-Tyr2,Nle4,D-Phe7]a-M SH  .
125Internalisation studies were undertaken to pursue the pathway of N“MTX-[ I-
2
Tyr ,Nle4,D-Phe7]a-M SH after the initial binding affinities had been 
established. The first experiments involved continual exposure of B16 cells to 
O.lnM NaMTX-[125I-Tyr2,Nle4,D-Phe7]a-M SH in the presence of NH4C1. The 
protocol (see Chapter 2.13.) was carried out at 37°C over a four hour period 
which was interrupted at regular intervals so that the dynamic process of 
internalisation could be examined at these time points. Citrate buffer (pH 2.5) 
was used to remove any radioactivity that was not associated internally, as this 
has been shown to be effective (Adams, 1993). The presence of NH4C1 was 
expected to increase the pH of the endosomal and lysosomal compartments to 
close to 7, due to the partitioning of ammonia into these compartments. This 
has the effect of neutralising the function of the proton pump which causes 
active accumulation of hydrogen ions in normal endosomes and lysosomes. 
The immediate consequence is an inactivation of proteolytic enzymes 
(particularly the thiol proteases known collectively as cathepsins) which have 
optimum enzymatic activity at low pH. Another consequence may be 
perturbation of vesicular traffic and intracellular compartmentalisation 
resulting in modifications of the pathways of internalised materials, such as 
hormone-receptor complexes. The result is the prevention of lysosomal 
degradation of the ligand-receptor complex.
Pulse-Chase labelling experiments allowed the binding of the ligand to the 
receptor over 2 hours at 4°C. This resulted in the immediate internalisation of 
molecules when the temperature of the experiment was increased to 37°C. 
NH4C1 was present for half of the Pulse-Chase experiments to allow the 
quantification of specifically internalised molecules over 4 hours. The
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experiments performed in the absence of NH4C1 presented a more realistic and 
dynamic profile as the receptor was recycled and the ligand degraded.
5.4.1. Continual exposure to N“MTX-[125I-Tyr2,Nle4,D-Phe7]a-M SH  at 
37°C: (In the presence o f  20mM NH4Cl)
See chapter 2.13.4. for a more detailed method, briefly:
5 x 105 B16 cells per well were seeded and incubated at 37°C overnight. Upon 
removal, from the incubator, the cells were washed with SFM and reincubated 
for 15 minutes at 37°C in SFM containing 20mM NH4C1. After 15 minutes 
0.1 nM of N“MTX-[125I-Tyr2,Nle4,D-Phe7]a-M SH in SFM was placed on the 
cells and they were incubated for various time intervals. Half of the cells were 
also incubated with excess (10 6M) non-iodinated ligand to assess the non­
specific binding. The cells were lysed with NaOH and assayed for radioactivity 
on the gammacounter. A parallel series of wells were washed with citrate 
buffer at pH 2.5 for 5 minutes prior to NaOH treatment. This acid treatment 
strips the radioactivity off the cell surface and hence allows the estimation of 
the level of specifically internalised radioactive ligand. It is assumed in the 
calculation of results of this experiment that all the radioactivity counted is due 
to the NaM TX-[125I-Tyr2,Nle4,D-Phe7]a-M SH even though this does not take 
into consideration the possibility that the conjugate may be degraded 
extracellularly and hence the radioactivity may be due to 125I-[Nle4,D-Phe7]a- 
MSH alone. It appeared that the specific binding was still increasing at four 
hours (see Figure 5.12.(a)) and to determine the change in progress of 
internalisation after four hours another experiment was performed.
The same protocol as above, was used, but with different time intervals from 2 
to 48 hours. It appeared (see Figure 5.12.(b)) that no further internalisation 
occurred after four hours. The reasons for this have not been fully elucidated 
although it is thought that the problems with non-specific binding are increased
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over time. It is also possible that the effects of NH4C1 became deleterious to 
the cells after prolonged exposure, which could be reflected in the cessation of 
internalisation.
The results of three experiments performed to show the pattern of 
internalisation of NaMTX-[125I-Tyr2,Nle4,D-Phe7]a-M SH over a four hour 
period clearly demonstrated that as time elapsed more internalisation occurred 
(Table 5.2. and Figures 5.13 and 5.14.). It should be stressed that the presence 
of NH4C1 resulted in continuous endocytosis of the radioligand over a four 
hour period which suggested that under these conditions the receptor was able 
to cycle between the plasma membrane and the early endosome but that 
sequestration or degradation of the receptor was unable to occur. No 
experiments were performed in the absence of NH4C1 because previous work 
(Adams, 1993) showed that there was a reduction in specifically bound ligand 
(125I-[Nle4,D-Phe7]a-MSH) after 60 minutes thought to be due to down- 
regulation of the receptor. It was assumed that a similar profile would have 
been obtained for the NaMTX-[125I-Tyr2,Nle4,D-Phe7]a-M SH in the absence 
of NH4C1. Chronic exposure to 0.1 nM of N“MTX-[125I-Tyr2,Nle4,D-Phe7]a- 
MSH in the presence of NH4C1 caused a continuous accumulation of ligand. 
The rate of internalisation, as estimated from the slope of the graphs of the 
three experiments, gave an average value of 9.3 molecules per cell per minute. 
As this occurred at receptor occupancy of 1.34% this suggested an uptake of 
42,000 molecules per cell per hour at 100% receptor occupancy. Three 
replicate experiments were performed and the average value for the number of 
molecules taken up by the cells over a four hour period as estimated by the 
mean of the three experiments is 1792.5. (Table 5.2). This result does not 
agree with the result estimated using the slope of the graph (i.e. 9.3 x 240= 
2232 molecules) but it still representative. The results are at variance with each
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other due to the interexperimental differences in receptor number expressed 
by the cells, which can vary between 5,000 and 25,000 (Sahm, 1994). The 
results of two representative experiments are given in Figures 5.13 and 5.14. 
Experiments on the rate of pinocytosis conducted by 125I-PVP suggested that at 
0.1 nM dissolved ligand the early endosome would contain about 6  molecules 
and that approximately 2  molecules would be delivered to the lysosome over 
60 minutes, (Richards, 1992). This compares to 448-558 molecules by receptor 
mediated endocytosis, depending on method of assessment, suggesting that 
targeted toxins could be as much as 279 times more toxic to target cells than 
cells which did not express the a-M SH receptor.
Table 5.2. Results of three replicate experiments (121,122 and 123) 
ascertaining the number of molecules of NaMTX-[l25I-Tyr2,Nle4,D-Phe7]a - 
MSH taken up by each cell in a B16 cell line. Column 1 contains the different 
time intervals and the following three columns give the number of molecules 
per cell.
Time (min.) 121 122 123
15 56.6 30.6 30.3
30 232.8 2 0 83.7
60 826 108.6 223
90 1325.4 481 238.8
120 1553.8 516.6 340.4
180 2374 1131 531.2
240 3462 1351.2 564.2
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5.4.2. Pulse Chase Internalisation of NaM TX-[125I-Tyr2,Nle4,D-Phe7]a - 
M SH : (In the absence o f  N H 4Cl)
See Chapter 2.13.5. for protocol.
B16 cells were seeded and incubated in the same way as for the previously 
described internalisation experiments. Once the cells had been incubated 
overnight, they were washed with SFM and incubated for 2 hours at 4°C in 
SFM containing NaMTX-[125I-Tyr2,Nle4,D-Phe7]a-M SH in the presence or 
absence of 10 6M non-iodinated ligand. After 2 hours the cells were washed 
and incubated at 37°C for various times. The radioactivity associated with the 
cells was assayed in the same way as before. All these Pulse-Chase 
experiments were performed at 37°C as it has been established in our 
laboratories (Adams, 1993) that at 4°C there was no evidence of ligand 
internalisation (125I-[Nle4,D-Phe7]a-M SH ) which implied that internalisation 
observed at 37°C involved an endocytic process requiring metabolic energy.
In the absence of NH4C1, a typical experimental profile was as follows: Due to 
the initial mass of radioligand bound to the surface of the cell, there was a high 
level of total activity and a high level of specific activity. As the time 
progressed and the ligand became internalised and subsequently degraded and 
was then released in to the extracellular fluid. The acid wash value was 
initially low, indicating that the specifically bound radioligand was localised at 
the cell surface. The overall process accounts for the decrease in intracellular 
radioactivity. After four hours, there was little specific activity associated with 
the cells which suggested that the ligand which had been bound at zero time, 
had now been internalised, and the waste iodinated molecules discarded. Four 
replicate experiments were performed and the results of one experiment are 
shown in Figure 5.15.
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5.4.3. Pulse Chase Internalisation of NaMTX-[125I-Tyr2,Nle4,D-Phe7]a- 
MSH : (In the presence o f NH4Cl)
A detailed account of the method is given in chapter 2.13.6.
The profile of this experiment differed from the experiment in the absence of 
NH4C1 in many respects. Firstly due to the prevention of (i) receptor recycling 
and (ii) release of the degraded ligand to the surface of the cell there was no 
degradation of internalised ligand so the acid wash value representing mass 
internalised, increased over time. The total activity was high at first and then 
started to decrease as the receptor recycling was prevented. As time progressed 
the amount of total radioactivity associated with the cell became constant as no 
new internalisation occurred and no degradation and subsequent release from 
the cells was allowed to proceed. Beyond the four hour period, a situation 
arose whereby there was a plateau phase of total and specific activity. 
Pulse-Chase experiments were carried out at approximately 0.67% receptor 
occupancy. This is exactly half the receptor occupancy for the continual 
exposure and was calculated on the basis that after 2  hours binding 
equilibration is not achieved and from time course experiments about 50% 
maximal binding is achieved after 2 hours. Under these conditions all bound 
ligand was internalised during the course of the experiment. In previous 
experiments, in our laboratories, (Adams, 1993) at approximately 10% 
receptor occupancy uptake, 500-1000 molecules of 125I-[Nle4,D-Phe7]a-M SH 
was observed per cell. In these studies it represented an uptake of between 20- 
500 molecules per cell after four hours. The results vary dramatically between 
20 and 500 molecules internalised which was due to fluctuations in receptor 
number (5,000-25,000) between experiments. The results of two representative 
Pulse-Chase Internalisation experiments are shown in Figures 5.16. and 5.17.
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Table 5.3. Results of four replicate experiments (126,129,131 and 140) in 
which the number of molecules of N“MTX-[125I-Tyr2,Nle4,D-Phe7]a-M SH
taken up intracellularly are given.
Molecules of Na MTX-[125ITyr2,Nle4,D-Phe7]a.MSH 
taken up by each B16 cell (in the presence of n h 4c i)
Time
(min.)
126 129 131 140
15 542 115.2 59.2 234
30 736 185.6 41.6 252
60 530 183.8 32.6 153.2
90 516 161.2 26.4 258
150 336 100 23.6 163.8
240 460 144.8 17.2 163.8
125The results show that there is an increase in specifically bound NaMTX-[ I- 
Tyr ,Nle4,D-Phe7]a-M SH  between 15 and 30 minutes but this is followed by a 
decrease at 60 minutes and there is little evidence of any increase as time 
progresses to 150 minutes and then tails off.
Summary:
It has been shown that binding of NaMTX-[125I-Tyr2,Nle4,D-Phe7]a-M SH to 
the MCI receptor occurred, (Kd=7.35nM). The subsequent internalisation 
process was examined and the results of continual exposure to 0.1 nM ligand,
125in the presence of NH4C1, showed that internalisation of NaMTX-[ I- 
Tyr ,Nle4,D-Phe7]a-M SH did take place over a four hour period with an 
average of 1793 molecules taken up by each cell in this time.
Pulse-Chase internalisation in the absence and presence of NH4C1 was also 
studied to gain further insight into the process of internalisation of the ligand-
1 2 2
receptor complex. In the presence of NH4C1, it was deduced that between 20 
and 500 molecules were taken intracellularly per cell in four hours following 
occupation of 0.67% of receptors.
Binding of NaMTX-[125I-Tyr2,Nle4,D-Phe7]a-M SH to the MC3 receptor was 
also investigated in this study using transformed 293 cells. This cell line is 
derived from human embryonic kidney (HEK) cells but these cells have been 
transformed so that they stably express the gene encoding the MC3 receptor. 
Other 293 cells that were used contain the gene vector alone and these were 
used as control cells. Due to the fact that a-M SH also binds to melanocortin 
receptors in the brain (MC3, MC4 and MC5) it was necessary to elucidate with 
what affinity the NaMTX-[125I-Tyr2,Nle4,D-Phe7]a-M SH bound to the MC3 
receptor, as this would have a significant impact on the usefulness of the
125conjugate. The results obtained indicated that the affinity of NraMTX-[ I- 
Tyr2,Nle4,D-Phe7]a-M SH for both the MCI and the MC3 receptors are quite 
close 7.35nM and 1.69nM respectively and this may present a problem of 
central nervous system (CNS) side-effects, if reflected by the unlabelled 
conjugate. The affinities of the MCI and MC3 receptors for the unlabelled 
conjugate was examined in competitive binding assays and Kd values of 
1.54nM and 1.06 x 10 7M respectively were found. These values were quite 
promising in terms of preferential drug targeting to the MCI receptor. There is 
also a great disparity in the number of MCI receptors expressed on the surface 
of B16 cells (5,000-25,000) which varies with passage, (Erskine-Grout, 1993) 
and the number of MC3 receptors expressed on the surface of transformed 293 
cells, (150,000-10,000) which is passage dependent, (Sahm,1994). The 
consequences of this disparity were hoped to be examined both in terms of the 
binding affinity and also in the growth inhibitory experiments with the MTT 
assay.
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5.5. Growth Inhibitory Effects of N“MTX-[Nle4,D-Phe7]a-M SH  as 
assessed by the MTT Assay:
See Chapter 2.14. for a detailed account of the methods used.
Concentrations of NaMTX-[Nle4.D-Phe7]a-M SH  ranging from 104 to 1 0 13M 
were employed to determine the E.C .50 value. Once the approximate value had 
been determined, the range was narrowed to achieve a more accurate estimate. 
All cells were seeded at a density of 4 x 103 cells/well in 96 microwell plates. 
The cells were exposed to N“MTX-[Nle4,D-Phe7] a-M SH  in medium, over an 
incubation period equivalent to three doubling times of the cell line under 
investigation. The MTT assay was then performed. Control cells were treated 
in exactly the same way but without the NaMTX-[Nle4,D-Phe7]a-MSH.
This series of experiments assessed the growth inhibitory effects of the 
hormone analogue-drug conjugate (NaMTX-[Nle4,D-Phe7]a-M SH) on B16 
murine melanoma cells and MeWo human melanoma cells. SVK14 
keratinocytes were used as control cells because they do not express 
melanocortin receptors on their surface. The growth inhibitory effects of 
NaMTX-[Nle4,D-Phe7]a-M SH on 293 cells transformed with the gene 
encoding the MC3 receptor was investigated to determine whether the higher 
number of receptors expressed influenced the cytotoxicity of NaMTX-[Nle4,D- 
Phe7]a-M SH . 293 cells which were transfected with the pcDNA/neo vector 
were used as control cells for the transformed 293 cells, to check if the process 
of transfection with a vector in any way increased the cell susceptibility to the 
conjugate.
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5.5.1. B16 murine melanoma cell line:
The results of the growth inhibition assays with B16 cells are given in Figures 
5.18. (a) and (b). The mean absorbances of the experiments are listed in Table
5.4., the coefficient of variation expressed as a percentage (%) (i.e. ((S.D. /  
mean) x 1 0 0 ) was 2 0 % for all of the experiments and demonstrated that there 
was a high degree of reproducibility between experiments.
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B16 murine melanoma cell line:
Table 5.4. This table represents the mean net absorbance values calculated by 
subtracting the reference absorbance readings at 690nm from the test 
absorbance readings at 540nm. The columns labelled 93, 120, 156 and 159 
contain the results of four replicate experiments. Each value is the mean of 8 
replicates with the exception of the control cells which involved 16 replicates. 
Column 1 contains the concentrations of N“MTX-[Nle4,D-Phe7] a-M S H  
used.The E.C .50 and standard deviation values were generated using the 






(93) (1 2 0 ) (156) (159)
Control 1.598 1.299 1.317 0.955
1.1  x 1 0 13 1.708 1.069 1.202
1.1 x 1 0 12 1.670 0.974 1.119
1.1 x 10 11 1.600 0.884 1.167
1.1 x 10 10 1.516 0.895 1.226
1.1 x 1 0 9 1.504 1.034 1.230
1.1 x 1 0 8 1.709 1.181 1.499 0.766
5.5 x 10 8 0.790
1.1 x 10  7 1.642 1.007 1.427 0.860
5.5 x 10 7 1.376
1.1 x 10  6 1.574 1.112 0.657 1.463
5.5 x 10-6 0.844
1.1 x 1 0 5 0.266 1.148 0.211 0.483
2 .2  x 1 0 5 0.581
5.5 x 1 0 5 0.380
1.1 x 10 4 0.087 0.259 0.191 0.367
E.C.50 (M) 2.5 x lO 6 4.4 xlO 5 9.0 xlO 7 1.2 xlO 5
S.D. (+/-) 8.5 xlO 7 8 .8  xlO 6 3.9 xlO 7 1.5 xlO 5
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5.5.2. MeW o hum an melanoma cell line:
Figure 5.19. shows the results of the growth inhibition assays with the MeWo 
human melanoma cell line.
Table 5.5. This table represents the mean net absorbance values calculated by 
subtracting the reference absorbance readings at 690nm from the test 
absorbance readings at 540nm. The columns labelled 76,95,96 and 98 contain 
the results of four replicate experiments. Each value is the mean of 8 replicates 
with the exception of the control cells which involved 16 replicates. Column 1 
contains the concentrations of N“MTX-[Nle4,D-Phe7] a-M S H  used. The E.C .50 







(76) (95) (96) (98)
Control 1.068 1.807 1.332 1.447
1 .1  x 1 0 13 1.317 1.106
1 .1  x 1 0 12 1.699 0.894
1 .1  x 1 0  11 1.274 1.071
1 .1  x 1 0 10 1.235 1.266
1.1  x 1 0 9 0.709 1.160 0.778 1.114
1 .1  x 1 0 8 1.126 1.479 1.032 1.369
5.5 x 10 8 1.358 1.325
1.1  x 1 0  7 0.781 1.204 1.095 0.971
5.5 x 10-7 0.552 1.446
1 .1  x 10  6 0.247 1.205 0.383 0.693
5.5 x 10 6 0.261 0.319
1.1  x 1 0  5 0.004 0.510 0.218 0.245
5.5 x 10 5 0.083 0.119
1 .1  x 1 0  4 0.003 0 .2 2 1 0.067 0.081
E.C.<„ (M) 2 .0  x lO 7 7.2 x lO 6 7.3 xlO 7 1 .8  x lO 6
S.D.(+/-) 1.3 x 10 7 4.5 x 10-6 3.7 x 10 7 7.8 x 10-7
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5.5.3. SVK14 keratinocvtes:
Figure 5.20. shows the results of growth inhibition assays with the
keratinocytes, SVK14 in the presence of NaMTX-[Nle4,D-Phe7]a-M SH .
Table 5.6. This table represents the mean net absorbance values calculated by 
subtracting the reference absorbance readings at 690nm from the test 
absorbance readings at 540nm. The columns labelled 88  and 94 contain the 
results of two replicate experiments. Each value is the mean of 8 replicates 
with the exception of the control cells which involved 16 replicates. Column 1 
contains the concentrations of NaMTX-[Nle4,D-Phe7]a-M SH  used. The E.C .50 
and standard deviation values were generated using the MINSQ non-linear 
regression program (weighting=l).
NET MEAN ABSORBANCE
N“MTX-[NIe4,DPhe7]a -M S H
(M)
(8 8 ) (94)
Control 1.069 0.992
1 .1  x 1 0 13 1.163
1 .1  x 10  12 1.065
1 .1  x 1 0 11 1.157
1 .1  x 1 0 10 0.969
1 .1  x 1 0 9 0.968 0.968
1 .1  x 1 0 8 1.047 0.946
1.1  x 1 0 7 1.091 0.912
1 .1  x 10  6 1.223 0.925
2 .2  x 10  6 0.646
5.5 x 10-6 0.107
1 .1  x 1 0 5 0.098 0.041
2 .2  x 1 0 5 0.039
5.5 x 1 0 5 0.031
1 .1  x 10  4 0.032 0.037
E.C.50 2.1 x 10 6M 1.2 x 10 6M
S.D.(+/-) 1.1  x 10  6 6 .0  x 10  7
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5.5.4. Effects of N“MTX-[NIe4,D-Phe7]a-M SH  on the transformed 293 
cells:
The effects of N“MTX-[Nle4,D-Phe7]a-M SH  on the transformed 293 cells was 
investigated in experiments 146 and 147. Experiment 146 involved the 
transformed 293 cells which stably expressed the MC3 receptor. Experiment 
147 involved the transfected 293 cells which had the vector alone (in the 
absence of any gene encoding information). The results of both experiments are 
given below in Table 5.7.
Figures 5.21. and 5.22. show the differences in the growth inhibitory effects of 
MTX versus NaMTX-[Nle4,D-Phe7]a-M SH  on the two different 293 cell lines 
i.e. in the presence and absence of cloned MC3 receptors respectively.
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Transformed 293 cell lines:
Table 5.7. This table represents the mean net absorbance values calculated by 
subtracting the reference absorbance readings at 690nm from the test 
absorbance readings at 540nm. The columns labelled 146 and 147 contain the 
results of two separate experiments with the NaMTX-[Nle4,D-Phe7]a-M SH  
conjugate. Each value is the mean of 8 replicates with the exception of the 
control cells which involved 16 replicates. Column 1 contains the 
concentrations of NaMTX-[Nle4,D-Phe7]a-M SH  used. The E.C .50 and standard 












1 x 1 0 13 0.760 0.650
1 x lO 12 0.550 0.489
1 x 10  11 1.085 0.948
1 x 1 0 10 0.699 0.701
1 x 10 9 0.880 0.728
1 x 1 0 8 1.209 0.957
1 x 10  7 1.104 1.284
1 x 1 0 6 1.237 0.544
1 x 10  5 0.438 0.140
1 x 10  4 0.176 0.147
E.C .50 1.1 x 10 5 M 1.7 x 10 6 M
S. D.(+/-) 1.4 x 1 0 5 2.1  x 10  6
It can be seen from the above table and also in Figures 5.21 and 5.22. that MTX 
is effective at killing 293 transformed cell lines at a much lower inhibition (<10- 
n M MTX) concentration than NaMTX-[Nle4,D-Phe7]a-M SH .
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Table 5.8. This table shows the E.C .50 values representing the growth inhibitory 
effects of MTX and NaMTX-[Nle4,D-Phe7]a-M SH on B16, MeWo, 293 





B16 cell line 1.67 x 10 8M 1.47 x 10 5M
MeWo cell line 1.31 x 10 9M 2.48 x 10 6M
MC3 receptors:




3.03 x 10 n M 1.07 x 10 5M
SVK14 cell line < 10 13M 1.68 x 10 6M
293(transformed: 
vector alone)
2.84 x 1 0 13M 1.66 x 10 6M
Only cells with active mitochondria are able to convert MTT to MTT formazan 
which can be solubilised by DMSO giving a dark purple solution. The MTT 
growth inhibition assay measures cell viability in direct relation to the 
absorbance of MTT Formazan. B16 cells were examined and results gave an 
average E.C .50 value 1.47 x 105M NaMTX-[Nle4,D-Phe7]a-M SH. The control 
values were quite high (>1.0AU) for most of the experiments and the 
absorbances remained at this level, if not greater, until a concentration of 
NaMTX-[Nle4,D-Phe7]a-M SH higher than 1.1 x 106M. At concentrations
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greater than 106M, a decrease in absorbance, and cell viability, was obvious in 
all experiments with this cell line. The decrease was quite dramatic e.g. 
experiment "93" where absorbance of 1.574 AU was found for cells exposed to 
10 6M NaMTX-[Nle4,D-Phe7]a-M SH and absorbance of 0.266 AU, i.e. a five 
fold decrease in cell viability, for 105M N“MTX-[Nle4,D-Phe7]a-MSH. 
Although the E.C .50 values obtained were over a wide range (1.152 x 10*5M— 
9.015 x 10_7M), the variation co-efficient was never higher than 20%. B16 cells 
have such a large variability in number of receptors expressed per cell (5,000- 
25,000) and this may have consequential effects on the uptake of the conjugate 
via receptor mediated endocytosis.
The effects of NaMTX-[Nle4,D-Phe7]a-M SH on the MeWo cell line showed 
that these cells were more sensitive to the conjugate than the B16 cells. The 
average E.C .50 value was 2.48 x 10 6M which was a greater than tenfold 
difference in susceptibility vis d vis the E.C .50 of 1.47 x 105M for B16 cells. 
This may be explained if the binding affinity of the unlabelled conjugate for the 
MCI receptors on MeWo cells was higher than the binding affinity of the MCI 
receptors on B16 cells (1.54nM) but this value has yet to be determined. 
However this assumes that the inhibition of the cells was due to the receptor 
mediated uptake of the conjugate. If the N“MTX-[Nle4,D-Phe7]a-M SH was 
degraded extracellularly then the MTX would be taken intracellularly via the 
folic acid pathway which would be independent of any binding data. However, 
this is not likely due to degradation profile.
The results of Chapter 4, where the effects of MTX alone were examined show 
that B16 cells had an E.C .50 value of 1.67 x 108M and MeWo cells had an 
E.C .50 value of 1.31 x 109M MTX. This showed a tenfold difference in their 
relative sensitivities to the inhibitor. In this respect the responses of B16 and 
MeWo cells to inhibiting agents are parallel, i.e. a thousand fold increase in
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concentration of NaMTX-[Nle4,D-Phe7]a-M SH relative to MTX concentration 
is necessary to cause the same reduction in growth.
The SVK14 cells possess no melanocortin receptors and hence act as control 
cells to examine whether their susceptibility to the conjugate relative to (i) 
effects of MTX on SVK14 cells and (ii) effects of the NaMTX-[Nle4,D- 
Phe7]a-M SH on cells with MSH receptors. Table 5.8. shows that the SVK14 
cells were highly sensitive to the cytotoxic effects mediated by MTX. Although 
a definite E.C .50 value was impossible to determine, it was clear from the 
distribution of data that extracellular concentrations of > 1 0 13M were effective 
at killing the cells. The effects of NaMTX-[Nle4,D-Phe7]a-M SH were not as 
dramatic and gave an average E.C .50 value of 1.68 x 106M. This concentration 
was lower than that required to effect the same level of inhibition in either the 
B16 or the MeWo cell lines. This would not be expected if MSH receptors were 
playing an integral role in the mediation of cytotoxic effects. On the contrary, it 
would be expected that the greater the number of MSH receptors expressed, the 
lower the extracellular concentration of N“MTX-[Nle4,D-Phe7]a-M SH 
necessary to reduce growth. This did not bode well for the theory of specific 
targeting of NaMTX-[Nle4,D-Phe7]a-M SH however when the overall effects of 
MTX and the conjugate were assessed, a more optimistic picture emerged: 
There was a thousand fold difference in the levels of NaMTX-[Nle4,D-Phe7]a- 
MSH and MTX necessary to have the same inhibitory effects on B16 and 
MeWo cell lines, but this difference is augmented to seven orders of magnitude 
for SVK14 cells. This implied that the conjugation of MTX to [Nle4,D-Phe7]a- 
MSH had decreased the sensitivity of SVK14 cells by seven orders of 
magnitude and this argued for selective route taken by the NaMTX-[Nle4,D- 
Phe7] a-MSH.
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Effects of the NaMTX-[Nle4,D-Phe7]a-M SH on transformed 293 cells with and 
without MC3 receptors was then examined. As mentioned previously, MC3 
receptors are located in the placenta, gut and most significantly, from a drug 
targeting viewpoint, the brain. The results of a preliminary experiment were 
reported, and showed an E.C .50 value of 1.07 x 105M for 293 cells with MC3 
receptors and 1.66 x 10 6M, for 293 cells, without. This demonstrated a similar 
profile to that of the SVK14 cells but the errors associated with data from these 
293 cells were quite high (variation co-efficient: 30%) and so further studies 
should be undertaken.
5.6. Control experiments in the presence of [Nle4,D-Phe7]a-MSH:
A control experiment was performed with [Nle4,D-Phe7]-a-M SH (1 0 4 to 10 
13M) which was incubated with the cells in the normal manner, this was done to 
establish its role in growth inhibition or indeed if such a role existed.The MTT 
assay was then performed. Control cells were treated in exactly the same way 
but the [Nle4,D-Phe7]-a-M SH was omitted.
The results of these experiments are shown in Figures 5.23 and 5.24 
respectively. It was clear that [Nle4,D-Phe7]-a-M SH does not adversely affect 
the growth of cells until a concentration of 106M or greater was used and at this 
point the cells experienced a decrease in viability which was transient. At the 
highest concentration of [Nle4,D-Phe7]-a-M SH (10 4M) the level of absorbance 
and hence viability of the cells was similar, if not higher than, the control 
values.
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5.7. Effects of lysomotropic agents on the growth inhibitory properties of 
N“MTX-[Nle4,D-Phe7]a-M SH :
The effects of the ionophore, monensin and also the lysomotropic agent, 
chloroquine were examined to see whether any augmentation or reduction in 
activity of NaMTX-[Nle4,D-Phe7]a-M SH  was observed.
5.7.1. Monensin:
A growth inhibitory assay was set up with B16 cells and NaMTX-[Nle4,D- 
Phe7]a-M SH  according to the protocol in chapter 2.14. Monensin (1 0 5M) was 
present at each concentration of NaMTX-[Nle4,D-Phe7]a-M SH  to and the 
results of three replicate experiments (160, 162 and 166) are given in Table 5.9. 
Figure 5.25. shows the results of one of these experiments. Monensin prevents 
receptor recycling to the surface of the cell and it would be expected that if 
NaMTX-[Nle4,D-Phe7]a-MSH exerted effects by receptor mediated 
endocytosis then the E.C .50 value for B16 cells in the presence of monensin, 
would be higher than for B16 cells with N“MTX-[Nle4,D-Phe7]a-M SH alone. 
The average E.C .50 value found was 1.56 x 105M which does not differ 
significantly from the 1.47 x 105M determined as the E.C .S0 for NaMTX- 
[Nle4,D-Phe7]a-M SH alone. This was an indication that the NaMTX-[Nle4,D- 
Phe7]a-M SH did not exert its effects via a surface membrane receptor that 
recycles.
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B16 murine melanoma cell line:
Table 5.9. This table represents the mean net absorbance values calculated by 
subtracting the reference absorbance readings at 690nm from the test 
absorbance readings at 540nm. The columns labelled 160, 162 and 166 contain 
the results of three separate experiments with the NaMTX-[Nle4,D-Phe7] a -  
MSH conjugate in the presence of 10 5M monensin. Each value is the mean of 8 
replicates with the exception of the control cells which involved 16 replicates. 
Column 1 contains the concentrations of NaMTX-[Nle4,D-Phe7]a-M S H  used. 
The E.C .50 and standard deviation values were generated using the MINSQ non­
linear regression program (weighting=l).
NET MEAN ABSORBANCE
N“MTX-[Nle4,D-
Phe7]a -M S H
(M)
160 162 166
Control 1.433 1.026 1.242
1 x 10  8 1.247 0.599 1.144
5 x 10 8 1.374 0.854 1.315
1 x 1 0 7 1.195 0.985 0.805
5 x 10-7 1.092 0.873 0.636
1 x 1 0 6 1.461 0.751 1.017
5 x 10 6 1.689 0.704 0.543
1 x 1 0 5 0.977 0.619 0.334
2  x 10  5 0.796 0.593 0.213
5 x 10-5 0.572 0.682 0.161
1 x 10  4 0.373
E.c.50 (M) 4.146 x 1 0 5 4.079 x 10 6 1.282 x 10  6
S. D. (+/-) 3.660 x 1 0 5 1.261 x 1 0 5 1.086 x 10  6
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5.7.2. Chloroquine:
Figure 5.26. represents the results of an experiment in which B16 cells were 
treated with a range of concentrations of NaMTX-[Nle4,D-Phe7]a -M S H  in the 
presence of 104M chloroquine. Previous experiments with chloroquine had 
demonstrated that it was quite a toxic agent at concentrations greater than 10- 
5M when placed on the cells in the absence of any other agent e.g. MTX or 
NaMTX-[Nle4,D-Phe7]a-M SH . Therefore the results o f the experiment shown 
by Figure 5.26. should be viewed in the light of this statement. The dramatic 
inhibition of cell growth may not be attributed to the augmentation of 
cytotoxicity of NaMTX-[Nle4JD-Phe7]cx-MSH. Further experiments need to be 
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Figure 5.1. This figure represents the HPLC trace of [NIe^,D-Phe^]a-MSH labelled "NLDP" 
217nm and 310nm.
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Figure 5.2. This figure shows the elution profile of Na MTX-[NIe4,D-Phe7]a-MSH labelled "MTX- 
NLDP" at 217nm and 310nm.
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Figure 5.3. This represents the elution profile of Na MTX-[Nle^,D-Phe^]a-MSH after incubation 
with B16 cells at 37°C for 72 hours.
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Figure 5.4. This shows the elution profile of the following samples at 217nm:
1: RPMI medium alone, 2: Na MTX-[NIe4,D-Phe7]a-MSH after 48 hours with B16 cells, 3: 
Na MTX-[Nle4,D-Phe7]a-MSH after 72 hours with B16 cells 4: Na MTX-[Nle4,D-Phe7]<x-MSH 
alone 5: [Nle4,D-Phe7]a-MSH alone. (See text for details).
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Figure 5.5. This figure represents the elution profile of the following samples at 310nm:
1: Na MTX-[Nle4,D-Phe']a-MSH after 24 hours with B16 cells, 2: Na MTX-[Nle4,D-Phe7]a-MSH 
after 48 hours with B16 cells, 3: Na MTX-[Nle4,D-Phe7]a-MSH after 72 hours with B16 cells, 4: 
RPMI medium alone, 5: MTX alone, 6: Na MTX-[Nle4,D-Phe7]a-MSH alone and 7: [Nle4,D-Phe7] 
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Figure 5.6. Binding isotherm with B16 cells incubated in the presence of 
various concentrations of 125I-[Nle4,D-Phe7]a-M SH in the presence and 
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Figure 5.7. Time course experiment performed with the MeWo cell line
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Figure 5.8. Binding isotherm with MeWo cells incubated in the presence 
of various concentrations of 125I-[NIe4,D-Phe7]a-MSH in the presence 
and absence of excess (10'6M) non-iodinated [Nle4,D-Phe7]a-M SH. Error 
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Figure 5.9. Binding isotherm with transformed 293 cells incubated in the 
presence of various concentrations of NaMTX-[ I-Tyr ,Nle4,D-Phe7]a- 
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Figure 5.10. Binding isotherm with transformed 293 cells, expressing 
MC3 receptors incubated in the presence of various concentrations of 
N“MTX-[125I-Tyr2,Nle4,D-Phe7]a-MSH in the presence and absence of 
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LOG CONCENTRATION OF INHIBITOR
Figure 5.11. This Figure shows the results of the competitive binding 
assay where O.lnM 125I- [Nle4,D-Phe7]a-M SH is incubated in the 
presence of varying concentrations of unlabelled [Nle4,D-Phe7]a-MSH  
a n d  NaMTX-[Nle4,D-Phe7]a-MSH and was performed on transformed 
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Figure 5.12.(a) Continual exposure internalisation of O.lnM NraMTX-
[123I-Tyr2,NIe4,D-Phe7]a-M SH  with B16 cells in the presence of 20mM
NH4C1. Experiment performed over 4 hours.
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Figure 5.12.(b) Continual exposure internalisation of O.lnM NaMTX-
[125I-Tyr2,NIe4,D-Phe7]a-MSH with B16 cells in the presence of 20mM
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Figure 5.13. Continual exposure internalisation of O.lnM NaMTX-[125I-
Tyr2,Nle4,D-Phe7]a-MSH with B16 cells in the presence of 20mM
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125Figure 5.14. Continual exposure internalisation of O.lnM N“MTX-[ I-
Tyr2,Nle4,D-Phe7]a-MSH with B16 cells in the presence of 20mM
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Figure 5.15. Pulse Chase internalisation of O.lnM NaMTX-[125I-
Tyr2,Nle4,D-Phe7]a-MSH with B16 cells in the absence of 20mM NH4CI.
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Figure 5.16. Pulse Chase internalisation of O.lnM NaMTX-[ I- 
Tyr2,Nle4,D-Phe7]a-MSH with B16 cells in the presence of 20mM 
NH4C1. Experiment performed over 4 hours.
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Figure 5.17. Pulse Chase internalisation of O.lnM N“MTX-[ I- 
Tyr2,Nle4,D-Phe7]a-MSH with B16 cells in the presence of 20mM 
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Figure 5.18.(a). Relative values obtained for absorbance of B16 cells 
exposed to N“MTX-[Nle4,D-Phe7]a-MSH . The results of 4 replicate 
experiments are shown. Each point is the mean of 8  wells. Error bars 
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LOG CONCENTRATION NaMTX-[Nle4,D-Phe7]cx-MSH
Figure 5.18.(b). Net absorbance readings (540-690nm) obtained with B16 
cells incubated with NaMTX-[NIe4,D-Phe7] . Each point is the mean of 8  
replicates. Control values are the mean of 16 replicates. Standard 
deviation is shown by error bars.
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LOG CONCENTRATION N“MTX-[Nlc4,D-Phe7]a-M SH
Figure 5.19.(a). Relative values obtained for absorbance of MeWo cells 
exposed to NaMTX-[Nle4,D-Phe7]a-MSH . The results of 4 replicate 
experiments are shown. Each point is the mean of 8  wells. Error bars 
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Figure 5.19.(b). Net absorbance readings (540-690nm) obtained with 
MeWo cells incubated with NaMTX-[Nle4,D-Phe7] . Each point is the 
mean of 8  replicates. Control values are the mean of 16 replicates. 
















Figure 5.20. Net absorbance readings (540-690nm) obtained with 
SVK14 cells incubated with NaMTX-[Nle4,D-Phe7]. Each point is the 
mean of 8  replicates. Control values are the mean of 16 replicates. Error 




























LOG CONCENTRATION OF INHIBITOR
Figure 5.21. Net absorbance readings (540-690nm) obtained with 
transformed 293 cells (with MC3 receptors) incubated with NaMTX- 
[NIe4,D-Phe7]. Each point is the mean of 8  replicates. Control values are 

















LOG CONCENTRATION OF INHIBITOR
Figure 5.22. Net absorbance readings (540-690nm) obtained with 
transformed 293 cells (without MC3 receptors) incubated with NaMTX- 
[Nle4,D-Phe7]. Each point is the mean of 8 replicates. Control values are 





























LOG CONCENTRATION OF [NIe4,D-Phe7]CC-MSH
Figure 5.23. Absorbance readings obtained at test (540nm), reference 
(690nm) and net absorbance (540-690nm) readings for B16 cells exposed 
to [Nle4,D-Phe7]a-MSH. Each point is the mean of 8 wells. Control 
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LOG CONCENTRATION OF .[Nlc4,D-Phe7]a-M SH
Figure 5.24. Absorbance readings obtained at test (540nm), reference 
(690nm) and net absorbance (540-690nm) readings for MeWo cells 
exposed to [Nle4,D-Phe7]a-M SH. Each point is the mean of 8  wells. 






























Log Cone. NaMTX-fNle4,I)-Phe7]a-M SH in the presence 
of 10'5M monensin
Figure 5.25. Absorbance readings obtained at test (540nm), reference 
(690nm) and net absorbance (540-690nm) readings for B16 cells exposed 
to [Nle4,D-Phe7]a-MSH in the presence of 10 5M monensin. Each point is 
the mean of 8  wells. Control values are the mean of 16 wells. Standard 
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Figure 5.26. Absorbance readings obtained at test (540nm), reference 
(690nm) and net absorbance (540-690nm) readings for B16 cells exposed 
to [Nle4,D-Phe7]a-MSH in the presence of 1 0 4M chloroquine. Each 
point is the mean of 8  wells. Control values are the mean of 16 wells. 
Standard deviation is shown by error bars.
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Figure 5.27. This photograph represents the growth inhibitory effects of Na MTX-[NIe^,D-Phe^]a- 
MSH on B16 cells. Columns 1 and 6 represent the control cells while, columns 2-12 have increasing 
concentrations of the inhibitor from 10'13M to lO^M. Each concentration has eight replicates 
labelled A-H.
Figure 5.28. This photograph shows the effects of [Nle^D-Phe^Ja-MSH on B16 cells. Columns 1 
and 6 represent the control cells while, columns 2-12 have increasing concentrations of [Nle4,D- 
Phe^]a-MSH from 10'13M to lO^M. Each concentration has eight replicates labelled A-H.
M
CHAPTER 6.
Determination of the intracellular mass of 
methotrexate required to effect growth inhibition in 
B16 mouse melanoma.
6.1. INTRODUCTION
Since methotrexate was the model drug used in the investigations of drug 
targeting to melanoma cells, via the a-M SH receptors, it was logical to 
determine how much MTX was needed for growth inhibition to predict whether 
sufficient MTX would be delivered by receptor-mediated endocytosis. The 
immediate aim of this part of the work was to determine the number of 
molecules of methotrexate (MTX) required, intracellularly, to effect 
antimetabolic activity (i.e. growth inhibition). By determining the number of 
moles of MTX taken up by the cells in each well, and the number of viable cells 
present, it was then possible to estimate the corresponding number of MTX 
molecules taken up per cell as a function of MTX concentration.
The effect of varying concentrations of methotrexate on B16 murine melanoma 
cells was assessed by three methods in parallel; (i) viable cell counting using the 
Trypan Blue dye exclusion assay, (ii) cytostasis assay using the MTT (3-[4,5- 
Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; Thiazoyl blue) 
metabolic assay (Mosmann, 1983) and finally (iii) determination of the cellular 
uptake of 3H-MTX by scintillation counting. Methods are described in more 
detail in chapter 2 .
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6.2. RESULTS AND DISCUSSION:
TABLE 6.1: The table below shows the results of 3 sets of replicate 
experiments (135,136,137). The E.C .50 value was estimated in two ways; from 
the results of the MTT assay and also from the Trypan blue assay. When the 
E.C.5o value was estimated with the MTT assay it was evaluated as the 
concentration of MTX required to reduce the absorbance to half that of the 
control cells. The no. of cells per well refers to the Trypan blue assay and the 
no. of moles per cell refers to the 3H-MTX uptake assay at the respective E.C .50 
value. When the E.C .50 value is estimated from the Trypan blue viable count, it 
refers to the concentration of MTX necessary to reduce the number of cells per 
well to half that of the control cells. The no.of moles per cell refers to the 3H- 
MTX uptake assay at the respective E.C.50 value. Each value is the mean of 8 
replicate wells.
Experim ent LJW 135 MTT Assay Trypan blue Assay
Mean St. Dev. Mean
E.C.50 (M) 1.66 x 10-8 +/- 4.80 x 10-9 1.08 x lO 8
moles per well 8.94 x 10-14 5.23 x 10-14
cells per well 4.54 x 104 6.15 x 104
moles per cell 1.97 x 1 0 18 8.50 x 1 0 19
molecules per cell 1.18 x 106 5.10 x 105
Experim ent LJW 136 MTT Assay Trypan blue Assay
Mean St. Dev. Mean
E.C.50 (M) 6.96 x 10-9 + /-7.81 x lO 9 5.41 x 10-10
moles per well 3.79 x 1 0 14 3.03 x 10-15
cells per well 4.56 x 104 7.1 x 104
moles per cell 8.31 x 10-19 4.27 x 10-20
molecules per cell 4.99 x 105 2.56 x 104
Experim ent LJW 137 MTT Assay Trypan blue Assay
Mean St. Dev. Mean
E.C.50 (M) 4.20 x 10-8 +/- 1.83 x lO 8 5 x lO 8
moles per well 7.34 x 10-14 8.84 x 10-14
cells per well 2.29 x 104 2.17 x 104
moles per cell 3.21 x 1 0 18 4.07 x 10-18
molecules per cell 1.92 x 106 2.44 x 106
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The E.C .50 value was defined as the concentration of methotrexate required in 
order to reduce the viability of the cells to half the viability relative to control 
cells. This was determined using the MTT assay and the Trypan blue assay. In 
each experiment there were two columns of control cells (equivalent to 16 
replicates). These were at columns 1 and 6  of the microwell plate so as to 
compensate for any inconsistencies which may have arisen purely due to the 
cells positioning on the plate (i.e. edge effects). Figures 6.1. and 6.2. show the 
results of experiments LJW135,136 and 137.
Experiment U W 135 had control absorbance values in the region of 1.5 AU and 
this gradually decreased with increasing concentration of MTX until 
approximately 1 x l0 8M. Above this concentration there was a dramatic change 
in absorbance between 2 x 108M and 5 x 108M MTX. Using the MINSQ non­
linear least square regression program (weighting = 2) estimate of the E.C .50 
value was 1.66 x 10 8 M MTX. When the E.C .50 value was calculated using the 
number of viable cells, the result obtained was 1.08 x 10 8M. Therefore in this 
experiment little disparity existed between both estimates, however because the 
number of moles and cells per well varied (depending upon the mode of 
calculation) the overall number of molecules per cell that was estimated varied 
between 1.18 x 106 (MTT) and 5.10 x 105 (Trypan blue).
The protocol observed in LJW135 was unchanged for the following two 
experiments. In LJW136, the untreated cells reached higher absorbance values 
(2.0-2.5) and these values were at the edge of the linear portion of the MTT 
formazan absorption spectrum (see Figure 3.1. and 3.2.). However as the 
concentration of MTX increased from 1 x 10',0M to 1 x 109M MTX, there was 
a dramatic change in the viability of the cells. The E.C.50 value calculated on the 
basis of absorbance gave 6.96 x 10 9M and when the Trypan blue assay was 
used; 5.41 x 10'10M. These results indicated that the B16 cells were more 
susceptible to the inhibitory effects of MTX because lower concentrations of
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MTX were needed to effect cell kill. In this experiment it was necessary to have 
an average of 2.62 x 105 molecules of MTX internalised per cell as opposed to 
the 8.45 x 105 molecules per cell for LJW135.
LJW137 control absorbance values were within the linear range and the E.C.50 
value calculated was 4.20 x 10‘8M. The interexperimental differences which 
arose between LJW135 and 137 were much smaller than the differences 
between either of these experiments versus LJW136 which would seem to imply 
that the former results were a more reasonable estimate of the cell reaction to 
MTX under identical conditions.
The direct relationship between the concentration of 3H-MTX present within 
each well and the number of moles of 3H-MTX taken up by the cells in each 
well is demonstrated by Figure 6.3. This level is initially very low but gradually 
a greater number of moles accumulated until a plateau was reached at 
approximately 1 x 10 7M. At this point there was a level of between 3.03 x 10-15 
and 8.94 x 1 0 14 moles in each well (depending on the experiment). This in itself 
does not allow estimation of cellular uptake until taken in conjuction with the 
results of the Trypan blue assays, which gives the number of viable cells at a 
given concentration of MTX, see Figure 6.4.
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Table 6.2. This shows the result of another determination of the intracellular 
mass of MTX needed to inhibit the growth of B16 cells. The E.C.50 value is 
estimated in two ways; from the results of the MTT assay and the Trypan blue 
assay. When the E.C.50 value is estimated with the MTT assay it is given in 
terms of the concentration of MTX required to reduce the absorbance to half 
that of the control cells. The no. of cells per well refers to the Trypan blue assay 
and the no.of moles per cell refers to the 3H-MTX uptake assay at the 
respective E.C .50 value. When the E.C .50 value is estimated from the Trypan 
blue viable count, it refers to the concentration of MTX necessary to reduce the 
number of cells per well to half that of the control cells.The no.of moles per cell 
refers to the 3H-MTX uptake assay at the respective E.C.50 value. Each value is 
the mean of 8 replicate wells.
Experiment LJW138 MTT Assay Trypan blue Assay
Mean St. Dev. Mean
E.C.50 (M) 2.42 x 1(H +/- 9.47 x 109 1 x 10-8
moles per well 1.64 x 1 0 14 9.19 x 1 0 15
cells per well 3.78 x 104 7.40 x 104
moles per cell 4.34 x lO 19 1.24 x 10-19
molecules per cell 2.60 x 105 7.45 x 104
In experiment LJW138, the protocol was changed: Four separate rinsings with 
200jll1 SFM were used instead of two as in the previous three experiments. This 
extra washing was done to reduce the non-specific binding of 3H-MTX to the 
plates. Inevitably it also caused increased cell stress with subsequent detachment 
of some cells. These cell effects were most noticeable in the disparity of results 
yielded. The E.C .50 estimated from MTT assay results gave a value of 2.42 x 10 
8M MTX and the number of cells that were consequently viable at this 
concentration was given as 3.78 x 104 per well. Based on the initial number of 
cells present in the control well of 1.48 x 105, the E.C .50 occurred at a 
concentration of MTX which corresponded to 7.4 x 1()4 cells per well. Although 
the wells all received the same number of washings and hence one well cannot 
have been subjected to more stress than another, the following was worth 
consideration; according to the results of the MTT assay, the number of cells
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per well present at a concentration of 2.42 x 108M MTX was 3.78 x 104 cells 
per well and since the scale of viability and absorbance was a linear one then this 
implied that at a level of 7.4 x 104 cells per well the concentration of MTX 
present should have been in the region of 4.74 x 108M.
The results of the Trypan blue assay have shown this level of cells corresponded 
to a value of 1 x 108M MTX. The difference between the two could be 
explained by the method of estimation of the values which were taken directly 
off the graphs (and hence subject to error) but some of the disparity must be 
due to the increased number of washing steps which placed more stress an B16 
cells already compromised by the presence of MTX. The subsequent effects on 
a molecular level were quite obvious as the values for the intracellular mass of 
MTX necessary to inhibit cell growth may have been underestimated.
There were many problems to overcome with regard to the maintenance of 
reproducibility of protocol in these experiments. The Trypan blue dye exclusion 
assay was not without complications. The main source of error associated with 
this method was the need to economise on time so that only a sample of cells 
were counted at any one time. One could only assume that this sample was 
representative of the whole population and also that enough samples were 
taken. The cells from four wells were pooled which gave two replicates per 
concentration gradient and four replicates for the control cells.
The principal difficulty associated with the tritiated MTX assay was the non­
specific 3H-MTX which was attached to the plastic wells. Table 6.3. shows the 
results a control experiment performed in order to determine how many washes, 
with SFM, were necessary to reduce the residual radioactivity, i.e. the non- 
specifically bound 3H-MTX, to an acceptable level.
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Table 6.3. This shows the "dpm" values obtained by incubating 1 x 10 6M 3H- 
MTX over 72 hours on a microwell plate versus the number of washing steps 
with 200pl SFM.









As can be seen from the table, the washing regimen adopted which included five 
separate rinsings with SFM removed the majority of radioactivity that was non 
cell bound. Eight washing steps would have removed ten times more non­
specific radioactivity and hence would have been preferable. However, each 
additional washing step caused cell stress which was manifested as cell 
detachment, therefore five washings steps was judged to be a sufficient number. 
Figure 6.5. demonstrates another experiment in which the microwell plate was 
treated with exactly the same concentrations of tritiated MTX in the absence of 
any B16 cells. It is clear from the graph that there was a quite a distinct 
difference in non-specific activity between the plates which were washed twice 
as opposed to five times and this was largely independent of the initial 
concentration, with the exception of 1 x 10'6M, but this concentration was 
higher than the concentrations used in uptake experiments.
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TABLE 6.4. The table below shows the results of 3 later experiments 
(151,152,154). The E.C .50 value is estimated in two ways; from the results of 
the MTT assay and the Trypan blue assay. When the E.C.50 value is estimated 
with the MTT assay it is given in terms of the concentration of MTX required 
to reduce the absorbance to half that of the control cells. The no. of cells per 
well refers to the Trypan blue assay and the no. of moles per cell refers to the 
3H-MTX uptake assay at the respective E.C .S0 value. When the E.C .50 value is 
estimated from the Trypan blue viable count, it refers to the concentration of 
MTX necessary to reduce the number of cells per well to half that of the control 
cells. The no.of moles per cell refers to the 3H-MTX uptake assay at the 
respective E.C .50 value. Each value is the mean of 8 replicates.
Experiment LJW151 MTT Assay Trypan blue Assay
Mean St. Dev. Mean
E .c .50 (M) 2 .8 6  x 10-10 +/-9.66 x 10-" 2.30 x 10-9
moles per well 9.50 x lO 15 2.14 x 10-14
cells per well 3.14 x 104 6.75 x 104
moles per cell 3.03 x 1 0 19 3.17 x 1 0 19
molecules per cell 1.82 x 105 1.90 x 105
Experiment LJW 152 MTT Assay Trypan blue Assay
Mean St. Dev. Mean
e . c .50 (M) 1.13 x lO 9 +/-5.36 x 10-10 3.26 x lO 9
moles per well 1 .12  x 1 0 14 5.51 x 1 0 15
cells per well 6.06 x 104 6.25 x 104
moles per cell 1.85 x 1 0 19 1.76 x 10-19
molecules per cell 1.11 x 105 1.06 x 105
Experiment LJW 154 MTT Assay Trypan blue Assay
Mean St. Dev. Mean
e . c .50 (M) 2.79 x 10-9 +/-8.61 x 1 0 10 7.14 x 10-9
moles per well 4.5 x 1 0 15 6.25 x 1 0 15
cells per well 7.63 x 104 5.09 x 104
moles per cell 5.90 x 10-20 1.23 x 1 0 19
molecules per cell 3.54 x 104 7.37 x 104
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Having established the optimum number of washing steps to use, the protocol 
was altered. In experiments LJW151 and 152 all of the plates were rinsed five 
times with SFM. The E.C .50 values obtained in LJW151 varied between 2.86 x 
10*10M (MTT assay) and 2.3 x l0 9M (Trypan blue). The intraexperimental 
differences cannot be fully explained in terms of the increased rinsings because 
the MTT assay suggested that the cells became more sensitive to MTX. This 
was also the result of LJW152 where the B.C .50 values were lower and in the 
10'9M range. This had consequential effects on the number of moles per cell and 
also cells per well which gave the overall estimate as 105 molecules (approx.) 
which were needed intracellularly to inhibit the growth of B16 cells.
In LJW154 a modification of the method to assess the mass of 3H-MTX taken 
up intracellularly was investigated making use of the "Millipore" multiscreen 
filtration plate. The contents of the wells containing the tritiated MTX and the 
cells were transferred to the filtration plate. With this technique the need to 
remove the cells from the well was obviated because after washing steps have 
been undertaken the wells themselves (made of "Durapore") were punched 
directly into the scintillation vials and the filter was then solubilised by use of 
1M HC1 and 1M NaOH in equal portions (lOOjil). Finally 2ml of "Optiphase" 
scintillation fluid was added to each scintillation vial. This method would have 
been preferred since no loss of cells occurred during washing. The MTT and the 
Trypan blue plates were rinsed twice with SFM as there was no need to ensure 
non-specific binding was minimised. The results (shown in table 6.4) indicated 
that despite the fact the rinsing steps were quite different depending on the 
aspect of the assay, the e .c .5o values were quite close. There was a decrease in 
the number of moles per well estimated and this lead to a calculation of 
molecules per cell in the 104 region. These were the lowest values obtained 
however this does not mean that it was an underestimation of the intracellular 
mass necessary to inhibit the cells but rather that due to the difference in 
protocol, a difference in the estimated value was to be expected.
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One of the problems with this method was that in order to compare the three 
parallel experiments, it would have been necessary to use the filtration plates for 
the MTT assay and this was attempted in LJW155. It proved to be impossible 
due to the problems encountered at the plate reading stage where the 
multiscreen filtration plate did not yield results that were comparable to other 
MTT assays. The manufacturers recommendations suggested that MTT assays 
should be possible, but this was not supported by the present study.
6.3. Summary.
As previously shown in Figures 6.3. and 6.4. the number of moles of H-MTX 
per well and the number of viable cells present at this concentration respectively 
can be estimated. It was then possible to work out the number of moles of MTX 
associated with each cell, an example of which is given in Figure 6 .6 . By 
multiplying the number of moles per cell by Avogadros number (6  x 1023), the 
number of molecules of MTX per cell was calculated. Given the problems 
associated with the assay procedures, a mean value for the E.C .5 0  was used 
based on the results of the MTT and Trypan blue assays. Therefore a conclusion 
can be drawn that by employing an extracellular concentration of MTX in the 
region of 1.34 x 108M and 1.2 x 108M MTX an average of 5.98 x 105 (+/- 
6.99 x 105) and 4.89 x 105 (+/- 8.76 x 105) molecules of MTX were taken up by 
each cell for the MTT and the Trypan blue estimation methods respectively i.e. 
each cell needs, in the region of, half a million molecules of MTX in order to be 
effectively inhibited. A detailed discussion on the plausibility of achieving this 













—A—GROWTH INHIBITORY EFFECTS OF MTX ON A B16 CELL LINE (LJW135)
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Figure 6.1: Net absorbance (540-690nm) of M TT formazan produced by 
B16 cells after treatm ent with varying concentrations of MTX over 72 
hour period. Each point is the mean of 8  wells. S tandard deviation is 
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LOG CONCENTRATION OF MTX
Figure 6.2: Percentage of control (i.e. maximum) absorbance (540-690nm) 
of MTT formazan produced by B16 cells in three replicate experiments 
after treatment with MTX. Each point is the mean of 8 wells. Error bars 


























Figure 6.3: Number of moles of 3H MTX remaining per well after 72 
hours and washing steps have been completed versus the initial molar 
concentration of 3H-MTX in the well. The results are for 3 replicate 
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Figure 6.4: Relationship between the number of cells per microwell as 
assessed by the Trypan blue assay versus the concentration of MTX per 
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Figure 6.5: Control experiment showing the "dpm" values obtained for 1 x 
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Figure 6.6: This illustrates the number of moles of methotrexate taken up 





The aim of this study was to verify whether the hormone-drug conjugate, 
N“MTX-[Nle4,D-Phe7]a-M SH, would successfully achieve site specific 
toxicity against melanoma cells in culture. The experiments described in 
Chapters 3, 4, 5, and 6  were undertaken in order to gain a greater insight in to 
the various aspects of the study including: the growth inhibition assay 
procedure used (Chapter 3), the growth inhibitory effects of the free drug, 
MTX, (Chapter 4), the uptake, internalisation and growth inhibitory effects of 
NaMTX-[Nle4,D-Phe7]a-MSH (Chapter 5), and the intracellular mass of 
MTX necessary to cause growth inhibition (Chapter 6 ). All of the results 
obtained in this work were then compared with related results obtained 
previously by others, Adams, (1993), Erskine-Grout, (1993) and Sahm, (1994). 
The cumulative results could then be assessed in their correct context and 
sensible conclusions could be drawn in the light of all the findings, as to the 
feasibility of using NaMTX-[Nle4,D-Phe7]a-MSH in site specific drug 
delivery.
The MTT assay provided a low cost, rapid and accurate method (Mosmann, 
1983) by which the growth inhibitory characteristics of MTX and NrtMTX- 
[Nle4,D-Phe7]a-M SH could be examined. The conditions of the assay were 
optimised for each cell line used e.g. B16 murine melanoma, MeWo human 
melanoma, SVK14 keratinocytes and the transformed 293 cells. Individual 
aspects of the protocol were examined e.g. the limits of linearity, seeding 
density, optimal incubation time and solvents. Using the Beer-Lambert laws, 
the limits of linearity of the assay were determined. Absorbance readings up to
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1.0 AU were in accordance with the laws whilst readings between 1.0-2.0 AU 
were still close to linear.
The seeding density was optimised at a level of 4 x 103 cells per microwell. 
This allowed for sufficient growth and ensured that throughout the experiment 
the cells could proliferate with adequate space and nutrients. In addition, the 
seeding density was low enough to preclude the refeeding of cells during the 
experiment, as this would have increased the potential for contamination.
A three hour incubation time was judged sufficient to allow conversion of the 
MTT to MTT formazan. DMSO was used as the solvent of choice because 
despite the deleterious effects on laboratory equipment and the possible risks to 
the operator, it was very efficient at rapid and complete solubilisation of the 
formazan crystals.
The majority of work carried out in this study has been performed on the B16 
murine melanoma cell line. In the MTT assessment of the growth inhibitory 
effects of MTX on B16 cells, a range of concentrations from 10' 2 down to 
10~n M MTX were employed. The results of five separate experiments were 
analysed by the MINSQ non-linear regression programme producing a mean 
E.C .50 value of 1.67 x 108M MTX. This implied that an extracellular 
concentration of 1.67 x 1(>8M or greater must be achieved in order to reduce 
the viability of the cells to 50% relative to the control cells. The result was in 
close agreement with similar experiments described in Chapter 6 , in which it 
was estimated that between 1.34 x 10 8M and 1.2 x 10_8M MTX were needed 
for a similar reduction in viability of B16 cells using the MTT and Trypan blue 
methods of assessment, respectively.
It is also shown in Chapter 6  that it is necessary to have an intracellular mass 
of 5.44 x 105 molecules of MTX in order to achieve growth inhibition of half 
the cells present. It is quite possible to achieve this level of intracellular MTX
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due to the folic acid transport pathway by which MTX is taken up 
intracellularly. However, the drawback of this approach lies in the localisation 
of this folic acid pathway i.e. it is a pathway not confined to specialised cells 
but rather found in all cells. This has more serious implications when related to 
an in vivo situation whereby the cells of the whole body will be placed under 
the same threat of the cytotoxic potential of MTX irrespective of whether or 
not these cells are cancerous. The more rapidly dividing the cell e.g. bone 
marrow, the more serious the consequences since MTX became lethal if 
exposed to cells in the S-phase during logarithmic growth. A whole host of 
side-effects ranging from nausea and vomiting to impaired renal function may 
then ensue.
The use of the hormone conjugate was postulated in order to reduce these side- 
effects by localising the actions of MTX to those cells where MSH receptors 
were present e.g. cells of the melanocyte lineage. It was also necessary to 
target the MTX to the MCI receptor specifically as the other four receptors 
(MC2-MC5) are found in areas other than the melanocytes e.g. brain, placenta, 
gut. However it is very difficult to achieve this level of specificity especially in 
light of the likely conformational similarities exhibited by all five of the MSH 
receptors identified to date, (Mountjoy et al., 1992, Chhajlani and Wikberg, 
1992, Gantz et al., 1993a and 1993b, Chhajlani et al., 1993). Thus the next 
step taken was to assess the binding affinity of NaMTX-[Nle4,D-Phe7]a-MSH 
and N“MTX-[I25I-Tyr2,Nle4,D-Phe7]a-MSH in the presence of both MCI (B16 
and MeWo cells) and MC3 (transformed 293 cells) receptors to establish 
whether or not a greater sensitivity was achieved by NaMTX-[Nle4,D-Phe7]a- 
MSH for the MCI rather than the MC3.
The labelled conjugate (NaMTX-[1“5I-Tyr2,Nle4,D-Phe7]a-MSH ) resulted in a 
binding affinity of 7.35nM for the MCI receptor as opposed to 1.69nM for the
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MC3 receptor implying a greater affinity of the N^MTX-f'^I-TyrMMle^D- 
Phe7]a-M SH for the MC3 receptor. This result suggested that the radiolabelled 
conjugate does not exhibit selective affinity for the MCI receptor but in fact 
binds with stronger affinity to the MC3 receptor. This result was discouraging 
from a targeting viewpoint as it would have been preferable to have the 
conjugate exhibiting greater affinity for the MCI receptors, which are located 
specifically on melanocytes. MC3 receptors are located in the placenta, gut, 
but more importantly, from the point of view of side-effects, the brain which 
could result in toxic CNS effects.
Internalisation data with continual exposure of B16 cells to 0.1 nM of NaMTX- 
[125I-Tyr2,Nle4,D-Phe7Ja-MSH in the presence of NH4C1 suggested that B16 
cells were capable, at this extracellular concentration, of internalising 1793 
molecules of ,25I-NrtMTX- [Nle4,D-Phe7Ja-MSH over a 4 hour period. This 
figure was calculated on the basis of radioactive counts using the data 
generated over three separate experiments. The variance in the number of 
molecules internalised ranged from 565 to 3,500 and was probably a reflection 
of the variable number of receptors expressed on the surface of B16 cells with 
changing conditions or passage. It is clear that the higher the number of 
receptors on the cell surface, the greater the number of molecules internalised 
and with a receptor number oscillating between 5,000-25,000 for B16 cells 
(Sahm, 1994), this degree of interexperimental disparity is understandable. It 
follows that if 1793 molecules are internalised over a four hour period that 448 
molecules of N“MTX-[125I-Tyr2,Nle4,D-Phe7]a-MSH are taken up per hour by 
receptor mediated endocytosis.
By using the slopes of the graphs of the specifically bound ligand in these
125experiments, it was possible to assess the mass of internalised NaMTX-[ I-
'•y
T yr\N le4,D-Phe7]a-MSH by a second method. An average value of 9.3
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molecules per cell per minute were internalised. However, the receptor 
occupancy at this point must be considered, a value of 1.34% has been 
estimated based on the affinity of the ligand for the receptor. This would 
amplify the result from 9.3 molecules per cell per minute at 1.34% receptor 
occupancy, to 42,000 molecules internalised per cell per hour at maximum 
receptor occupancy. Obviously although it would be theoretically possible to 
achieve this, it would require a huge increase in the concentration of 
extracellular ligand and such a level is neither desired nor realistic for drug 
targeting studies. The aim is to introduce the minimum efficient level of active 
substance sufficient to cause growth inhibition of the cancerous cells whilst 
limiting the harmful effects to healthy cells. In the Pulse-Chase internalisation
125experiments carried out at 0.1 nM, only 20-500 molecules N“MTX-[ I- 
Tyr2,Nle4,D-Phe7]a-MSH were taken up specifically as opposed to 500-1000 
molecules of 125I- [Nle4,D-Phe7]a-MSH (Adams, 1993). However although 
Pulse-Chase labelling studies were performed at approximately 10% receptor 
occupancy for 125I- [Nle4,D-Phe7ja-MSH, this was substantially reduced to 
0.67% for NaMTX-[125I-Tyr2,Nle4,D-Phe7]a-MSH. This explains the decrease 
in internalisation of N(XMTX-[125I-Tyri',Nle4,D-Phe7ja-M SH, relative to 125I- 
[Nle4,D-Phe7]a-MSH. Another possibility for the reduced number of 
molecules of NaMTX-[125I-Tyr2,Nle4,D-Phe7]a-M SH internalised may be the 
conjugation of MTX to [Nle4,D-Phe7]a-MSH which resulted in a reduction in 
the uptake of the latter, which may have been due to the increased size of 
N«MTX-[Nle4,D-Phe7]a-MSH (FW:2040) as opposed to [Nle4,D-Phe7]cc-MSH 
(FW:1648) possibly inducing conformational changes and difficulties at the 
receptor site.
Data obtained from the growth inhibitory effects of NaMTX-[Nle4,D-Phe7Jcx- 
MSH on the B16 cells suggested that an extracellular concentration of 1.47 x
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10*5M was necessary to reduce the viability of the cells to 50% relative to 
control cells. This is a thousand fold greater concentration than the level 
required for the MTX alone and implied that instead of the conjugate 
decreasing the amount of drug needed quite the reverse had occurred. A further 
implication of this was that the pathway taken by NaMTX-[Nle4,D-Phe7]a- 
MSH was a 1000 fold less effective at delivering MTX to the intracellular 
compartments and therefore a greater concentration of the conjugate was 
necessary to achieve the same decrease in cell viability.
Varga et al., (1977) used a melanotropin-daunomycin conjugate to show 
receptor mediated cytotoxicity in cultured murine melanoma cells. On a molar 
basis, their conjugate was 3 times more toxic to melanoma cells than free 
daunomycin. This contrasts dramatically with the results obtained in the 
growth inhibition assays with NaMTX-[Nle4,D-Phe7Ja-MSH using cultured 
murine melanoma cells, where a 103 increase in conjugate concentration is 
required to effect the same level of inhibition as free MTX.
MeWo human melanoma cells were also treated by MTX and NraMTX- 
[Nle4,D-Phe7]a-MSH. The results indicated that an extracellular concentration 
of 1.31 x 109M MTX reduced the viability of the MeWo cells to 50% of the 
viability of control cells. This concentration was tenfold lower than that 
necessary to inhibit the B16 cells and implied that MeWo cells were more 
susceptible to the effects of MTX. It was therefore expected that the conjugate 
would exhibit a similar profile namely: a tenfold lower concentration necessary 
to show the same decrease relative to the effects of NaMTX-[Nle4,D-Phe7]a- 
MSH to B16 cells. The results gave an E.C.50 value of 2.48 x 1()'6M, which 
although lower than the B16 cells required, was still a very high concentration 
of N“MTX-[Nle4,D-Phe7]a-M SH and the difference with respect to free MTX 
was also a thousand fold.
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The results of neither the B 16 nor the MeWo cells indicated a greater efficacy 
of the conjugate over MTX as demonstrated by the results above.
SVK14 keratinocytes were used as a control specifically due to the fact that 
they possess few, if any, MSH receptors on their surface. Therefore if the 
effects of the conjugate were mediated exclusively through these receptors it 
would be logical to assume that a very high level of NaMTX-[Nle4,D-Phe7]oc- 
MSH must be present before any effect is seen. This concentration should be in 
excess of the levels previously required by B16 and MeWo cells or else 
selectivity for MSH receptors cannot be said to be shown. This was similar to 
the use of 3T3 fibroblasts by Varga and co-workers (1977) in the testing of 
selectivity exhibited by their melanotropin-daunomycin conjugate. They found 
that whereas daunomycin was toxic to the 3T3 cells, the conjugate was not 
showing the selectivity of this inhibitor for cells which possessed the relevant 
(MSH) receptor.
The E.C.50 value achieved for the SVK14 keratinocytes in the presence of 
MTX could not be accurately estimated by the MINSQ programme. This was 
because there were only two levels of viability obvious from the results namely 
the growth levels of the control cells and the lack of growth by all of the 
treated cells. Therefore in the first experiment (88), all that can be deduced was 
that a level of MTX equivalent to 10 n M was too high and effectively killed 
the cells. For the next experiment (94) a level of 1 0 13M was still too high and 
exerted lethal effects on all the cells.
Although this did not yield an E.C.50 value for the MTX with SVK14 cells, it 
did give an estimate of the sensitivity of these keratinocytes to the 
antimetabolite. In the presence of N“MTX-[NIe4,D-Phe7]a-M SH an E.C.50 
value of 1.68 x 1()-6M (n=2) was found. This contrasted dramatically to the 
effects of free MTX and showed that these keratinocytes are at least seven
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orders of magnitude more susceptible to MTX than to NaMTX-[Nle4,D-Phe7]a  
-MSH. This result was what would be expected because in the exposure of 
SVK14 cells to MTX, the MTX would be taken up via the folic acid pathway 
which is present in SVK14 cells. However, because of the lack of MSH 
receptor sites on the surface of the keratinocytes, the NaMTX-[Nle4,D-Phe7]a- 
MSH does not have a proper pathway of entry and hence would not be taken 
up into the cell actively but rather any uptake process would be both passive 
and non-specific e.g. pinocytosis. This would require a high extracellular 
concentration of NaMTX-[Nle4,D-Phe7]a-MSH so that sufficient NraMTX- 
[Nle4,D-Phe7]a-M SH is taken into the cell and subsequently degraded 
allowing the release of MTX which is then free to exert its effects. The other 
means by which the conjugate may have exerted its toxic effects include 
degradation of the hormone-drug conjugate extracellularly and subsequent 
internalisation of the MTX molecules. It is clear that these modes of entry of 
MTX would seem to exist only in the presence of very high concentrations of 
NaMTX-[Nle4,D-Phe7]a-MSH (>106M). However, it has been shown that 
B16 and MeWo cells need an equal if not greater level of NaMTX-[Nle4,D- 
Phe7]a-M SH before the latter exerts any significant growth inhibitory effects. 
Hence although internalisation data would seem to suggest that 125I-N“MTX- 
[Nle4,D-Phe7]a-M SH was specifically taken up into melanoma cells, this may 
not be true. This finding was based on the assumption that the radioactivity 
associated intracellularly was 125I-NaMTX- [Nle4,D-Phe7]a-M SH whereas it 
may be that the MTX was cleaved so that only 125I- [Nle4,D-Phe7]a-M SH was 
internalised with the MTX portion dissociated. An attempt to rule out this 
possibility was carried out by demonstrating, using HPLC, that over the period 
of culture the MTX configuration was stable. A further argument in favour of 
selective uptake by melanoma cells can be made: If the toxicity was due to free
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MTX released into the medium and then taken up by the active transport 
system one would have expected that the conjugate would have been more 
toxic to SVK14 cells which were very highly sensitive to free MTX. In fact 
with SVK14 cells there was at least a 107 fold difference in the toxicity of free 
MTX and conjugate, whereas the comparative figure for melanomas was 103. 
The growth inhibitory capacity of the NaMTX-[Nle4,D-Phe7]a-M SH on the 
293 (transformed) cell lines was also examined. The 293 cells containing the 
MC3 receptors yielded and E.C.S0 value of 3.03 x 10 n M for MTX. This 
showed that these 293 cells were more sensitive to the effects of MTX than the 
B16 or MeWo cells. It would be expected that since these cells possess such 
large numbers of MC3 melanocortin receptors on their surfaces that their 
ability to internalise the NaMTX-|Nle4,D-Phe7]cx-MSH would be greater than 
for example: SVK14 cells which do not possess any of the MSH receptors. 
However this assumes that the major route of internalisation of NreMTX- 
[Nle4,D-Phe7]a-MSH is via receptor mediated endocytosis, something which is 
not supported by recent experiments. The E.C.50 value for the 293 cells with 
MC3 receptors treated with NaMTX-[Nle4,D-Phe7]a-MSH was 1.07 x 105M 
which was higher than the E.C.50 obtained with SVK14 cells.
293 cells which possess the vector alone in the absence of any receptors were 
even more sensitive to MTX treatment (E.C.50= 2.84 x 1 0 I3M) and yet they 
required an order of magnitude less of the NCiMTX-[Nle4,D-Phe7]a-MSH to 
achieve the same degree of inhibition as the 293 cells with MC3 receptors 
(E.C.50= 1.66 x 106M). This may imply that the process of transfection of the 
vector alone had heightened the sensitivity of the 293 cells, since the cells with 
both the vector and the gene encoding information were more resistant to the 
effects of MTX and NaMTX-[Nle4,D-Phe7]a-M SH, however the inhibitory 
effects of untreated 293 (HEK) would also have to be examined to substantiate
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this theory. Even though the results of the 293 cells were only preliminary and 
further replicates should be done to confirm the above conclusions, the 
experiments labelled 146 and 147 are still valid as giving representative 
results. The results obtained with transformed 293 cells could be explained if 
the rate of receptor-mediated endocytosis was slow, or if the release and 
degradation of the conjugate was impaired. More work needs to be done to 
explore these effects.
Control experiments in the presence of [Nle4,D-Phe7]a-M SH alone with B16 
and MeWo cells were performed to establish whether the [Nle4,D-Phe7]a-MSH 
exerted any growth inhibitory effects. It has been shown (Figures 5.25 and 
5.26) that any decrease in viability was transient and at the highest 
concentration of [Nle4,D-Phe7la-M SH (1()-4M) there was no reduction in 
absorbance and hence no reduction in cell viability. This implied that the 
[Nle4,D-Phe7]a-M SH portion of the NaMTX-[Nle4,D-Phe7]a-M SH was not 
inherently toxic and therefore any inhibitory effects mediated by the latter 
were due solely to the MTX portion.
The effects of monensin on the inhibitory actions of NaMTX-[Nle4,D-Phe7]a- 
MSH were examined by incubating the B16 cells with a range of 
concentrations of N“MTX-[Nle4,D-Phe7]a-MSH in the presence of a fixed (10- 
5M) concentration of monensin. The theory behind this was that monensin is 
an ionophore which prevents receptor recycling in its role as a lysomotropic 
agent. Therefore if the N“MTX-[Nle4,D-Phe7]a-M SH was internalised 
specifically via MSH receptor mediated endocytosis then treatment with 
monensin would decrease the number of available receptors, over time, and the 
overall result would be an increase in the E.C.50 value relative to the E.C.50 
value of B16 cells untreated by monensin. These experiments yielded a mean 
E.C.50 value of 1.56 x 1()-5M (n=3) which compared to 1.47 x 10 5M for
193
untreated B16 cells. Therefore any effects on receptor recycling within the 
cells were not manifested by a parallel increase in concentration of NaMTX- 
[Nle4,D-Phe7]a-M SH necessary to inhibit growth and so one of two 
conclusions may be drawn: (i) the receptor recycling of the MSH receptors was 
not significantly reduced by the 10'5M monensin or, (ii) there was a significant 
reduction in receptor recycling but this did not interfere with the actions of the 
NaMTX-[Nle4,D-Phe7]a-MSH as receptor mediated endocytosis was not the 
major route of entry for NaMTX-[Nle4,D-Phe7]cx-MSH.
Finally the cells were treated with 104M chloroquine which caused cell death 
in the absence of any other agent and hence no conclusions could be drawn as 
to the efficacy of chloroquine in reduction in receptor recycling and if this 
affected the NaMTX-[Nle4,D-Phe7]a-MSH.
The lack of efficacy shown by NaMTX-[Nle4,D-Phe7]-a-MSH in growth 
inhibition of cells relative to MTX was disappointing in so far as a selective 
effect on melanoma cells could not be demonstrated and this contrasted with 
the previous success of others in the field.
Morandini et al. (1994) used four peptide-melphalan conjugates: Pepl and 
Pep2 (central fragments) which contained the 4-10 sequence known to be the 
main a-M SH binding site and Pep3 and Pep4 which comprised two C terminal 
fragments. They were all tested against melanoma, carcinoma and fibroblasts. 
When comparisons were made on the basis of the E.C.50 values, a clear 
selective cytotoxic effect on melanoma cells could be observed even though all 
four were less active than melphalan alone. The results obtained by this group 
and by Varga et al. (1977) using daunomycin conjugates of (3-MSH are all the 
more surprising when the binding affinity of the conjugates is considered. Data 
from the Bath group shows that coupling of drugs to the N-terminus of a-MSH 
is acceptable without extensive loss of affinity. Other sites of coupling would
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be expected to have a considerable effect on binding. Varga et al. (1977) did 
not determine receptor binding but this conjugate would be expected to have 
low affinity for MCI receptors.
Bard et al. (1986, 1990) showed how a-MSH derivatives could aid imaging of 
melanoma: Conjugation of MSH to diethylenetriaminepenta-acetic acid 
(DTPA) was done initially in order to investigate the ability of MSH-DPTA to 
target H1In to Cloudman melanoma cells and tumours. The results obtained 
showed that MSH-DTPA-m In was selectively retained by tumour tissue.
This was then enhanced by the synthesis of to-M SH-DTPA by Bard et al. 
(1990) in which two molecules of the hormone were cross-linked by DPTA. 
When DBA/2 mice were injected with the /?fv-MSH-DPTA-,MIn, the 
radioactivity was rapidly associated with the melanoma tissue. The 
radioactivity in tumour tissue was significantly higher (PcO.OOl) than in the 
spleen, lung, brain, eye or the skin. A conclusion that b/s-MSH-DTPA may 
offer an alternative to antibody targeting in the imaging of malignant 
melanoma , was reached by the authors. This would be a great advantage to aid 
imaging of melanoma since the reliable detection of metastases presents a 
major clinical problem in the management of malignant melanoma.
The conjugation of a-M SH to diphtheria toxin forming a fusion protein: 
DAB389-MSH by Murphy et al. (1986) was developed into a system for use 
with MC receptors in human melanoma metastases by Tatro et al. (1992). Due 
to the results of competitive binding of DAB389-MSH in the presence of ,25I- 
[Nle4,D-Phe7]a-MSH on biopsy specimens of human and mouse melanoma 
metastases, it was concluded that DAB3g9-MSH could displace the ,25I- 
[Nle4,D-Phe7]a-MSH from its receptor site. Other probes tested were [Nle4,D- 
Phe7]a-M SH and a-MSH and they were ranked in decreasing order of binding 
affinities as follows: [Nle4,D-Phe7]a-MSH, 1.8()nM, a-M SH, 2.43nM and
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DAB389-MSH, 11.9nM. These values were very close and since melanotropin 
receptors are detectable in melanoma metastases of about 80% of human 
patients (Tatro et al., 1990) it has been postulated (Tatro et al., 1992) that 
malignant melanoma cells of many patients may be susceptible to the targeted 
cytotoxin DAB3g9-MSH.
Future work in our laboratories will involve the use of the diphtheria toxin 
fusion protein conjugated to a-M SH in our system, where it is hoped to act as 
a positive control showing that selectivity does occur but that MTX may not be 
the optimal choice for demonstrating this. Although MTX is a toxic molecule, 
it is also possible that fewer diphtheria toxin molecules would be needed to 
effect cell kill and hence this may be a more efficient site specific delivery 
system.
In vitro work is an important first step on the road to more efficacious therapy 
and even though it may not necessarily reflect success in vivo (Suli-Vargha et 
al., 1990), it is still a valuable indicator.
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